DrugMAP Full Data Download File
Title - DrugMAP drug to drug-metabolizing enzyme (DME) mapping information in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
            College of Pharmaceutical Sciences
            Zhejiang University
            https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)

EI: DME_ID
EN: DME_Name
DI: Drug_ID
DN: Drug_Name
RN: Reference_Name
RU: Reference_URL

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIKQH5
DE4LYSA	DN	Hydroxyprogesterone caproate
DE4LYSA	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDRQZU
DE4LYSA	DN	Ethanol
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPMYE8
DE4LYSA	DN	Miconazole
DE4LYSA	RN	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15135088

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM13495
DE4LYSA	DN	Fesoterodine
DE4LYSA	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4QTBN
DE4LYSA	DN	Isotretinoin
DE4LYSA	RN	The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004 May;75(5):464-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15116059

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXBR27
DE4LYSA	DN	D-600
DE4LYSA	RN	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos. 1999 Nov;27(11):1254-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534309

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQ314B
DE4LYSA	DN	VA-10872
DE4LYSA	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTP1DC
DE4LYSA	DN	Irbesartan
DE4LYSA	RN	Drug interactions with irbesartan. Clin Pharmacokinet. 2001;40(8):605-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11523726

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSQZE2
DE4LYSA	DN	Asenapine maleate
DE4LYSA	RN	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23356509

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXTMBJ
DE4LYSA	DN	Azelastine
DE4LYSA	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW83TP
DE4LYSA	DN	Pimozide
DE4LYSA	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYZ57N
DE4LYSA	DN	Albendazole
DE4LYSA	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBD4K3
DE4LYSA	DN	Selinexor
DE4LYSA	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZAL7W
DE4LYSA	DN	Promazine
DE4LYSA	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCXRZF
DE4LYSA	DN	LY-2603618
DE4LYSA	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0E6S3
DE4LYSA	DN	Suvorexant
DE4LYSA	RN	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26955275

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK5I07
DE4LYSA	DN	AN-16649
DE4LYSA	RN	Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003 Jan;10(1):40-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12489027

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD157S
DE4LYSA	DN	Montelukast sodium
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT4VSE
DE4LYSA	DN	BMY-42569
DE4LYSA	RN	Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600718

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOYE70
DE4LYSA	DN	HOE-239
DE4LYSA	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMINO7Z
DE4LYSA	DN	WSM-3978G
DE4LYSA	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNFUZR
DE4LYSA	DN	Enalapril
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM24XYQ
DE4LYSA	DN	Bromperidol
DE4LYSA	RN	CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11133003

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7HXWT
DE4LYSA	DN	Nilotinib
DE4LYSA	RN	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20810928

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLUA9D
DE4LYSA	DN	Simeprevir sodium
DE4LYSA	RN	Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015 May-Jun;23(2):92-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26200709

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK1GBJ
DE4LYSA	DN	Trazodone hydrochloride
DE4LYSA	RN	Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15978881

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMX4GND
DE4LYSA	DN	Meperidine
DE4LYSA	RN	Is meperidine the drug that just won't die? J Pediatr Pharmacol Ther. 2011 Jul;16(3):167-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22479158

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD7L94
DE4LYSA	DN	Palbociclib
DE4LYSA	RN	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28203301

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZDCS0
DE4LYSA	DN	Bezafibrate
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY1UGV
DE4LYSA	DN	BC-3781
DE4LYSA	RN	BC-3781: Evaluation of the CYP3A Interaction Potential.
DE4LYSA	RU	https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2011-bc-3781-and-cyp3a-interaction-potential.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMG26Z
DE4LYSA	DN	Dolasetron mesylate
DE4LYSA	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIZKOP
DE4LYSA	DN	Thiotepa
DE4LYSA	RN	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002 Jun;49(6):461-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12107550

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCZGRE
DE4LYSA	DN	Dolutegravir sodium
DE4LYSA	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5T6US
DE4LYSA	DN	Estrone
DE4LYSA	RN	Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25678418

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMI6HUW
DE4LYSA	DN	Terbinafine hydrochloride
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN6DXL
DE4LYSA	DN	Risperidone
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLW57T
DE4LYSA	DN	Teniposide
DE4LYSA	RN	Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11770832

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCA7FN
DE4LYSA	DN	DX-8951
DE4LYSA	RN	Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin Cancer Res. 2001 Oct;7(10):3056-64.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11595695

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1IQRP
DE4LYSA	DN	DA-8159
DE4LYSA	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVXFYE
DE4LYSA	DN	Vinorelbine tartrate
DE4LYSA	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9CIUW
DE4LYSA	DN	Ribociclib succinate
DE4LYSA	RN	P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm. 2019 Sep 3;16(9):3842-3852.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31329454

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG6OYJ
DE4LYSA	DN	Lorcaserin
DE4LYSA	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1YBRM
DE4LYSA	DN	Cyclobenzaprine
DE4LYSA	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML83IW
DE4LYSA	DN	LY-450139
DE4LYSA	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBAPFG
DE4LYSA	DN	Brinzolamide
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSLJP4
DE4LYSA	DN	Ziconotide
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCVPXO
DE4LYSA	DN	Lurasidone
DE4LYSA	RN	Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017 May;56(5):493-503.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27722855

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF28YC
DE4LYSA	DN	Atorvastatin calcium
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTUPZ2
DE4LYSA	DN	CJ-11974
DE4LYSA	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM28UJG
DE4LYSA	DN	Dapagliflozin
DE4LYSA	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKR3C5
DE4LYSA	DN	Ergotamine tartrate
DE4LYSA	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT2FDC
DE4LYSA	DN	Desipramine
DE4LYSA	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNKG1Z
DE4LYSA	DN	Atenolol
DE4LYSA	RN	Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27019

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDKF3M
DE4LYSA	DN	Raloxifene
DE4LYSA	RN	The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16959878

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM471KJ
DE4LYSA	DN	Omeprazole
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQUSBT
DE4LYSA	DN	Daunorubicin
DE4LYSA	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4KI7O
DE4LYSA	DN	Zidovudine
DE4LYSA	RN	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8053924

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBGZI3
DE4LYSA	DN	Chlorpromazine hydrochloride
DE4LYSA	RN	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23406751

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZNFPG
DE4LYSA	DN	ZK-31224
DE4LYSA	RN	Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med. 2002 Apr-Jun;6(2):189-98.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12169204

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMFVB3
DE4LYSA	DN	Difluprednate
DE4LYSA	RN	Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27084892

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGVH6N
DE4LYSA	DN	Axitinib
DE4LYSA	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDYA31
DE4LYSA	DN	Pretomanid
DE4LYSA	RN	FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
DE4LYSA	RU	https://www.fda.gov/media/127592/download

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMS0AFE
DE4LYSA	DN	Desoxycorticosterone acetate
DE4LYSA	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DE4LYSA	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC4GEI
DE4LYSA	DN	Ospemifene
DE4LYSA	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCRGY4
DE4LYSA	DN	BNP-1350
DE4LYSA	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM49DUI
DE4LYSA	DN	Tretinoin
DE4LYSA	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW649X
DE4LYSA	DN	Eletriptan hydrobromide
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH6NG5
DE4LYSA	DN	Fendiline
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA4MRX
DE4LYSA	DN	Perphenazine
DE4LYSA	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPAZHC
DE4LYSA	DN	Cabazitaxel
DE4LYSA	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DE4LYSA	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTP2NJ
DE4LYSA	DN	Desonide
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKA8J4
DE4LYSA	DN	Etonogestrel
DE4LYSA	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRADYL
DE4LYSA	DN	Pinacidil
DE4LYSA	RN	Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry. 2002 Feb 26;41(8):2712-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11851418

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMB9U5E
DE4LYSA	DN	HE-3286
DE4LYSA	RN	Studies of the pharmacology of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol, a synthetic anti-inflammatory androstene. Int J Clin Exp Med. 2011;4(2):119-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21686136

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM65AGJ
DE4LYSA	DN	Oxymorphone
DE4LYSA	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQCTIH
DE4LYSA	DN	Digoxin
DE4LYSA	RN	Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458401

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG2KI4
DE4LYSA	DN	Fluocinolone acetonide
DE4LYSA	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6A0X7
DE4LYSA	DN	Pravastatin
DE4LYSA	RN	Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000 Dec;39(6):397-412.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192473

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8H7OA
DE4LYSA	DN	RWJ-241947
DE4LYSA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCT3I8
DE4LYSA	DN	Ifosfamide
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZC90K
DE4LYSA	DN	LS-248
DE4LYSA	RN	Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr. 2007 Dec;2(3):249-56.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18850180

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6L4H2
DE4LYSA	DN	Cobicistat
DE4LYSA	RN	Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017 Apr 24;31(7):917-952.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28060009

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPWGBR
DE4LYSA	DN	Triclabendazole
DE4LYSA	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMSDOY
DE4LYSA	DN	Stiripentol
DE4LYSA	RN	Product characteristics of Diacomit.
DE4LYSA	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCDZ15
DE4LYSA	DN	LY-2484595
DE4LYSA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4K7GQ
DE4LYSA	DN	Erythromycin stearate
DE4LYSA	RN	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEL9UT
DE4LYSA	DN	Chenyltaurine
DE4LYSA	RN	6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim Biophys Acta. 1999 Apr 19;1438(1):47-54.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10216279

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2GHCR
DE4LYSA	DN	OPC-12759
DE4LYSA	RN	Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573-86.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12162853

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJE6KO
DE4LYSA	DN	Desvenlafaxine succinate
DE4LYSA	RN	Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22098230

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH1DYU
DE4LYSA	DN	AS-703026
DE4LYSA	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSWYF5
DE4LYSA	DN	Quinine sulfate
DE4LYSA	RN	Quinine induced simvastatin toxicity through cytochrome inhibition - a case report. BMC Geriatr. 2016 Oct 1;16(1):168.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27716084

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEV954
DE4LYSA	DN	Sulfinpyrazone
DE4LYSA	RN	CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065438

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJX6ZG
DE4LYSA	DN	Codeine
DE4LYSA	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQJHR7
DE4LYSA	DN	Indacaterol maleate
DE4LYSA	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWJE9D
DE4LYSA	DN	EXR-202
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5IXKQ
DE4LYSA	DN	Vismodegib
DE4LYSA	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAPO0T
DE4LYSA	DN	ADD-3878
DE4LYSA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN4H2O
DE4LYSA	DN	Azithromycin
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0C9IL
DE4LYSA	DN	Ranolazine
DE4LYSA	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM45OJN
DE4LYSA	DN	Mometasone furoate
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN3GCH
DE4LYSA	DN	Darunavir
DE4LYSA	RN	Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19492868

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6PR40
DE4LYSA	DN	Paramethasone
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCE985
DE4LYSA	DN	Antipyrine
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRMDWA
DE4LYSA	DN	Estropipate
DE4LYSA	RN	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXCM7H
DE4LYSA	DN	Cerivastatin sodium
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIWFRL
DE4LYSA	DN	Tolvaptan
DE4LYSA	RN	Tolvaptan: a new therapeutic agent. Rev Recent Clin Trials. 2011 May;6(2):177-88.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20868352

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGW1ID
DE4LYSA	DN	Sirolimus
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9PLRH
DE4LYSA	DN	Doxazosin
DE4LYSA	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY4D87
DE4LYSA	DN	Quazepam
DE4LYSA	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKJ485
DE4LYSA	DN	Pioglitazone hydrochloride
DE4LYSA	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7ADGX
DE4LYSA	DN	BRN-0456976
DE4LYSA	RN	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27495118

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG3Y89
DE4LYSA	DN	Trabectedin
DE4LYSA	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6LOQU
DE4LYSA	DN	Celecoxib
DE4LYSA	RN	Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10773015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPW5SB
DE4LYSA	DN	BAY-8697661
DE4LYSA	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6RZ9Q
DE4LYSA	DN	Clonidine
DE4LYSA	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWTAOI
DE4LYSA	DN	Estramustine
DE4LYSA	RN	Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12686819

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1BV7W
DE4LYSA	DN	Aliskiren
DE4LYSA	RN	Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18611061

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMIAXO
DE4LYSA	DN	Betamethasone valerate
DE4LYSA	RN	Studies on Drug Interactions between CYP3A4 Inhibitors and Glucocorticoids.
DE4LYSA	RU	https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWLC57
DE4LYSA	DN	Brentuximab vedotin
DE4LYSA	RN	Brentuximab vedotin.
DE4LYSA	RU	https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTPQ84
DE4LYSA	DN	NSC-9705
DE4LYSA	RN	Studies on pharmacokinetic drug interaction potential of vinpocetine. Medicines (Basel). 2015 Jun 5;2(2):93-105.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28930203

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6AVR4
DE4LYSA	DN	Hydroquinone
DE4LYSA	RN	Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos. 2003 Jan;31(1):122-32.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485961

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZMSCT
DE4LYSA	DN	Cilostazol
DE4LYSA	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM53IP1
DE4LYSA	DN	Ethchlorvynol
DE4LYSA	RN	Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 1982 Oct;25(10):1174-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7143353

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6F1PU
DE4LYSA	DN	Vortioxetine hydrobromide
DE4LYSA	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQZ9GF
DE4LYSA	DN	Trilostane
DE4LYSA	RN	Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2014;2014:140083.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25535576

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCX0K3
DE4LYSA	DN	Cinacalcet hydrochloride
DE4LYSA	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4F29C
DE4LYSA	DN	Crizotinib
DE4LYSA	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQ8JIK
DE4LYSA	DN	Chenodeoxycholic acid
DE4LYSA	RN	Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18583509

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM65KL8
DE4LYSA	DN	Fluocinonide
DE4LYSA	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGPF0N
DE4LYSA	DN	Estrone sulfate
DE4LYSA	RN	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHY3IP
DE4LYSA	DN	CKD-501
DE4LYSA	RN	Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Devel Ther. 2015 Mar 2;9:737-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25767371

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM3L6Z
DE4LYSA	DN	Ketobemidone
DE4LYSA	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM02A65
DE4LYSA	DN	Temazepam
DE4LYSA	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZK0FQ
DE4LYSA	DN	Dienogest
DE4LYSA	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQ4HIN
DE4LYSA	DN	Cabergoline
DE4LYSA	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPQAGE
DE4LYSA	DN	Mycophenolate mofetil
DE4LYSA	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBHMOX
DE4LYSA	DN	Palonosetron hydrochloride
DE4LYSA	RN	Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004 Nov;25(8):329-37.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15378559

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDH9KX
DE4LYSA	DN	Megestrol acetate
DE4LYSA	RN	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct;48(10):973-983.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29050522

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW1TV2
DE4LYSA	DN	Rifaximin
DE4LYSA	RN	Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011 May;45(5):e25.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21505109

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM79NTF
DE4LYSA	DN	Propranolol hydrochloride
DE4LYSA	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHP21E
DE4LYSA	DN	Hydromorphone
DE4LYSA	RN	Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16718649

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7TOWX
DE4LYSA	DN	ABT-333
DE4LYSA	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWQ4MZ
DE4LYSA	DN	Gilteritinib
DE4LYSA	RN	ClinicalTrials.gov (NCT02456883) Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors.
DE4LYSA	RU	https://clinicaltrials.gov/ct2/show/NCT02456883

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7YNV9
DE4LYSA	DN	Iclaprim
DE4LYSA	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQI43G
DE4LYSA	DN	BMS-650032
DE4LYSA	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZOLBI
DE4LYSA	DN	Carbamazepine
DE4LYSA	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM72FOD
DE4LYSA	DN	AZD-3839
DE4LYSA	RN	MedChemExpress: AZD3839.
DE4LYSA	RU	https://www.medchemexpress.com/AZD3839-free-base.html

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSVOZT
DE4LYSA	DN	Nifedipine
DE4LYSA	RN	Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9384469

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVR628
DE4LYSA	DN	Lilly-112531
DE4LYSA	RN	Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8452560

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJ90O5
DE4LYSA	DN	Medrysone
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPNTDL
DE4LYSA	DN	ABT-001
DE4LYSA	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCOZJY
DE4LYSA	DN	Tenapanor
DE4LYSA	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXBLMP
DE4LYSA	DN	Riociguat
DE4LYSA	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM78IME
DE4LYSA	DN	Histamine
DE4LYSA	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQYUWG
DE4LYSA	DN	Toremifene citrate
DE4LYSA	RN	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726172

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4KDYJ
DE4LYSA	DN	Nortriptyline hydrochloride
DE4LYSA	RN	Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 2000 Feb 14;855(2):235-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10677595

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSOX7I
DE4LYSA	DN	Cocaine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFQWNI
DE4LYSA	DN	Clomipramine hydrochloride
DE4LYSA	RN	Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17471183

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSH108
DE4LYSA	DN	CYC-202
DE4LYSA	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBEX4O
DE4LYSA	DN	Methylergometrine
DE4LYSA	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1YBHK
DE4LYSA	DN	Rifabutin
DE4LYSA	RN	The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9585795

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA8FS5
DE4LYSA	DN	Dronedarone hydrochloride
DE4LYSA	RN	Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22971242

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHNQOG
DE4LYSA	DN	Zafirlukast
DE4LYSA	RN	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22108774

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHZJCG
DE4LYSA	DN	Pentamidine isethionate
DE4LYSA	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMQYL9
DE4LYSA	DN	CC-223
DE4LYSA	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRQD04
DE4LYSA	DN	Tramadol hydrochloride
DE4LYSA	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKMWQG
DE4LYSA	DN	Olopatadine
DE4LYSA	RN	Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433826

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH75KV
DE4LYSA	DN	G-23350
DE4LYSA	RN	Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19843835

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWTPCA
DE4LYSA	DN	L-651582
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSPWMF
DE4LYSA	DN	Niguldipine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3YXP8
DE4LYSA	DN	PR-934423
DE4LYSA	RN	Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002 May;49(3):247-54.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12076846

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRTD16
DE4LYSA	DN	Talinolol
DE4LYSA	RN	Stereoselective disposition of talinolol in man. J Pharm Sci. 2002 Feb;91(2):303-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11835190

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1V5ZS
DE4LYSA	DN	Felbamate
DE4LYSA	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW210B
DE4LYSA	DN	Emopamil
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTW3R8
DE4LYSA	DN	Sulfadiazine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8JXPZ
DE4LYSA	DN	Glibenclamide
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5QF9V
DE4LYSA	DN	Tamsulosin
DE4LYSA	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJZHT1
DE4LYSA	DN	Tadalafil
DE4LYSA	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF6Y0L
DE4LYSA	DN	FCU-2711
DE4LYSA	RN	FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMX6OE3
DE4LYSA	DN	Dabrafenib mesylate
DE4LYSA	RN	Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29574693

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM93VBZ
DE4LYSA	DN	Abemaciclib
DE4LYSA	RN	LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]-Abemaciclib.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/books/NBK548807/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKNCVM
DE4LYSA	DN	JTT-705
DE4LYSA	RN	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin. 2009 Apr;25(4):891-902.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19245299

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6Q05K
DE4LYSA	DN	Dotarizine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMX9ZM4
DE4LYSA	DN	EZN-2208
DE4LYSA	RN	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23543270

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIV8CT
DE4LYSA	DN	Parecoxib
DE4LYSA	RN	Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice. J Pharm Biomed Anal. 2018 Sep 5;158:1-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29843006

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA17D0
DE4LYSA	DN	Dorzolamide hydrochloride
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD8Q3J
DE4LYSA	DN	Gemfibrozil
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3P5DA
DE4LYSA	DN	Rofecoxib
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMO0R76
DE4LYSA	DN	BS-572
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7XW5Y
DE4LYSA	DN	ABT-384
DE4LYSA	RN	Effect of ketoconazole on the pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos. 2013 May;41(5):1035-45.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23431112

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJYDVK
DE4LYSA	DN	Cariprazine hydrochloride
DE4LYSA	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML53ZJ
DE4LYSA	DN	Mirtazapine
DE4LYSA	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF3AN7
DE4LYSA	DN	Loratadine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPRI8G
DE4LYSA	DN	Buprenorphine hydrochloride
DE4LYSA	RN	Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20132117

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVN2E6
DE4LYSA	DN	AY-27,255
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM27U4Y
DE4LYSA	DN	Desogestrel
DE4LYSA	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMANBZI
DE4LYSA	DN	Abiraterone acetate
DE4LYSA	RN	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1TMA3
DE4LYSA	DN	Imiquimod
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYN8MA
DE4LYSA	DN	Tianeptine
DE4LYSA	RN	Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant? J Psychiatr Pract. 2004 Sep;10(5):323-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15361747

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNE56X
DE4LYSA	DN	ABT-263
DE4LYSA	RN	Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25047139

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJ2O7B
DE4LYSA	DN	Gemtuzumab ozogamicin
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPI98T
DE4LYSA	DN	Doxepin hydrochloride
DE4LYSA	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEQL9U
DE4LYSA	DN	CAM-2028
DE4LYSA	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOL793
DE4LYSA	DN	Trifarotene
DE4LYSA	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5PVQE
DE4LYSA	DN	Paroxetine hydrochloride
DE4LYSA	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML2A03
DE4LYSA	DN	Alosetron hydrochloride
DE4LYSA	RN	Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2001 Apr;41(4):452-4.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304902

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYNJHI
DE4LYSA	DN	ARC-029
DE4LYSA	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV9ADG
DE4LYSA	DN	Pilocarpine
DE4LYSA	RN	The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol. 1995 Feb;114(4):832-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7773543

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUZNIG
DE4LYSA	DN	Troleandomycin
DE4LYSA	RN	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica. 1996 Nov;26(11):1143-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948090

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGLAX1
DE4LYSA	DN	Halcinonide
DE4LYSA	RN	NCIthesaurus: Halcinonide
DE4LYSA	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47552&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHO0AR
DE4LYSA	DN	Ergocalciferol
DE4LYSA	RN	CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005856

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM29GAD
DE4LYSA	DN	Lumefantrine
DE4LYSA	RN	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017 Aug 30;106:20-33.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28546104

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHDF7B
DE4LYSA	DN	Thiamylal
DE4LYSA	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMODJ40
DE4LYSA	DN	Ethinyl estradiol
DE4LYSA	RN	Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15554232

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZ7XNQ
DE4LYSA	DN	Tacrolimus
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLK2QH
DE4LYSA	DN	Nateglinide
DE4LYSA	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2VOQ3
DE4LYSA	DN	Mosapride
DE4LYSA	RN	The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos. 2000 Oct;28(10):1231-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997945

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMERM0K
DE4LYSA	DN	RS-8359
DE4LYSA	RN	Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Chirality. 2005 Mar;17(3):135-41.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15704197

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHN027
DE4LYSA	DN	Levothyroxine sodium
DE4LYSA	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5GFIK
DE4LYSA	DN	BPI-2009
DE4LYSA	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9OZWQ
DE4LYSA	DN	Lovastatin
DE4LYSA	RN	Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11475198

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4UAPD
DE4LYSA	DN	EPX-100
DE4LYSA	RN	Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
DE4LYSA	RU	https://pubmed.ncbi.nlm.nih.gov/23143674

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM1JL9
DE4LYSA	DN	Amcinonide
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOH8VY
DE4LYSA	DN	Dacomitinib
DE4LYSA	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3VFPD
DE4LYSA	DN	Troglitazone
DE4LYSA	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVE3TK
DE4LYSA	DN	Bromocriptine mesylate
DE4LYSA	RN	Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16229479

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1DBV5
DE4LYSA	DN	Dexlansoprazole
DE4LYSA	RN	Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22455762

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY4UMW
DE4LYSA	DN	Atovaquone
DE4LYSA	RN	Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/11956669

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8RZ9H
DE4LYSA	DN	Eszopiclone
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2NUH3
DE4LYSA	DN	Imipramine hydrochloride
DE4LYSA	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0D9YJ
DE4LYSA	DN	Dirithromycin
DE4LYSA	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUL5EW
DE4LYSA	DN	Posaconazole
DE4LYSA	RN	Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20181649

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUY35B
DE4LYSA	DN	Progesterone
DE4LYSA	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBGUDR
DE4LYSA	DN	SPC-100270
DE4LYSA	RN	Sex differences in rat hepatic cytolethality of the protein kinase C inhibitor safingol: role of biotransformation. Toxicol Appl Pharmacol. 1996 Apr;137(2):173-81.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8661342

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCT2YF
DE4LYSA	DN	Q-100155
DE4LYSA	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZPHIK
DE4LYSA	DN	Beclomethasone dipropionate
DE4LYSA	RN	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23512537

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGJCDR
DE4LYSA	DN	MP-513
DE4LYSA	RN	Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. J Clin Pharm Ther. 2019 Oct;44(5):720-725.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31094010

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTWS9E
DE4LYSA	DN	Apremilast
DE4LYSA	RN	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27869356

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2R86O
DE4LYSA	DN	BAF-312
DE4LYSA	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDHYM7
DE4LYSA	DN	CP-529414
DE4LYSA	RN	Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008 Nov;36(11):2185-98.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18694908

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP2BFG
DE4LYSA	DN	MK-0859
DE4LYSA	RN	Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010 Mar;38(3):474-83.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20016053

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP6SC2
DE4LYSA	DN	Irinotecan hydrochloride
DE4LYSA	RN	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19852077

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYILBE
DE4LYSA	DN	Modafinil
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC0GSJ
DE4LYSA	DN	Efavirenz
DE4LYSA	RN	Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15496645

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSYRBX
DE4LYSA	DN	Atazanavir
DE4LYSA	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7MT6E
DE4LYSA	DN	Prasugrel hydrochloride
DE4LYSA	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM08E9O
DE4LYSA	DN	Diazepam
DE4LYSA	RN	Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487724

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2AOTZ
DE4LYSA	DN	Perazine
DE4LYSA	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLB0EZ
DE4LYSA	DN	Tamoxifen citrate
DE4LYSA	RN	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15159443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML0B41
DE4LYSA	DN	Naloxegol oxalate
DE4LYSA	RN	Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25471070

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCMT4V
DE4LYSA	DN	NOVA-63035
DE4LYSA	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT6E5N
DE4LYSA	DN	ZK-299
DE4LYSA	RN	Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16330661

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOMK1V
DE4LYSA	DN	Halofantrine
DE4LYSA	RN	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426515

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMI6E0R
DE4LYSA	DN	Midostaurin
DE4LYSA	RN	Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28270565

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMERWUC
DE4LYSA	DN	BRN-3148038
DE4LYSA	RN	Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica. 2002 Feb;32(2):109-18.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11871398

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCMBHA
DE4LYSA	DN	Erlotinib hydrochloride
DE4LYSA	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5N1OB
DE4LYSA	DN	ASP-2151
DE4LYSA	RN	Amenamevir: studies of potential CYP3A-mediated pharmacokinetic interactions with midazolam, cyclosporine, and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):844-859.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30044899

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJ8AUE
DE4LYSA	DN	Y-100032
DE4LYSA	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1TJXA
DE4LYSA	DN	FT-0755769
DE4LYSA	RN	Metabolism of benzalkonium chlorides by human hepatic cytochromes P450. Chem Res Toxicol. 2019 Dec 16;32(12):2466-2478.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31730751

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5UGDK
DE4LYSA	DN	Mephenytoin
DE4LYSA	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML0RAE
DE4LYSA	DN	Methoxyflurane
DE4LYSA	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXYJ9C
DE4LYSA	DN	Busulfan
DE4LYSA	RN	Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9469685

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQXYRG
DE4LYSA	DN	NSC-603071
DE4LYSA	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFI46A
DE4LYSA	DN	Argatroban
DE4LYSA	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8MC6O
DE4LYSA	DN	Estradiol valerate
DE4LYSA	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM82Z30
DE4LYSA	DN	Topiramate
DE4LYSA	RN	Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14636322

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSV12M
DE4LYSA	DN	Isavuconazole
DE4LYSA	RN	Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27273461

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVP5YE
DE4LYSA	DN	Doxorubicin
DE4LYSA	RN	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17279585

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCA7LN
DE4LYSA	DN	Oxycodone hydrochloride
DE4LYSA	RN	Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26227254

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3GTAL
DE4LYSA	DN	SHP-620
DE4LYSA	RN	Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16569820

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFKXDY
DE4LYSA	DN	Fenofibrate
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZD5QR
DE4LYSA	DN	Cytarabine
DE4LYSA	RN	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181153

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME7VZD
DE4LYSA	DN	BAY-1002670
DE4LYSA	RN	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29330782

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6JTSZ
DE4LYSA	DN	MB-07811
DE4LYSA	RN	Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18703645

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3BH1Y
DE4LYSA	DN	Lapatinib ditosylate
DE4LYSA	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFRM1I
DE4LYSA	DN	Canagliflozin
DE4LYSA	RN	Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26185406

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4MDJY
DE4LYSA	DN	Fluvastatin sodium
DE4LYSA	RN	Effects of fluvastatin on the pharmacokinetics of eepaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by fluvastatin. Korean J Physiol Pharmacol. 2013 Jun;17(3):245-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23776402

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM36C17
DE4LYSA	DN	AD-5423
DE4LYSA	RN	Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587-94.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23766647

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWV3TZ
DE4LYSA	DN	Finasteride
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBDAZV
DE4LYSA	DN	Amlodipine maleate
DE4LYSA	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG5C8D
DE4LYSA	DN	GS-9620
DE4LYSA	RN	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25733157

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFJTDI
DE4LYSA	DN	Sibutramine
DE4LYSA	RN	Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10492502

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBY31K
DE4LYSA	DN	CS-011
DE4LYSA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4BDON
DE4LYSA	DN	Methylprednisolone
DE4LYSA	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3FIC2
DE4LYSA	DN	ABT-761
DE4LYSA	RN	Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos. 1998 Oct;26(10):970-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763401

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYHDCA
DE4LYSA	DN	Pranlukast
DE4LYSA	RN	Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. Drug Metab Pharmacokinet. 2008;23(6):428-33.;
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19122337

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUNTE3
DE4LYSA	DN	E-3A
DE4LYSA	RN	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22837389

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFK9HG
DE4LYSA	DN	Escitalopram
DE4LYSA	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR8ONJ
DE4LYSA	DN	Leflunomide
DE4LYSA	RN	Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015 May 18;28(5):872-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25860621

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME8FZ9
DE4LYSA	DN	Methoxsalen
DE4LYSA	RN	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003103

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4KLPT
DE4LYSA	DN	Terfenadine
DE4LYSA	RN	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSEVBH
DE4LYSA	DN	UK-453,061
DE4LYSA	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJPGUA
DE4LYSA	DN	CV-4093
DE4LYSA	RN	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669846

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK1ZOR
DE4LYSA	DN	Vincamine
DE4LYSA	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFA5MY
DE4LYSA	DN	Metoclopramide hydrochloride
DE4LYSA	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHO56W
DE4LYSA	DN	Equilenin
DE4LYSA	RN	The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin. Chem Biol Interact. 2012 Mar 5;196(1-2):1-10.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22290292

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAL4G0
DE4LYSA	DN	Flurazepam
DE4LYSA	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN4ZKC
DE4LYSA	DN	Paraoxon
DE4LYSA	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0ZOGX
DE4LYSA	DN	DUP-996
DE4LYSA	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCYVDT
DE4LYSA	DN	Chlorzoxazone
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2POTE
DE4LYSA	DN	Colchicine
DE4LYSA	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGFWSM
DE4LYSA	DN	Zaleplon
DE4LYSA	RN	Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12419014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSI5CB
DE4LYSA	DN	Chloroquine
DE4LYSA	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW4M97
DE4LYSA	DN	Clevidipine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRPU10
DE4LYSA	DN	BMS-488043
DE4LYSA	RN	Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21078951

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHSY1I
DE4LYSA	DN	Regorafenib
DE4LYSA	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMFCIH
DE4LYSA	DN	Clotrimazole
DE4LYSA	RN	Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21037909

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZ4P3A
DE4LYSA	DN	Telithromycin
DE4LYSA	RN	Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16556082

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBUNVW
DE4LYSA	DN	Prednicarbate
DE4LYSA	RN	HEP Drug interaction: daclatasvir and abacavir.
DE4LYSA	RU	https://hep-druginteractions.org/interactions/1205/all

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWGRQD
DE4LYSA	DN	LU-AE58054
DE4LYSA	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR5ZUP
DE4LYSA	DN	Paramethadione
DE4LYSA	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMTW9K
DE4LYSA	DN	SCH-417690
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVRIC2
DE4LYSA	DN	Zileuton
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHZCPO
DE4LYSA	DN	Ibrutinib
DE4LYSA	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXNZM4
DE4LYSA	DN	Oxazepam
DE4LYSA	RN	Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng. 2000 Apr;2(2):115-25.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10935727

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7A8TW
DE4LYSA	DN	Ezetimibe
DE4LYSA	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6A4NW
DE4LYSA	DN	Etoricoxib
DE4LYSA	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUDJZM
DE4LYSA	DN	Dextromethorphan hydrobromide
DE4LYSA	RN	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11602530

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTW6IU
DE4LYSA	DN	Methadone
DE4LYSA	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7GCVW
DE4LYSA	DN	Acalabrutinib
DE4LYSA	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM783CH
DE4LYSA	DN	Levobupivacaine
DE4LYSA	RN	Clinical profile of levobupivacaine in regional anesthesia: A systematic review. J Anaesthesiol Clin Pharmacol. 2013 Oct;29(4):530-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24249993

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMINOX3
DE4LYSA	DN	Vincristine sulfate
DE4LYSA	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYP4XC
DE4LYSA	DN	Norgestimate
DE4LYSA	RN	Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28283499

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSPJG2
DE4LYSA	DN	Ropivacaine hydrochloride
DE4LYSA	RN	Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology. 1995 Jan;82(1):214-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7832304

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCS6M5
DE4LYSA	DN	Voxelotor
DE4LYSA	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSFK9V
DE4LYSA	DN	Daclatasvir dihydrochloride
DE4LYSA	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWO5ZR
DE4LYSA	DN	AZD-2171
DE4LYSA	RN	In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20634336

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV0RNS
DE4LYSA	DN	Deflazacort
DE4LYSA	RN	Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos. 2019 Feb;47(2):135-144.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30442649

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0PHEW
DE4LYSA	DN	Erythromycin salnacedin
DE4LYSA	RN	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM15F0X
DE4LYSA	DN	Gefitinib
DE4LYSA	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDBX5F
DE4LYSA	DN	Ivermectin
DE4LYSA	RN	Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998 Mar;28(3):313-21.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9574819

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0DTF7
DE4LYSA	DN	Zonisamide
DE4LYSA	RN	Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319920

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4PRFC
DE4LYSA	DN	Bupivacaine hydrochloride
DE4LYSA	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLMXE0
DE4LYSA	DN	Amprenavir
DE4LYSA	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM21C09
DE4LYSA	DN	BRN-0498823
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTIVEN
DE4LYSA	DN	Metronidazole
DE4LYSA	RN	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17374625

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMB4OLE
DE4LYSA	DN	Propofol
DE4LYSA	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTGBAX
DE4LYSA	DN	Pomalidomide
DE4LYSA	RN	Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015 Feb;55(2):168-78.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25159194

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUANF3
DE4LYSA	DN	MLN-8054
DE4LYSA	RN	MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett. 2015 Apr 22;6(6):630-4.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26101564

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMICDLV
DE4LYSA	DN	Lorlatinib
DE4LYSA	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1F42Z
DE4LYSA	DN	KW-4354
DE4LYSA	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM7CHK
DE4LYSA	DN	Trimethoprim
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBDPY0
DE4LYSA	DN	KW-5338
DE4LYSA	RN	Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21281268

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7RJXL
DE4LYSA	DN	Imatinib mesylate
DE4LYSA	RN	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22014153

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLZIT2
DE4LYSA	DN	GTPL-463
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKBJWP
DE4LYSA	DN	Caffeine
DE4LYSA	RN	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17652830

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7NPJS
DE4LYSA	DN	Paliperidone
DE4LYSA	RN	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18708991

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPZI3Q
DE4LYSA	DN	Ketoconazole
DE4LYSA	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6VFO1
DE4LYSA	DN	Pregnenolone
DE4LYSA	RN	Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb;36(2):435-41.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048490

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFI7A8
DE4LYSA	DN	O-Benzylguanine
DE4LYSA	RN	Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7503788

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNH3PG
DE4LYSA	DN	Etoposide
DE4LYSA	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5URA2
DE4LYSA	DN	Chlorpheniramine
DE4LYSA	RN	Drug Interactions Flockhart Table
DE4LYSA	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM160FM
DE4LYSA	DN	Darodipine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY7PED
DE4LYSA	DN	Cisapride
DE4LYSA	RN	Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621386

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGV8QU
DE4LYSA	DN	Etravirine
DE4LYSA	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2KQ71
DE4LYSA	DN	PNU-100480
DE4LYSA	RN	TB and HIV therapeutics: pharmacology research priorities. AIDS Res Treat. 2012;2012:874083.
DE4LYSA	RU	https://www.hindawi.com/journals/art/2012/874083/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSHPW8
DE4LYSA	DN	Tolterodine tartrate
DE4LYSA	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR1NMD
DE4LYSA	DN	Nimesulide
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0VEC1
DE4LYSA	DN	Ergometrine
DE4LYSA	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH07Y3
DE4LYSA	DN	Letrozole
DE4LYSA	RN	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19198839

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCIJBH
DE4LYSA	DN	Edoxaban
DE4LYSA	RN	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27530188

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHKJ5I
DE4LYSA	DN	GW-1000
DE4LYSA	RN	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23621668

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV41P5
DE4LYSA	DN	JNJ-37822681
DE4LYSA	RN	CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo. International Clinical Psychopharmacology, 2006, 21(4):A33.
DE4LYSA	RU	https://www.researchgate.net/figure/Cloning-and-expression-CYP3A43-and-CYP3A4-and-metabolism-of-alprazolam-in-vitro-by_fig13_5310993

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTBGW8
DE4LYSA	DN	Vardenafil hydrochloride
DE4LYSA	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM83EBP
DE4LYSA	DN	DEB-025
DE4LYSA	RN	Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013;7:105-15.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23440335

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8XP26
DE4LYSA	DN	Rolapitant hydrochloride
DE4LYSA	RN	Pharmacokinetic interactions of rolapitant with cytochrome P450 3A substrates in healthy subjects. J Clin Pharmacol. 2019 Apr;59(4):488-499.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30422319

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTO13J
DE4LYSA	DN	Clonazepam
DE4LYSA	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOJZQ9
DE4LYSA	DN	Loperamide hydrochloride
DE4LYSA	RN	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18192961

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9H34M
DE4LYSA	DN	Benzodiazepine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4O2Z7
DE4LYSA	DN	Cyclophosphamide
DE4LYSA	RN	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29129847

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM5ZX6
DE4LYSA	DN	EPO-906
DE4LYSA	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18451235

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6QHDJ
DE4LYSA	DN	RO-7-0207
DE4LYSA	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM96SE0
DE4LYSA	DN	Haloperidol decanoate
DE4LYSA	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQ8FR2
DE4LYSA	DN	Prednisolone
DE4LYSA	RN	Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19795924

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTAREC
DE4LYSA	DN	Rimexolone
DE4LYSA	RN	Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011 Jan;39(1):151-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20966043

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9HPW3
DE4LYSA	DN	Exemestane
DE4LYSA	RN	In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28603633

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT2EJP
DE4LYSA	DN	Podophyllotoxin
DE4LYSA	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM23HCX
DE4LYSA	DN	Dextropropoxyphene
DE4LYSA	RN	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764408

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1O0DV
DE4LYSA	DN	ICN-2001-3
DE4LYSA	RN	Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16940083

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF98Q0
DE4LYSA	DN	CYT-387
DE4LYSA	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAYTRK
DE4LYSA	DN	H3B-6527
DE4LYSA	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU7YEL
DE4LYSA	DN	Sufentanil
DE4LYSA	RN	Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9264313

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNORK8
DE4LYSA	DN	Ruxolitinib phosphate
DE4LYSA	RN	Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23061804

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM80OZ5
DE4LYSA	DN	Halothane
DE4LYSA	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM72JXH
DE4LYSA	DN	Losartan potassium
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMX0K3Q
DE4LYSA	DN	Epinastine
DE4LYSA	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV7YFT
DE4LYSA	DN	Darolutamide
DE4LYSA	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPYQ7B
DE4LYSA	DN	Trimebutine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8WAHT
DE4LYSA	DN	Fentanyl citrate
DE4LYSA	RN	Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490933

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJYCVW
DE4LYSA	DN	Warfarin sodium
DE4LYSA	RN	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615193

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM58WKG
DE4LYSA	DN	Panobinostat lactate
DE4LYSA	RN	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26503877

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNOKBV
DE4LYSA	DN	Phenytoin
DE4LYSA	RN	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15247556

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME5Y64
DE4LYSA	DN	Tranilast
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJV2EK
DE4LYSA	DN	Dasatinib
DE4LYSA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBHO9Y
DE4LYSA	DN	Adinazolam
DE4LYSA	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME6G97
DE4LYSA	DN	Lefamulin
DE4LYSA	RN	Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30019769

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKSQG0
DE4LYSA	DN	Tiagabine
DE4LYSA	RN	Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11030437

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBS370
DE4LYSA	DN	Tofacitinib citrate
DE4LYSA	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGC5DB
DE4LYSA	DN	Ciprofibrate
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMS104F
DE4LYSA	DN	Temsirolimus
DE4LYSA	RN	Drug Interactions Flockhart Table
DE4LYSA	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8HJX6
DE4LYSA	DN	Tipranavir
DE4LYSA	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAE84F
DE4LYSA	DN	Alclometasone
DE4LYSA	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAKIDV
DE4LYSA	DN	Dydrogesterone
DE4LYSA	RN	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26796435

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK4S8I
DE4LYSA	DN	Promegestone
DE4LYSA	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDNJHG
DE4LYSA	DN	Aztreonam
DE4LYSA	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXBHR6
DE4LYSA	DN	DRF-2593
DE4LYSA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM20VSK
DE4LYSA	DN	Istradefylline
DE4LYSA	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4W9B3
DE4LYSA	DN	Fosamprenavir
DE4LYSA	RN	Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16485915

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRJFN9
DE4LYSA	DN	Theophylline
DE4LYSA	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZSWQC
DE4LYSA	DN	Flunisolide
DE4LYSA	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3WP0N
DE4LYSA	DN	Al3-818
DE4LYSA	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEWC7N
DE4LYSA	DN	Prazepam
DE4LYSA	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSPN58
DE4LYSA	DN	WY-1485
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMME8LH
DE4LYSA	DN	Alitretinoin
DE4LYSA	RN	Alitretinoin in dermatology-an update. Indian J Dermatol. 2015 Sep-Oct;60(5):520.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26538721

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEKAYI
DE4LYSA	DN	R-1124
DE4LYSA	RN	Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019 Apr;59(4):472-487.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30412271

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAOJBX
DE4LYSA	DN	CBT-1
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVO0UB
DE4LYSA	DN	Alfentanil
DE4LYSA	RN	Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15731592

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRICNP
DE4LYSA	DN	Vandetanib
DE4LYSA	RN	FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3NF5G
DE4LYSA	DN	Delavirdine mesylate
DE4LYSA	RN	Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11327199

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG6TS2
DE4LYSA	DN	GW-873140
DE4LYSA	RN	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18070967

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2AR7L
DE4LYSA	DN	Meloxicam
DE4LYSA	RN	Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10381752

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZ6YPV
DE4LYSA	DN	Cyamemazine
DE4LYSA	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCHV4I
DE4LYSA	DN	Rifapentine
DE4LYSA	RN	Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26094899

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMK42O
DE4LYSA	DN	FCF-89
DE4LYSA	RN	Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica. 2000 Sep;30(9):905-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11055268

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQH1NV
DE4LYSA	DN	MKC-442
DE4LYSA	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWT905
DE4LYSA	DN	Mefloquine hydrochloride
DE4LYSA	RN	Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11092571

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM053KT
DE4LYSA	DN	Aprepitant
DE4LYSA	RN	Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15723220

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYGJQO
DE4LYSA	DN	Ponatinib hydrochloride
DE4LYSA	RN	Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27137144

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM30SGU
DE4LYSA	DN	Simvastatin
DE4LYSA	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMB1N6P
DE4LYSA	DN	Clobetasol propionate
DE4LYSA	RN	Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304077

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLHOA0
DE4LYSA	DN	Alfuzosin hydrochloride
DE4LYSA	RN	Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15555475

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3NUMH
DE4LYSA	DN	Aripiprazole lauroxil
DE4LYSA	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJCP1Y
DE4LYSA	DN	Yohimbine
DE4LYSA	RN	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004 Aug;76(2):139-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289791

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV6KFY
DE4LYSA	DN	Dapoxetine
DE4LYSA	RN	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
DE4LYSA	RU	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2003.11.123

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1N62C
DE4LYSA	DN	Quetiapine fumarate
DE4LYSA	RN	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22688609

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTQLIJ
DE4LYSA	DN	Amlodipine besylate
DE4LYSA	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGN1PW
DE4LYSA	DN	Indapamide
DE4LYSA	RN	Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19074530

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9S2JW
DE4LYSA	DN	BRN-3224996
DE4LYSA	RN	Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010 Feb 23;121(7):934-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20177008

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBI4JG
DE4LYSA	DN	Isosorbide dinitrate
DE4LYSA	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOJ0V6
DE4LYSA	DN	Metoprolol succinate
DE4LYSA	RN	Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
DE4LYSA	RU	https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBGWPH
DE4LYSA	DN	Medroxyprogesterone acetate
DE4LYSA	RN	Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18725509

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM92S6N
DE4LYSA	DN	Levamlodipine
DE4LYSA	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTL9IP
DE4LYSA	DN	Meprednisone
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM89JLN
DE4LYSA	DN	Apixaban
DE4LYSA	RN	In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19940026

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCMDVR
DE4LYSA	DN	PG-490
DE4LYSA	RN	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30112986

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5H0R9
DE4LYSA	DN	LY-317615
DE4LYSA	RN	Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs. 2013 Jun;31(3):653-60.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22766773

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMICMXE
DE4LYSA	DN	SSR-97193
DE4LYSA	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1D8XY
DE4LYSA	DN	Dantrolene sodium
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM983QP
DE4LYSA	DN	Manidipine 2HCl
DE4LYSA	RN	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669846

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2HG4X
DE4LYSA	DN	Prednisone
DE4LYSA	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIYDT4
DE4LYSA	DN	Cabozantinib
DE4LYSA	RN	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29089775

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMWZET
DE4LYSA	DN	Dexamethasone acetate
DE4LYSA	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMO14SG
DE4LYSA	DN	Mebendazole
DE4LYSA	RN	Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection. 2004 Oct;32(5):299-302.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15624896

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG3F94
DE4LYSA	DN	Mestranol
DE4LYSA	RN	Prescribrt's digital referenve - Ethinyl estradiol/norethindrone; mestranol/norethindrone - Drug Summary
DE4LYSA	RU	http://www.pdr.net/drug-summary/Necon-ethinyl-estradiol-norethindrone----mestranol-norethindrone-2049

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPIBJK
DE4LYSA	DN	Propafenone hydrochloride
DE4LYSA	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3VR1L
DE4LYSA	DN	Selegiline hydrochloride
DE4LYSA	RN	P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17495414

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPC1J7
DE4LYSA	DN	Clofibrate
DE4LYSA	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIUW25
DE4LYSA	DN	Granisetron hydrochloride
DE4LYSA	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGB035
DE4LYSA	DN	Armodafinil
DE4LYSA	RN	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18076219

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM602WT
DE4LYSA	DN	Idelalisib
DE4LYSA	RN	FDA label of Idelalisib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOX3LB
DE4LYSA	DN	Fosphenytoin sodium
DE4LYSA	RN	Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013 Jul;4(4):263-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25032007

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1EO3G
DE4LYSA	DN	MK-0822
DE4LYSA	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUIBV8
DE4LYSA	DN	NE-10064
DE4LYSA	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMACBIW
DE4LYSA	DN	WIN 55212-2
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSRZAO
DE4LYSA	DN	Eliglustat tartrate
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8QB1D
DE4LYSA	DN	Olaparib
DE4LYSA	RN	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25981132

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMIQ7G
DE4LYSA	DN	Rosuvastatin
DE4LYSA	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGLX0T
DE4LYSA	DN	Grepafloxacin
DE4LYSA	RN	MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18040809

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3IWS8
DE4LYSA	DN	TV-5600
DE4LYSA	RN	Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011 Mar;26(2):111-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21163185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0YZC6
DE4LYSA	DN	Fulvestrant
DE4LYSA	RN	Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006 Sep;40(9):1572-83.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16912252

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM67VKL
DE4LYSA	DN	Dehydroepiandrosterone
DE4LYSA	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNSJ7V
DE4LYSA	DN	Tropisetron
DE4LYSA	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0FB1J
DE4LYSA	DN	Sertraline hydrochloride
DE4LYSA	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJSKUI
DE4LYSA	DN	Norcisapride
DE4LYSA	RN	Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717173

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8X2EH
DE4LYSA	DN	Everolimus
DE4LYSA	RN	The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15041395

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3UZ95
DE4LYSA	DN	Bisoprolol
DE4LYSA	RN	Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763205

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN9CWF
DE4LYSA	DN	Salbutamol
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSBZ29
DE4LYSA	DN	Agmatine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2NA4K
DE4LYSA	DN	Ciclesonide
DE4LYSA	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOTQ1I
DE4LYSA	DN	Ondansetron
DE4LYSA	RN	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223773

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZ0Q1G
DE4LYSA	DN	Permethrin
DE4LYSA	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGXENV
DE4LYSA	DN	Saxagliptin hydrochloride
DE4LYSA	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQMBZ1
DE4LYSA	DN	Rivaroxaban
DE4LYSA	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1DX4Q
DE4LYSA	DN	Eribulin
DE4LYSA	RN	Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18431572

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMZXIW
DE4LYSA	DN	Rabeprazole sodium
DE4LYSA	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTWLXY
DE4LYSA	DN	LCZ-696
DE4LYSA	RN	FDA label of Sacubitril and valsartan. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGEMB7
DE4LYSA	DN	Hydrocortisone
DE4LYSA	RN	Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10772626

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9ERH1
DE4LYSA	DN	AG-1549
DE4LYSA	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF5EK1
DE4LYSA	DN	Vilanterol
DE4LYSA	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23116485

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUHCF1
DE4LYSA	DN	Fluoxymesterone
DE4LYSA	RN	Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2880590

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTD7AB
DE4LYSA	DN	SB-939
DE4LYSA	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEGFYD
DE4LYSA	DN	LAS-17177
DE4LYSA	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG592Q
DE4LYSA	DN	Solifenacin succinate
DE4LYSA	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSOPAU
DE4LYSA	DN	PD-115934
DE4LYSA	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUTEX3
DE4LYSA	DN	Amiodarone hydrochloride
DE4LYSA	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIEU69
DE4LYSA	DN	Salmeterol xinafoate
DE4LYSA	RN	Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11825095

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAY7H4
DE4LYSA	DN	Valdecoxib
DE4LYSA	RN	Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12657846

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCZWOK
DE4LYSA	DN	BRN-5220127
DE4LYSA	RN	An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos. 1999 Jul;27(7):776-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383920

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT5GNL
DE4LYSA	DN	Romidepsin
DE4LYSA	RN	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21377994

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV23GL
DE4LYSA	DN	Lidoflazine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3IJMN
DE4LYSA	DN	CB-44212
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC7XDN
DE4LYSA	DN	Alprazolam
DE4LYSA	RN	No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15856409

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLQVTJ
DE4LYSA	DN	Octopamine
DE4LYSA	RN	Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol. 2001 Oct;41(10):1059-63.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11583473

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOU1PK
DE4LYSA	DN	Praziquantel
DE4LYSA	RN	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17357589

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGCSVF
DE4LYSA	DN	Fluticasone furoate
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUVMWZ
DE4LYSA	DN	LAS-X-113
DE4LYSA	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5A31S
DE4LYSA	DN	Eravacycline
DE4LYSA	RN	Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01810-18.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30559132

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWVIGP
DE4LYSA	DN	Digitoxin
DE4LYSA	RN	Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1944247

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG3NFZ
DE4LYSA	DN	BMS-298585
DE4LYSA	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5SYZP
DE4LYSA	DN	Disopyramide phosphate
DE4LYSA	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP0OVQ
DE4LYSA	DN	Gestrinone
DE4LYSA	RN	Adverse drug interactions: a handbook for prescribers. Taylor and Francis group.2010.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040554/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCYANK
DE4LYSA	DN	Doxapram hydrochloride
DE4LYSA	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM13DI
DE4LYSA	DN	ANA-756
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW6ZJI
DE4LYSA	DN	Levocetirizine
DE4LYSA	RN	FDA label of Levocetirizine dihydrochloride. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6AUFY
DE4LYSA	DN	Iloperidone
DE4LYSA	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM48QOT
DE4LYSA	DN	Artemether
DE4LYSA	RN	The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999 Oct;66(4):408-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10546925

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4LT8A
DE4LYSA	DN	Dapsone
DE4LYSA	RN	Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8742227

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY89KQ
DE4LYSA	DN	Flosequinan
DE4LYSA	RN	Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. Drug Metab Dispos. 1997 Jun;25(6):716-24.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9193873

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOBIKY
DE4LYSA	DN	Bexarotene
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOL54H
DE4LYSA	DN	Clopidogrel bisulfate
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8LGWR
DE4LYSA	DN	LY-2811376
DE4LYSA	RN	Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22090477

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKC0J5
DE4LYSA	DN	GW-766994
DE4LYSA	RN	GW766994 CCR3 receptor antagonist.
DE4LYSA	RU	https://mrc.ukri.org/funding/browse/mrc-industry-asset-sharing-initiative-2016/compounds-list-2016/ccr3-receptor-antagonist/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBQPA5
DE4LYSA	DN	GBR-12909
DE4LYSA	RN	Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11502731

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV50R1
DE4LYSA	DN	HE-3235
DE4LYSA	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DE4LYSA	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1975O
DE4LYSA	DN	FRC-8653
DE4LYSA	RN	Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin. 2003 Mar;24(3):263-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12617777

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAOL2S
DE4LYSA	DN	Voriconazole
DE4LYSA	RN	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17433262

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME0TC8
DE4LYSA	DN	KB-2796
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIMF8J
DE4LYSA	DN	RG-7916
DE4LYSA	RN	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019 Jan;85(1):181-193.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30302786

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0YROF
DE4LYSA	DN	Ethylmorphine
DE4LYSA	RN	Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997 May;18(5):1085-92.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9163700

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5SXUV
DE4LYSA	DN	Repaglinide
DE4LYSA	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM26PRD
DE4LYSA	DN	Reboxetine
DE4LYSA	RN	Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192474

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIG8DW
DE4LYSA	DN	Dexamethasone sodium phosphate
DE4LYSA	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8WI3R
DE4LYSA	DN	Alogliptin
DE4LYSA	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIYG7Z
DE4LYSA	DN	Donepezil hydrochloride
DE4LYSA	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMI782S
DE4LYSA	DN	Erdafitinib
DE4LYSA	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPN1TW
DE4LYSA	DN	Dofetilide
DE4LYSA	RN	Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801060

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMPTLH
DE4LYSA	DN	Entrectinib
DE4LYSA	RN	Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31372957

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0659E
DE4LYSA	DN	Cannabidiol
DE4LYSA	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU8L7C
DE4LYSA	DN	CBL-0102
DE4LYSA	RN	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16581945

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6HX9B
DE4LYSA	DN	Nevirapine
DE4LYSA	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRQAM0
DE4LYSA	DN	Phenacetin
DE4LYSA	RN	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421611

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3OWT4
DE4LYSA	DN	Tinidazole
DE4LYSA	RN	FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1UV7F
DE4LYSA	DN	Baloxavir marboxil
DE4LYSA	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDI269
DE4LYSA	DN	Docetaxel
DE4LYSA	RN	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15657405

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF8Y74
DE4LYSA	DN	Hydroxyzine
DE4LYSA	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DE4LYSA	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTI8YE
DE4LYSA	DN	Bosutinib
DE4LYSA	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAI7ZV
DE4LYSA	DN	Diltiazem hydrochloride
DE4LYSA	RN	Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124305

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSIVND
DE4LYSA	DN	Hydroxychloroquine sulfate
DE4LYSA	RN	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29438998

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMP65N
DE4LYSA	DN	Sertindole
DE4LYSA	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2HKC4
DE4LYSA	DN	Fluorometholone
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZFIGQ
DE4LYSA	DN	SB-1317
DE4LYSA	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHG57U
DE4LYSA	DN	Brexpiprazole
DE4LYSA	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM70IK5
DE4LYSA	DN	Dronabinol
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR6QH0
DE4LYSA	DN	Venlafaxine hydrochloride
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZGXUM
DE4LYSA	DN	Estazolam
DE4LYSA	RN	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16012077

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC3JST
DE4LYSA	DN	Clorazepic acid
DE4LYSA	RN	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11251565

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPWSEM
DE4LYSA	DN	TJN-324
DE4LYSA	RN	Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1(3):173-82.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319103

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBL79I
DE4LYSA	DN	Proguanil
DE4LYSA	RN	In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501186

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1SMAI
DE4LYSA	DN	DW-1030
DE4LYSA	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHIDUE
DE4LYSA	DN	Phenelzine
DE4LYSA	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNUWST
DE4LYSA	DN	Flucloxacillin
DE4LYSA	RN	Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30447161

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMX0E5B
DE4LYSA	DN	Bimatoprost
DE4LYSA	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DE4LYSA	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7U5QJ
DE4LYSA	DN	Cinnarizine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWSMND
DE4LYSA	DN	Cevimeline hydrochloride
DE4LYSA	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF0NQR
DE4LYSA	DN	Eplerenone
DE4LYSA	RN	Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14503934

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDZ9LT
DE4LYSA	DN	Ethosuximide
DE4LYSA	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLOQ1V
DE4LYSA	DN	Tasimelteon
DE4LYSA	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6QOVN
DE4LYSA	DN	Neratinib
DE4LYSA	RN	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27284682

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG9B1U
DE4LYSA	DN	Elvitegravir
DE4LYSA	RN	FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203100s030lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME2A8X
DE4LYSA	DN	HSDB-3466
DE4LYSA	RN	Metabolism of 5-methoxypsoralen by Saccharomyces cerevisiae. Photochem Photobiol. 1991 Nov;54(5):689-95.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1798745

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZIXU9
DE4LYSA	DN	Dihydralazine
DE4LYSA	RN	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDO279
DE4LYSA	DN	Phenprocoumon
DE4LYSA	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA7PEW
DE4LYSA	DN	Verapamil hydrochloride
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCBJSR
DE4LYSA	DN	Sunitinib malate
DE4LYSA	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM215WE
DE4LYSA	DN	Doravirine
DE4LYSA	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM15HL8
DE4LYSA	DN	Clindamycin
DE4LYSA	RN	In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814964

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF2KLU
DE4LYSA	DN	Oxybutynin chloride
DE4LYSA	RN	A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20428289

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM58JY
DE4LYSA	DN	Ziprasidone
DE4LYSA	RN	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537577

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8VCBE
DE4LYSA	DN	Ibuprofen
DE4LYSA	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZM84R
DE4LYSA	DN	Ethynodiol diacetate
DE4LYSA	RN	News and information in drug research: Ethynodiol diacetate.
DE4LYSA	RU	http://genelabs.com/drugsdb/details/ethynodiol-diacetate/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0IO13
DE4LYSA	DN	CCRIS-1920
DE4LYSA	RN	Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther. 1997 Jul-Aug;4(7-8):229-38.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10423615

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSY4ZG
DE4LYSA	DN	Tenofovir disoproxil fumarate
DE4LYSA	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM59AZT
DE4LYSA	DN	Clotiazepam
DE4LYSA	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP9TWZ
DE4LYSA	DN	Corticotropin
DE4LYSA	RN	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPGHY8
DE4LYSA	DN	Roflumilast
DE4LYSA	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGX5Q0
DE4LYSA	DN	Org-33062
DE4LYSA	RN	Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15057659

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVKA4O
DE4LYSA	DN	Mianserin
DE4LYSA	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUDIR8
DE4LYSA	DN	Fludrocortisone
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA6S1D
DE4LYSA	DN	Ropinirole hydrochloride
DE4LYSA	RN	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9224778

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM20MDU
DE4LYSA	DN	RO-5190591
DE4LYSA	RN	Comprehensive Medicinal Chemistry III. Page: 569.
DE4LYSA	RU	https://books.google.fr/books?id=iZHUDQAAQBAJ&pg=RA1-PA569&lpg=RA1-PA569&dq=Danoprevir+metabolizing+enzyme+metabolize&source=bl&ots=PaQ6yPgIDJ&sig=ACfU3U1Rask-Lef8fItwvzwnqUH9ud6e2Q&hl=zh-CN&sa=X&ved=2ahUKEwi8oo2mxrfnAhUQyxoKHV0GBtAQ6AEwCHoECAsQAQ

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMB08GE
DE4LYSA	DN	Sulfamethoxazole
DE4LYSA	RN	The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9602961

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEO794
DE4LYSA	DN	Galantamine hydrobromide
DE4LYSA	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7ICNU
DE4LYSA	DN	Doxycycline
DE4LYSA	RN	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10716067

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBPN7T
DE4LYSA	DN	Rupatadine
DE4LYSA	RN	Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020424

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMKHEQL
DE4LYSA	DN	RO-408757
DE4LYSA	RN	Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654192

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXE76K
DE4LYSA	DN	Delamanid
DE4LYSA	RN	Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26055620

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOY7W3
DE4LYSA	DN	Artemisinin
DE4LYSA	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7ISKJ
DE4LYSA	DN	Nisoldipine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLOS5R
DE4LYSA	DN	Copanlisib
DE4LYSA	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEBOFW
DE4LYSA	DN	Clofazimine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQTUH8
DE4LYSA	DN	NSC-675451
DE4LYSA	RN	Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol. 2017 Jul 19;8:479.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28769808

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP79A1
DE4LYSA	DN	Macitentan
DE4LYSA	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT81LZ
DE4LYSA	DN	Apalutamide
DE4LYSA	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJ2AH4
DE4LYSA	DN	NSC-122758
DE4LYSA	RN	Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 Mar;28(3):315-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681376

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM70DTN
DE4LYSA	DN	Flibanserin
DE4LYSA	RN	Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26412054

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW1OQ0
DE4LYSA	DN	Clobazam
DE4LYSA	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0L594
DE4LYSA	DN	Ivabradine hydrochloride
DE4LYSA	RN	Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007 Apr;16(88):53-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458043

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNO38U
DE4LYSA	DN	Bortezomib
DE4LYSA	RN	Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103134

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7APNJ
DE4LYSA	DN	Zomepirac
DE4LYSA	RN	Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos. 2006 Jan;34(1):145-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16251255

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCDYW7
DE4LYSA	DN	Nicardipine hydrochloride
DE4LYSA	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLT0E1
DE4LYSA	DN	Conjugated estrogens
DE4LYSA	RN	Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28798519

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSWLM5
DE4LYSA	DN	CP-122721
DE4LYSA	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWQ16I
DE4LYSA	DN	Primaquine
DE4LYSA	RN	Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510705

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWOSKJ
DE4LYSA	DN	Zolpidem tartrate
DE4LYSA	RN	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20552178

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8ZVJ7
DE4LYSA	DN	Calcitriol
DE4LYSA	RN	Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIJATC
DE4LYSA	DN	Benzphetamine
DE4LYSA	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEGIQ6
DE4LYSA	DN	Nitrazepam
DE4LYSA	RN	Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica. 2008 Apr;38(4):353-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18340561

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF3VXA
DE4LYSA	DN	Zotepine
DE4LYSA	RN	New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr Opin Investig Drugs. 2002 Jul;3(7):1073-80.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12186270

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMB0FWL
DE4LYSA	DN	Dihydrocodeine
DE4LYSA	RN	Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510141

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJ0QOW
DE4LYSA	DN	Rilpivirine hydrochloride
DE4LYSA	RN	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23428312

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSVOCZ
DE4LYSA	DN	Pantoprazole sodium
DE4LYSA	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMW9NY0
DE4LYSA	DN	Methaqualone
DE4LYSA	RN	Assessment of the stereoselective metabolism of methaqualone in man by capillary electrophoresis. Electrophoresis. 2003 Aug;24(15):2598-607.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12900872

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM07U2A
DE4LYSA	DN	Estradiol acetate
DE4LYSA	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWX5CO
DE4LYSA	DN	Nicotine
DE4LYSA	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8M2N3
DE4LYSA	DN	BRN-0077922
DE4LYSA	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPIHLS
DE4LYSA	DN	Diclofenac sodium
DE4LYSA	RN	Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950847

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNQXV8
DE4LYSA	DN	Encorafenib
DE4LYSA	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM52HUD
DE4LYSA	DN	CR-2017
DE4LYSA	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVU687
DE4LYSA	DN	JNJ-54135419
DE4LYSA	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3PD2C
DE4LYSA	DN	Fluoxetine hydrochloride
DE4LYSA	RN	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752104

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUWBIJ
DE4LYSA	DN	Propiverine
DE4LYSA	RN	Product monograph: Mictoryl (Propiverine hydrochloride modified-release capsules).
DE4LYSA	RU	https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM702MU
DE4LYSA	DN	ITX-5061
DE4LYSA	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7IW9J
DE4LYSA	DN	Ramelteon
DE4LYSA	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG60XN
DE4LYSA	DN	Phentermine
DE4LYSA	RN	FDA Label of Qsymia. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJSBT6
DE4LYSA	DN	Silodosin
DE4LYSA	RN	Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071497

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM27Z5T
DE4LYSA	DN	Estradiol cypionate
DE4LYSA	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGDKXN
DE4LYSA	DN	Sitagliptin
DE4LYSA	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBS632
DE4LYSA	DN	Buspirone
DE4LYSA	RN	Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17376576

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJDYNQ
DE4LYSA	DN	Perampanel
DE4LYSA	RN	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25495693

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMETYK5
DE4LYSA	DN	Triazolam
DE4LYSA	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP1I6Y
DE4LYSA	DN	Alectinib hydrochloride
DE4LYSA	RN	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica. 2018 Jun;48(6):546-554.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28657423

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIOGBU
DE4LYSA	DN	Bosentan
DE4LYSA	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17496208

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0Q8MZ
DE4LYSA	DN	Trimethadione
DE4LYSA	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGMF6V
DE4LYSA	DN	Capsaicin
DE4LYSA	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFO843
DE4LYSA	DN	Fluspirilene
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMITQS0
DE4LYSA	DN	Lopinavir
DE4LYSA	RN	Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11378352

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8AI9U
DE4LYSA	DN	Loxapine succinate
DE4LYSA	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUIE76
DE4LYSA	DN	Acetaminophen
DE4LYSA	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXOELT
DE4LYSA	DN	Midazolam hydrochloride
DE4LYSA	RN	Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20203109

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU1LXS
DE4LYSA	DN	AK-602
DE4LYSA	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMT5HA4
DE4LYSA	DN	Ketamine
DE4LYSA	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIM5AP
DE4LYSA	DN	TAK-875
DE4LYSA	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBSHMF
DE4LYSA	DN	Boceprevir
DE4LYSA	RN	Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23529734

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5IKUF
DE4LYSA	DN	Dihydroergotamine
DE4LYSA	RN	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14998425

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCR1MV
DE4LYSA	DN	Itraconazole
DE4LYSA	RN	Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16418697

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBNI20
DE4LYSA	DN	Ulipristal
DE4LYSA	RN	Emergency contraception. Gynecol Endocrinol. 2013 Mar;29 Suppl 1:1-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23437846

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0T3YH
DE4LYSA	DN	Indinavir sulfate
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6AUHV
DE4LYSA	DN	Fostamatinib
DE4LYSA	RN	Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from In vitro and phase I clinical studies. Drugs R D. 2016 Mar;16(1):81-92.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26739683

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZMSPF
DE4LYSA	DN	Bicalutamide
DE4LYSA	RN	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509184

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZWBKG
DE4LYSA	DN	Fluprednisolone
DE4LYSA	RN	NCIthesaurus: Fluprednisolone
DE4LYSA	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA16BR
DE4LYSA	DN	Vorapaxar sulfate
DE4LYSA	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJHLSD
DE4LYSA	DN	Famciclovir
DE4LYSA	RN	Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8095215

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1V329
DE4LYSA	DN	Conivaptan hydrochloride
DE4LYSA	RN	Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17919259

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNP60F
DE4LYSA	DN	Anastrozole
DE4LYSA	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTJWIQ
DE4LYSA	DN	LY-2940680
DE4LYSA	RN	Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018 May 1;24(9):2082-2091.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29483143

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2OZ3G
DE4LYSA	DN	Ixabepilone
DE4LYSA	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18451235

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGR5Z3
DE4LYSA	DN	Flunitrazepam
DE4LYSA	RN	Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi. 2003;105(5):631-42.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12875231

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGMC8H
DE4LYSA	DN	LY-333531
DE4LYSA	RN	The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos. 2002 Sep;30(9):957-61.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12167559

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGM2Z6
DE4LYSA	DN	EBP-994
DE4LYSA	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH7IPW
DE4LYSA	DN	EMD-128130
DE4LYSA	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMS8IFC
DE4LYSA	DN	Sorafenib
DE4LYSA	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSA4B3
DE4LYSA	DN	Desoxycorticosterone pivalate
DE4LYSA	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DE4LYSA	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC9O43
DE4LYSA	DN	Sevoflurane
DE4LYSA	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEXMYK
DE4LYSA	DN	Alpelisib
DE4LYSA	RN	Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28566285

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZC1HS
DE4LYSA	DN	Ivacaftor
DE4LYSA	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU9VDS
DE4LYSA	DN	Mibefradil
DE4LYSA	RN	Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003 Oct;43(10):1091-100.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14517191

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQZ5HF
DE4LYSA	DN	KNI-272
DE4LYSA	RN	Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10049266

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHTEAO
DE4LYSA	DN	Carvedilol
DE4LYSA	RN	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27354764

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5TVS3
DE4LYSA	DN	Vinblastine sulfate
DE4LYSA	RN	Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20959500

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF29Q5
DE4LYSA	DN	Guanfacine hydrochloride
DE4LYSA	RN	Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9396389

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRMS0L
DE4LYSA	DN	Morphine
DE4LYSA	RN	Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16204972

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBR01X
DE4LYSA	DN	Ticagrelor
DE4LYSA	RN	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551239

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG814N
DE4LYSA	DN	Saquinavir mesylate
DE4LYSA	RN	Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19792991

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML8M5T
DE4LYSA	DN	HY-126236
DE4LYSA	RN	Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25266247

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOSW35
DE4LYSA	DN	Felodipine
DE4LYSA	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSZPR3
DE4LYSA	DN	KW-3902
DE4LYSA	RN	Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J. 2013 Apr;15(2):498-504.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23355301

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCTE9R
DE4LYSA	DN	Mexiletine hydrochloride
DE4LYSA	RN	Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000 Jul;68(1):44-57.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10945315

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML4ZOT
DE4LYSA	DN	Lidocaine
DE4LYSA	RN	Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26730802

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMG8K57
DE4LYSA	DN	Cortisone acetate
DE4LYSA	RN	Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26924289

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCL2OK
DE4LYSA	DN	Disulfiram
DE4LYSA	RN	Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24118434

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMS1GYT
DE4LYSA	DN	Mirabegron
DE4LYSA	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD1QXW
DE4LYSA	DN	Ambrisentan
DE4LYSA	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4LECQ
DE4LYSA	DN	Vilazodone hydrochloride
DE4LYSA	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8QTJI
DE4LYSA	DN	Loteprednol etabonate
DE4LYSA	RN	EMC: Lotemax 0.5% w/v Eye Drops, Suspension.
DE4LYSA	RU	https://www.medicines.org.uk/emc/product/6212

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4ZS8M
DE4LYSA	DN	Nefazodone
DE4LYSA	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCME17
DE4LYSA	DN	Lisuride
DE4LYSA	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMRV29
DE4LYSA	DN	Telaprevir
DE4LYSA	RN	Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Dis (Hoboken). 2012 Apr 26;1(2):36-40.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31186844

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPB36I
DE4LYSA	DN	YMB-1002
DE4LYSA	RN	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20663044

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4IF32
DE4LYSA	DN	Pyrazinamide
DE4LYSA	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0J2ZT
DE4LYSA	DN	Safinamide mesylate
DE4LYSA	RN	Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24136086

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQ0RKZ
DE4LYSA	DN	Nimodipine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7JNTV
DE4LYSA	DN	Eribulin mesylate
DE4LYSA	RN	Eribulin, a microtubule inhibitor for metastatic breast cancer. Oncology (Williston Park). 2011 Feb;25(2 Suppl Nurse Ed):46-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25373284

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6OC53
DE4LYSA	DN	Belinostat
DE4LYSA	RN	Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23382909

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYXOHV
DE4LYSA	DN	KRM-1648
DE4LYSA	RN	Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10923859

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK0O7U
DE4LYSA	DN	Flutamide
DE4LYSA	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHB2C3
DE4LYSA	DN	Z-4828
DE4LYSA	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2HN6Q
DE4LYSA	DN	Astemizole
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMN3UXQ
DE4LYSA	DN	Diethylstilbestrol
DE4LYSA	RN	Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. Reprod Toxicol. 2013 Jun;37:24-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23384967

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHCI9S
DE4LYSA	DN	Flurandrenolide
DE4LYSA	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4MZXE
DE4LYSA	DN	TD-758
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVMIK2
DE4LYSA	DN	Roxithromycin
DE4LYSA	RN	Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. Ann Pharmacother. 2006 Apr;40(4):767-70.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16595573

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0RKS4
DE4LYSA	DN	Bepridil hydrochloride
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM3906J
DE4LYSA	DN	Bedaquiline fumarate
DE4LYSA	RN	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24513655

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWXLYZ
DE4LYSA	DN	Darifenacin hydrobromide
DE4LYSA	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM2G9AE
DE4LYSA	DN	Citalopram hydrobromide
DE4LYSA	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM75CXN
DE4LYSA	DN	Avanafil
DE4LYSA	RN	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23675780

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMK7F9S
DE4LYSA	DN	Amitriptyline hydrochloride
DE4LYSA	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMM74PK
DE4LYSA	DN	ABT-627
DE4LYSA	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4ONW5
DE4LYSA	DN	Baricitinib
DE4LYSA	RN	FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJIBAW
DE4LYSA	DN	Budesonide
DE4LYSA	RN	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726657

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXZOCG
DE4LYSA	DN	Phenobarbital
DE4LYSA	RN	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 Dec;29(6):687-710.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18043468

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM62UG5
DE4LYSA	DN	Vemurafenib
DE4LYSA	RN	Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23094782

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4V8WF
DE4LYSA	DN	TAK-652
DE4LYSA	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DE4LYSA	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMYLMU0
DE4LYSA	DN	Isosorbide mononitrate
DE4LYSA	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFC71L
DE4LYSA	DN	Clozapine
DE4LYSA	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWLFGO
DE4LYSA	DN	Methyltestosterone
DE4LYSA	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4M1SG
DE4LYSA	DN	Clarithromycin
DE4LYSA	RN	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24035278

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMOEARH
DE4LYSA	DN	AZD-2014
DE4LYSA	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH7RJ1
DE4LYSA	DN	BIIB-014
DE4LYSA	RN	Frontiers in CNS Drug Discovery. Edited by Atta-ur Rahman, M. Iqbal Choudhary. Page: 318.
DE4LYSA	RU	https://books.google.nl/books?id=ip-Pz5C3_loC&pg=PA318&lpg=PA318&dq=BIIB014++metabolizing+enzyme&source=bl&ots=G8YeDCzw5_&sig=ACfU3U1ZkEaPcDy58jtvOlzdzR-s3sNz4g&hl=zh-CN&sa=X&ved=2ahUKEwiGkem-7rnnAhVP4qQKHfNzAi4Q6AEwFXoECAwQAQ#v=onepage&q=BIIB014%20%20metabolizing%20enzyme&f=false

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGZQEF
DE4LYSA	DN	Mifepristone
DE4LYSA	RN	Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29785610

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZA5PQ
DE4LYSA	DN	Glipizide
DE4LYSA	RN	Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15099124

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZLGRB
DE4LYSA	DN	Pimecrolimus
DE4LYSA	RN	Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16467136

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1A9W3
DE4LYSA	DN	Drospirenone
DE4LYSA	RN	Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018 May;11(3):251-260.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986954

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD5JU8
DE4LYSA	DN	Cefalexin
DE4LYSA	RN	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep;16(9):1352-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10496649

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIFCY2
DE4LYSA	DN	H3B-6545
DE4LYSA	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSFWT7
DE4LYSA	DN	SHR-1020
DE4LYSA	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DE4LYSA	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC68DF
DE4LYSA	DN	GTPL7557
DE4LYSA	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM1FBZ7
DE4LYSA	DN	Tiotropium Bromide
DE4LYSA	RN	Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15350163

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM082ZW
DE4LYSA	DN	ATL-2502
DE4LYSA	RN	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMH7MUV
DE4LYSA	DN	Zalcitabine
DE4LYSA	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPI6Z0
DE4LYSA	DN	Zopiclone
DE4LYSA	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU764S
DE4LYSA	DN	Ritonavir
DE4LYSA	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4OKXI
DE4LYSA	DN	Benzotetronic acid
DE4LYSA	RN	CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol. 1995 Jan;39(1):71-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7756103

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMI3J0F
DE4LYSA	DN	CTK1G9578
DE4LYSA	RN	Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18422-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20937904

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFG5ST
DE4LYSA	DN	Almotriptan malate
DE4LYSA	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY2AH1
DE4LYSA	DN	Aminophenazone
DE4LYSA	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMA12HL
DE4LYSA	DN	Azelnidipine
DE4LYSA	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
DE4LYSA	RU	http://www.genome.jp/dbget-bin/www_bget?D01145

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJSDBE
DE4LYSA	DN	Barnidipine
DE4LYSA	RN	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica. 1997 Sep;27(9):885-900.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9381730

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLKUG7
DE4LYSA	DN	Beclabuvir
DE4LYSA	RN	Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos. 2016 Aug;44(8):1372-80.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27226352

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7H3VY
DE4LYSA	DN	Bencyclane
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWNP6B
DE4LYSA	DN	Benidipine
DE4LYSA	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMMF5IE
DE4LYSA	DN	GS-9883
DE4LYSA	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGXD5T
DE4LYSA	DN	Brotizolam
DE4LYSA	RN	Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005 Aug;60(2):172-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16042670

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9X2FV
DE4LYSA	DN	Butyrfentanyl
DE4LYSA	RN	Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623-630.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30930421

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV7WSN
DE4LYSA	DN	CC-25430
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8KLU9
DE4LYSA	DN	Cenobamate
DE4LYSA	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM64K0A
DE4LYSA	DN	Chlormadinone
DE4LYSA	RN	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29130574

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM6C4YJ
DE4LYSA	DN	Chlorphenamine
DE4LYSA	RN	Drug Interactions Flockhart Table
DE4LYSA	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBG0N4
DE4LYSA	DN	Cibenzoline
DE4LYSA	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMAZJFX
DE4LYSA	DN	Ciclosporin
DE4LYSA	RN	Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction. Pharmacol Rep. 2019 Apr;71(2):201-205.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30785057

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPS7U2
DE4LYSA	DN	GTPL-9088
DE4LYSA	RN	Product Information of Eumovate.
DE4LYSA	RU	https://www.medsafe.govt.nz/Profs/Datasheet/e/Eumovatecrm.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLPXNC
DE4LYSA	DN	Clorindione
DE4LYSA	RN	CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011 Jun;39(6):1039-46.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21383203

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLMOIJ
DE4LYSA	DN	Cyproterone acetate
DE4LYSA	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMV5KTJ
DE4LYSA	DN	Demegestone
DE4LYSA	RN	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29130574

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9P4JW
DE4LYSA	DN	Dexverapamil
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMPDQSV
DE4LYSA	DN	Dihydrostreptomycin
DE4LYSA	RN	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQRX24
DE4LYSA	DN	Ebastine
DE4LYSA	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJLE18
DE4LYSA	DN	Elbasvir
DE4LYSA	RN	Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557529

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9WPIH
DE4LYSA	DN	Ergonovine maleate
DE4LYSA	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7ITZK
DE4LYSA	DN	Ethinylestradiol propanesulfonate
DE4LYSA	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR5Z2A
DE4LYSA	DN	Ethyl biscoumacetate
DE4LYSA	RN	Diet Drug Porfimer sodium Safe, Effective, Study Finds.
DE4LYSA	RU	http://pastande.org/diet-drug-porfimer-sodium-safe-effective-study-finds/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8TNX3
DE4LYSA	DN	Etizolam
DE4LYSA	RN	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15232663

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMR7U8F
DE4LYSA	DN	Etoperidone
DE4LYSA	RN	In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica. 2002 Nov;32(11):949-62.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487725

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7GSLB
DE4LYSA	DN	SC-20713
DE4LYSA	RN	News and information in drug research: Ethynodiol diacetate.
DE4LYSA	RU	http://genelabs.com/drugsdb/details/ethynodiol-diacetate/

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DML2DCR
DE4LYSA	DN	Fedratinib hydrochloride
DE4LYSA	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUNG4A
DE4LYSA	DN	Flumethasone
DE4LYSA	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQKXSW
DE4LYSA	DN	BRN-3122594
DE4LYSA	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9R1YU
DE4LYSA	DN	Gestodene
DE4LYSA	RN	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000 Oct;50(4):333-7.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012556

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM9BPLW
DE4LYSA	DN	Grazoprevir
DE4LYSA	RN	FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMIAPBE
DE4LYSA	DN	Hydrocodone bitartrate
DE4LYSA	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZKABS
DE4LYSA	DN	Imipramine oxide
DE4LYSA	RN	Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993 May;43(5):827-32.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8502233

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMD45S9
DE4LYSA	DN	Isavuconazonium
DE4LYSA	RN	Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015 Nov;35(11):1037-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26598096

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM170OH
DE4LYSA	DN	Ketazolam
DE4LYSA	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMQP5I3
DE4LYSA	DN	Lacidipine
DE4LYSA	RN	The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001 Feb;51(2):147-52.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259986

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMXYLQ3
DE4LYSA	DN	Lansoprazole
DE4LYSA	RN	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9744552

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVQKB3
DE4LYSA	DN	NCI-C50000
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM429AE
DE4LYSA	DN	Levomethadyl acetate hydrochloride
DE4LYSA	RN	Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clin Pharmacokinet. 2005;44(7):731-51.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15966756

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSTXWR
DE4LYSA	DN	Liotrix
DE4LYSA	RN	A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. 2002 Winter;9(4):191-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584577

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLB4PE
DE4LYSA	DN	Lomitapide mesylate
DE4LYSA	RN	Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26120010

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM82JP0
DE4LYSA	DN	Lynestrenol
DE4LYSA	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNKSX3
DE4LYSA	DN	Medazepam
DE4LYSA	RN	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18175099

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM0UGYX
DE4LYSA	DN	Medifoxamine
DE4LYSA	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMNEAJG
DE4LYSA	DN	Medrogestone
DE4LYSA	RN	Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sci. 2003 Nov 7;73(25):3201-12.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14561525

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DME1X96
DE4LYSA	DN	Mexazolam
DE4LYSA	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDQK9G
DE4LYSA	DN	Miocamycin
DE4LYSA	RN	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998 Sep;64(3):278-85.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9757151

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFX6G8
DE4LYSA	DN	Nelfinavir mesylate
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8OGMA
DE4LYSA	DN	Niludipine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMRP8XB
DE4LYSA	DN	Nomegestrol
DE4LYSA	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMHAWYQ
DE4LYSA	DN	Nordazepam
DE4LYSA	RN	Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10359672

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMU1JVW
DE4LYSA	DN	Otilonium
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMF57DM
DE4LYSA	DN	Pazopanib
DE4LYSA	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM4OIMZ
DE4LYSA	DN	Pinaverium
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8PTSY
DE4LYSA	DN	Prenylamine
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMLPICK
DE4LYSA	DN	Quinidine
DE4LYSA	RN	10th North American ISSX meeting. October 24-28, 2000. Indianapolis, Indiana, USA. Abstracts. Drug Metab Rev. 2000;32 Suppl 2:137-340.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11057336

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5DSFZ
DE4LYSA	DN	Rifampicin
DE4LYSA	RN	Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124517

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMY6EAO
DE4LYSA	DN	Rosiglitazone
DE4LYSA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMP7X6Q
DE4LYSA	DN	Rotigotine
DE4LYSA	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMSWJ5X
DE4LYSA	DN	Sildenafil citrate
DE4LYSA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMVCMUJ
DE4LYSA	DN	Siponimod
DE4LYSA	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM72409
DE4LYSA	DN	Sonidegib phosphate
DE4LYSA	RN	Sonidegib: first global approval. Drugs. 2015 Sep;75(13):1559-66.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26323341

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMTQF4A
DE4LYSA	DN	Tenofovir alafenamide
DE4LYSA	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM62IPN
DE4LYSA	DN	Tenofovir disoproxil
DE4LYSA	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMC1TEV
DE4LYSA	DN	Testosterone cypionate
DE4LYSA	RN	Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 2017 Dec;45(12):1266-1275.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986474

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMZNIAG
DE4LYSA	DN	LS-172108
DE4LYSA	RN	Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther. 1996 May;277(2):982-90.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627581

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMBIJZ6
DE4LYSA	DN	Tocopherol
DE4LYSA	RN	A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007 Jul;193(1):229-33.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16860808

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8J0MK
DE4LYSA	DN	GEA-6414
DE4LYSA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM8T2OI
DE4LYSA	DN	Upadacitinib
DE4LYSA	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMGF8ZQ
DE4LYSA	DN	Velpatasvir
DE4LYSA	RN	Product characteristics of Epclusa.
DE4LYSA	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_en.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMWQUC9
DE4LYSA	DN	Vitamin D
DE4LYSA	RN	Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013 Jul;136:54-8.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/22985909

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMCOJPS
DE4LYSA	DN	Vonoprazan
DE4LYSA	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMUR5NG
DE4LYSA	DN	Zanubrutinib
DE4LYSA	RN	FDA label of Zanubrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DE4LYSA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMDGCQP
DE4LYSA	DN	Norethindrone acetate
DE4LYSA	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7LRKD
DE4LYSA	DN	Triamcinolone diacetate
DE4LYSA	RN	Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20456080

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM31YVO
DE4LYSA	DN	Glecaprevir
DE4LYSA	RN	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30199279

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMJAS3O
DE4LYSA	DN	Hydroxyamphetamine
DE4LYSA	RN	Stereoselective method development and validation for determination of concentrations of amphetamine-type stimulants and metabolites in human urine using a simultaneous extraction-chiral derivatization approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 1;879(1):8-16.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21147046

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMEYMHB
DE4LYSA	DN	NSC-303812
DE4LYSA	RN	The mechanism of aphidicolin bioinactivation by rat liver in vitro systems. Xenobiotica. 1990 Mar;20(3):273-87.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2110702

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM5GKOV
DE4LYSA	DN	Pergolide mesylate
DE4LYSA	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DMFIQ20
DE4LYSA	DN	Orphenadrine citrate
DE4LYSA	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DE4LYSA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM26SR7
DE4LYSA	DN	Benzyloxyresorufin
DE4LYSA	RN	P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001 Mar;29(3):304-12.
DE4LYSA	RU	https://pubmed.ncbi.nlm.nih.gov/11181500

DE4LYSA	EI	DE4LYSA
DE4LYSA	EN	Cytochrome P450 3A4 (CYP3A4)
DE4LYSA	DI	DM7WFR0
DE4LYSA	DN	VUFB-11502
DE4LYSA	RN	The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
DE4LYSA	RU	https://pubmed.ncbi.nlm.nih.gov/27285897

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DMFWKG1
DEQX145	DN	Nandrolone
DEQX145	RN	Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3347045

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DM3S8XC
DEQX145	DN	Androstanolone
DEQX145	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DMTW6IU
DEQX145	DN	Methadone
DEQX145	RN	Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588727

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DMH07Y3
DEQX145	DN	Letrozole
DEQX145	RN	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10448261

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DM67VKL
DEQX145	DN	Dehydroepiandrosterone
DEQX145	RN	Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=53430

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DM429AE
DEQX145	DN	Levomethadyl acetate hydrochloride
DEQX145	RN	N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15104241

DEQX145	EI	DEQX145
DEQX145	EN	Aromatase (CYP19A1)
DEQX145	DI	DMC1TEV
DEQX145	DN	Testosterone cypionate
DEQX145	RN	Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
DEQX145	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18063054

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMDRQZU
DEJGDUW	DN	Ethanol
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMQ314B
DEJGDUW	DN	VA-10872
DEJGDUW	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSQZE2
DEJGDUW	DN	Asenapine maleate
DEJGDUW	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMXTMBJ
DEJGDUW	DN	Azelastine
DEJGDUW	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMW83TP
DEJGDUW	DN	Pimozide
DEJGDUW	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMYZ57N
DEJGDUW	DN	Albendazole
DEJGDUW	RN	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451431

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZAL7W
DEJGDUW	DN	Promazine
DEJGDUW	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM2HU9I
DEJGDUW	DN	Triamterene
DEJGDUW	RN	Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16035375

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMOGFIX
DEJGDUW	DN	Eltrombopag olamine
DEJGDUW	RN	Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 Feb 27;2(4):454-461.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29487060

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMOYE70
DEJGDUW	DN	HOE-239
DEJGDUW	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5T6US
DEJGDUW	DN	Estrone
DEJGDUW	RN	A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10930541

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM9BI7M
DEJGDUW	DN	Duloxetine hydrochloride
DEJGDUW	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMI6HUW
DEJGDUW	DN	Terbinafine hydrochloride
DEJGDUW	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFH15Z
DEJGDUW	DN	Bendamustine
DEJGDUW	RN	Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25829094

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMG6OYJ
DEJGDUW	DN	Lorcaserin
DEJGDUW	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1YBRM
DEJGDUW	DN	Cyclobenzaprine
DEJGDUW	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMR2IQ4
DEJGDUW	DN	Tizanidine hydrochloride
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCMETN
DEJGDUW	DN	Ixazomib
DEJGDUW	RN	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30;8(8):70.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30061664

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMXZRW0
DEJGDUW	DN	Carmustine
DEJGDUW	RN	Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7967709

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMYNMDP
DEJGDUW	DN	Tocainide
DEJGDUW	RN	The effect of tocainide on theophylline metabolism. Br J Clin Pharmacol. 1993 Apr;35(4):437-40.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8485025

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM9PVX8
DEJGDUW	DN	Rucaparib
DEJGDUW	RN	Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017 Jun 19;10:3029-3037.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28790837

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM28UJG
DEJGDUW	DN	Dapagliflozin
DEJGDUW	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKR3C5
DEJGDUW	DN	Ergotamine tartrate
DEJGDUW	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMT2FDC
DEJGDUW	DN	Desipramine
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMQUSBT
DEJGDUW	DN	Daunorubicin
DEJGDUW	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMBGZI3
DEJGDUW	DN	Chlorpromazine hydrochloride
DEJGDUW	RN	Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17611010

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGVH6N
DEJGDUW	DN	Axitinib
DEJGDUW	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMA4MRX
DEJGDUW	DN	Perphenazine
DEJGDUW	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMVRH9C
DEJGDUW	DN	Lomefloxacin
DEJGDUW	RN	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510417

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPWGBR
DEJGDUW	DN	Triclabendazole
DEJGDUW	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6VZFQ
DEJGDUW	DN	Pirfenidone
DEJGDUW	RN	Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab Dispos. 2018 Jun;46(6):835-845.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29572333

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMMSDOY
DEJGDUW	DN	Stiripentol
DEJGDUW	RN	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16022579

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM4K7GQ
DEJGDUW	DN	Erythromycin stearate
DEJGDUW	RN	Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9806945

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSQDLE
DEJGDUW	DN	Flecainide acetate
DEJGDUW	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSWYF5
DEJGDUW	DN	Quinine sulfate
DEJGDUW	RN	The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther. 1999 Nov;66(5):454-60.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10579472

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSJDTY
DEJGDUW	DN	Menadione
DEJGDUW	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMLSABI
DEJGDUW	DN	Hypoxanthine
DEJGDUW	RN	Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004;18(23):2921-33.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15529418

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCE985
DEJGDUW	DN	Antipyrine
DEJGDUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPWB7T
DEJGDUW	DN	Maprotiline hydrochloride
DEJGDUW	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM42GP9
DEJGDUW	DN	DOV-220075
DEJGDUW	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6EUL5
DEJGDUW	DN	Betaxolol
DEJGDUW	RN	Drugs that may have potential CYP1A2 interactions.
DEJGDUW	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6RZ9Q
DEJGDUW	DN	Clonidine
DEJGDUW	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DML2NIB
DEJGDUW	DN	Aminophylline
DEJGDUW	RN	Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9855322

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZMSCT
DEJGDUW	DN	Cilostazol
DEJGDUW	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMVU9X1
DEJGDUW	DN	CT-1501R
DEJGDUW	RN	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):403-12.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25663650

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCX0K3
DEJGDUW	DN	Cinacalcet hydrochloride
DEJGDUW	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGPF0N
DEJGDUW	DN	Estrone sulfate
DEJGDUW	RN	Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):551-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16537715

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM79NTF
DEJGDUW	DN	Propranolol hydrochloride
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZOLBI
DEJGDUW	DN	Carbamazepine
DEJGDUW	RN	Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22332980

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSVOZT
DEJGDUW	DN	Nifedipine
DEJGDUW	RN	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805063

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3TON2
DEJGDUW	DN	Temafloxacin
DEJGDUW	RN	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510417

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM4KDYJ
DEJGDUW	DN	Nortriptyline hydrochloride
DEJGDUW	RN	Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9193876

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1S4AG
DEJGDUW	DN	Lumiracoxib
DEJGDUW	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFQWNI
DEJGDUW	DN	Clomipramine hydrochloride
DEJGDUW	RN	Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol. 1996 Summer;6(2):133-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9231305

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZU5JP
DEJGDUW	DN	Flunarizine
DEJGDUW	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMAT2XH
DEJGDUW	DN	Nabumetone
DEJGDUW	RN	A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19204080

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMHZJCG
DEJGDUW	DN	Pentamidine isethionate
DEJGDUW	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMH75KV
DEJGDUW	DN	G-23350
DEJGDUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUM7HZ
DEJGDUW	DN	Fluorouracilo
DEJGDUW	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMBVYDI
DEJGDUW	DN	Benzyl alcohol
DEJGDUW	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3P5DA
DEJGDUW	DN	Rofecoxib
DEJGDUW	RN	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006 Sep;62(3):345-57.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16934051

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DML53ZJ
DEJGDUW	DN	Mirtazapine
DEJGDUW	RN	Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15538128

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMF3AN7
DEJGDUW	DN	Loratadine
DEJGDUW	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1TMA3
DEJGDUW	DN	Imiquimod
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMTYOPD
DEJGDUW	DN	Dinoprostone
DEJGDUW	RN	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15224350

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPI98T
DEJGDUW	DN	Doxepin hydrochloride
DEJGDUW	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMEQL9U
DEJGDUW	DN	CAM-2028
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM7RE8P
DEJGDUW	DN	Frovatriptan
DEJGDUW	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5PVQE
DEJGDUW	DN	Paroxetine hydrochloride
DEJGDUW	RN	CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics. 2010 Nov;11(11):1535-43.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21121774

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DML2A03
DEJGDUW	DN	Alosetron hydrochloride
DEJGDUW	RN	Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010 May;3(3):165-72.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21180598

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3WKQ4
DEJGDUW	DN	Rasagiline mesylate
DEJGDUW	RN	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17296539

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5GFIK
DEJGDUW	DN	BPI-2009
DEJGDUW	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM2NUH3
DEJGDUW	DN	Imipramine hydrochloride
DEJGDUW	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMTWS9E
DEJGDUW	DN	Apremilast
DEJGDUW	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6VP9U
DEJGDUW	DN	INN-00835
DEJGDUW	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DEJGDUW	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMC0GSJ
DEJGDUW	DN	Efavirenz
DEJGDUW	RN	CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31339646

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM08E9O
DEJGDUW	DN	Diazepam
DEJGDUW	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM2AOTZ
DEJGDUW	DN	Perazine
DEJGDUW	RN	Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Pol J Pharmacol. 2002 Jul-Aug;54(4):407-10.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12523495

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMLB0EZ
DEJGDUW	DN	Tamoxifen citrate
DEJGDUW	RN	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25157097

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKER83
DEJGDUW	DN	Hesperetin
DEJGDUW	RN	In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol. 2002 May;40(5):609-16.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11955666

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMEDKZH
DEJGDUW	DN	Doxofylline
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMYLT67
DEJGDUW	DN	ANW-60941
DEJGDUW	RN	A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29101463

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCMBHA
DEJGDUW	DN	Erlotinib hydrochloride
DEJGDUW	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMMZSXQ
DEJGDUW	DN	Azathioprine
DEJGDUW	RN	Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10837004

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5UGDK
DEJGDUW	DN	Mephenytoin
DEJGDUW	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMMT1YQ
DEJGDUW	DN	NSC-149027
DEJGDUW	RN	Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metab Dispos. 1998 Oct;26(10):1048-51.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763414

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DML0RAE
DEJGDUW	DN	Methoxyflurane
DEJGDUW	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM8MC6O
DEJGDUW	DN	Estradiol valerate
DEJGDUW	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMYHV17
DEJGDUW	DN	PNU-95666
DEJGDUW	RN	Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019 Jan 1;180(1):31-40.
DEJGDUW	RU	http://www.ncbi.nlm.nih.gov/pubmed/30400048

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMIK367
DEJGDUW	DN	Procarbazine
DEJGDUW	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM7YCK3
DEJGDUW	DN	Thiabendazole
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUNTE3
DEJGDUW	DN	E-3A
DEJGDUW	RN	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15217502

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMR8ONJ
DEJGDUW	DN	Leflunomide
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMK1ZOR
DEJGDUW	DN	Vincamine
DEJGDUW	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMK7CYX
DEJGDUW	DN	ASA-404
DEJGDUW	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFA5MY
DEJGDUW	DN	Metoclopramide hydrochloride
DEJGDUW	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMN4ZKC
DEJGDUW	DN	Paraoxon
DEJGDUW	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCYVDT
DEJGDUW	DN	Chlorzoxazone
DEJGDUW	RN	Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9825829

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMVRIC2
DEJGDUW	DN	Zileuton
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6A4NW
DEJGDUW	DN	Etoricoxib
DEJGDUW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMTW6IU
DEJGDUW	DN	Methadone
DEJGDUW	RN	Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15501692

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMU3DNC
DEJGDUW	DN	Pentoxifylline
DEJGDUW	RN	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9394024

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM783CH
DEJGDUW	DN	Levobupivacaine
DEJGDUW	RN	Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. Br J Anaesth. 2005 Oct;95(4):524-9.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16100236

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSPJG2
DEJGDUW	DN	Ropivacaine hydrochloride
DEJGDUW	RN	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9834040

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMB4OLE
DEJGDUW	DN	Propofol
DEJGDUW	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMTGBAX
DEJGDUW	DN	Pomalidomide
DEJGDUW	RN	Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25556560

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUANF3
DEJGDUW	DN	MLN-8054
DEJGDUW	RN	MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett. 2015 Apr 22;6(6):630-4.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26101564

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKWFBT
DEJGDUW	DN	Melatonin
DEJGDUW	RN	Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15626586

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMBDPY0
DEJGDUW	DN	KW-5338
DEJGDUW	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM7RJXL
DEJGDUW	DN	Imatinib mesylate
DEJGDUW	RN	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24369535

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMLHSE3
DEJGDUW	DN	Oxtriphylline
DEJGDUW	RN	PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012 Jan;22(1):73-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21989077

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKBJWP
DEJGDUW	DN	Caffeine
DEJGDUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFI7A8
DEJGDUW	DN	O-Benzylguanine
DEJGDUW	RN	Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7503788

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMNH3PG
DEJGDUW	DN	Etoposide
DEJGDUW	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM0GUSX
DEJGDUW	DN	Ranitidine
DEJGDUW	RN	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223772

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5I621
DEJGDUW	DN	Methyldopa
DEJGDUW	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMK54YG
DEJGDUW	DN	Griseofulvin
DEJGDUW	RN	Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry. 1975 Oct 7;14(20):4459-65.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=126078

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1P6FR
DEJGDUW	DN	Binimetinib
DEJGDUW	RN	FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
DEJGDUW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM96SE0
DEJGDUW	DN	Haloperidol decanoate
DEJGDUW	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSQ8MD
DEJGDUW	DN	Anagrelide hydrochloride
DEJGDUW	RN	Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23378182

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMF98Q0
DEJGDUW	DN	CYT-387
DEJGDUW	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZ5RGV
DEJGDUW	DN	Naproxen
DEJGDUW	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMDINC4
DEJGDUW	DN	Thiothixene
DEJGDUW	RN	In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28357125

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMY9TCW
DEJGDUW	DN	Bromazepam
DEJGDUW	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJYCVW
DEJGDUW	DN	Warfarin sodium
DEJGDUW	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJV2EK
DEJGDUW	DN	Dasatinib
DEJGDUW	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM51FY6
DEJGDUW	DN	Tacrine hydrochloride
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUPFLI
DEJGDUW	DN	Deutetrabenazine
DEJGDUW	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DEJGDUW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM31ZQM
DEJGDUW	DN	Tegafur
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM20VSK
DEJGDUW	DN	Istradefylline
DEJGDUW	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMRJFN9
DEJGDUW	DN	Theophylline
DEJGDUW	RN	Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):257-63.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23167834

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJ7YDS
DEJGDUW	DN	Dexfenfluramine
DEJGDUW	RN	Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. J Clin Psychopharmacol. 1998 Aug;18(4):338-41.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9690701

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZ6YPV
DEJGDUW	DN	Cyamemazine
DEJGDUW	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM053KT
DEJGDUW	DN	Aprepitant
DEJGDUW	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMECBWN
DEJGDUW	DN	Riluzole
DEJGDUW	RN	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752377

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMM8D3F
DEJGDUW	DN	SC-15090
DEJGDUW	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM89JLN
DEJGDUW	DN	Apixaban
DEJGDUW	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPIBJK
DEJGDUW	DN	Propafenone hydrochloride
DEJGDUW	RN	Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998 Apr;45(4):361-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578183

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3VR1L
DEJGDUW	DN	Selegiline hydrochloride
DEJGDUW	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPC1J7
DEJGDUW	DN	Clofibrate
DEJGDUW	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMIUW25
DEJGDUW	DN	Granisetron hydrochloride
DEJGDUW	RN	Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999 Jan;27(1):110-2.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884318

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGLX0T
DEJGDUW	DN	Grepafloxacin
DEJGDUW	RN	Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26936044

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1WXA6
DEJGDUW	DN	Lofexidine
DEJGDUW	RN	The Drugs.com International Drug Name Database: Lofexidine
DEJGDUW	RU	https://www.drugs.com/ppa/lofexidine.html

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM0FB1J
DEJGDUW	DN	Sertraline hydrochloride
DEJGDUW	RN	The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001 Spring;7(1):1-24.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11420570

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMXZ84M
DEJGDUW	DN	Malathion
DEJGDUW	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMOTQ1I
DEJGDUW	DN	Ondansetron
DEJGDUW	RN	Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2006 Sep;29(9):1931-5.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16946512

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMTD7AB
DEJGDUW	DN	SB-939
DEJGDUW	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM0JETC
DEJGDUW	DN	BIO-300
DEJGDUW	RN	Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol. 2010 Jul-Aug;24(4):230-4.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20806393

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5QWEL
DEJGDUW	DN	Guanabenz
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSOPAU
DEJGDUW	DN	PD-115934
DEJGDUW	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUTEX3
DEJGDUW	DN	Amiodarone hydrochloride
DEJGDUW	RN	Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11907638

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMOU1PK
DEJGDUW	DN	Praziquantel
DEJGDUW	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFBOQ7
DEJGDUW	DN	Xanthine
DEJGDUW	RN	Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom. 2004;18(23):2921-33.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15529418

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5SYZP
DEJGDUW	DN	Disopyramide phosphate
DEJGDUW	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJKROX
DEJGDUW	DN	Fluvoxamine maleate
DEJGDUW	RN	Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007;46(7):613-22.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17596106

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMQFDRC
DEJGDUW	DN	Idebenone
DEJGDUW	RN	Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20955109

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMOL54H
DEJGDUW	DN	Clopidogrel bisulfate
DEJGDUW	RN	Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25559342

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM1IB4Q
DEJGDUW	DN	Zolmitriptan
DEJGDUW	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMRQAM0
DEJGDUW	DN	Phenacetin
DEJGDUW	RN	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178771

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMXLHYN
DEJGDUW	DN	BAX-2793Z
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZFIGQ
DEJGDUW	DN	SB-1317
DEJGDUW	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMBL79I
DEJGDUW	DN	Proguanil
DEJGDUW	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMIZ6W2
DEJGDUW	DN	Norfloxacin
DEJGDUW	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM7U5QJ
DEJGDUW	DN	Cinnarizine
DEJGDUW	RN	Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19590965

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMLOQ1V
DEJGDUW	DN	Tasimelteon
DEJGDUW	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DME2A8X
DEJGDUW	DN	HSDB-3466
DEJGDUW	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZIXU9
DEJGDUW	DN	Dihydralazine
DEJGDUW	RN	Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol. 1999 Oct;12(10):1028-32.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10525281

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMA7PEW
DEJGDUW	DN	Verapamil hydrochloride
DEJGDUW	RN	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8232610

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM0IO13
DEJGDUW	DN	CCRIS-1920
DEJGDUW	RN	Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes. Xenobiotica. 2007 Mar;37(3):246-59.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17624023

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKBYWI
DEJGDUW	DN	Trifluoperazine
DEJGDUW	RN	Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
DEJGDUW	RU	https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v4-id1085.php

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPGHY8
DEJGDUW	DN	Roflumilast
DEJGDUW	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMVKA4O
DEJGDUW	DN	Mianserin
DEJGDUW	RN	Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8764331

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMA6S1D
DEJGDUW	DN	Ropinirole hydrochloride
DEJGDUW	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMH7GN8
DEJGDUW	DN	Ramosetron
DEJGDUW	RN	Ondansetron, ramosetron, or palonosetron: which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy? Anesth Essays Res. 2011 Jul-Dec;5(2):182-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25885385

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMKHEQL
DEJGDUW	DN	RO-408757
DEJGDUW	RN	Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654192

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJ2AH4
DEJGDUW	DN	NSC-122758
DEJGDUW	RN	Carotenoids as regulators for inter-species difference in cytochrome P450 1A expression and activity in ungulates and rats. Food Chem Toxicol. 2010 Nov;48(11):3201-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20797421

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMNO38U
DEJGDUW	DN	Bortezomib
DEJGDUW	RN	Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764713

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMLT0E1
DEJGDUW	DN	Conjugated estrogens
DEJGDUW	RN	Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006 Nov;46(11):1299-307.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050794

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMWQ16I
DEJGDUW	DN	Primaquine
DEJGDUW	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMWOSKJ
DEJGDUW	DN	Zolpidem tartrate
DEJGDUW	RN	Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00849.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21494350

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMF3VXA
DEJGDUW	DN	Zotepine
DEJGDUW	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSVOCZ
DEJGDUW	DN	Pantoprazole sodium
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPGUCF
DEJGDUW	DN	Dopamine hydrochloride
DEJGDUW	RN	Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9682270

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM07U2A
DEJGDUW	DN	Estradiol acetate
DEJGDUW	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMWX5CO
DEJGDUW	DN	Nicotine
DEJGDUW	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPIHLS
DEJGDUW	DN	Diclofenac sodium
DEJGDUW	RN	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27034690

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3PD2C
DEJGDUW	DN	Fluoxetine hydrochloride
DEJGDUW	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM7IW9J
DEJGDUW	DN	Ramelteon
DEJGDUW	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM27Z5T
DEJGDUW	DN	Estradiol cypionate
DEJGDUW	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM93L4X
DEJGDUW	DN	Dexmedetomidine hydrochloride
DEJGDUW	RN	Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17973897

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMJDYNQ
DEJGDUW	DN	Perampanel
DEJGDUW	RN	Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27904300

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM3RWXL
DEJGDUW	DN	SRT-501
DEJGDUW	RN	Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15276085

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGMF6V
DEJGDUW	DN	Capsaicin
DEJGDUW	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM8AI9U
DEJGDUW	DN	Loxapine succinate
DEJGDUW	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMUIE76
DEJGDUW	DN	Acetaminophen
DEJGDUW	RN	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26049587

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM6JQ2I
DEJGDUW	DN	HWA-285
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMPFN6Y
DEJGDUW	DN	Olanzapine
DEJGDUW	RN	Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003 Mar;28(2):99-112.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12670127

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMBNI20
DEJGDUW	DN	Ulipristal
DEJGDUW	RN	The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476-83.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25228633

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGR5Z3
DEJGDUW	DN	Flunitrazepam
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMH7IPW
DEJGDUW	DN	EMD-128130
DEJGDUW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMS8IFC
DEJGDUW	DN	Sorafenib
DEJGDUW	RN	Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22927483

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMHTEAO
DEJGDUW	DN	Carvedilol
DEJGDUW	RN	Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31086844

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCTE9R
DEJGDUW	DN	Mexiletine hydrochloride
DEJGDUW	RN	Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide. J Pharmacol Exp Ther. 1999 May;289(2):853-8.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215663

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMA2GHJ
DEJGDUW	DN	AV-650
DEJGDUW	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DML4ZOT
DEJGDUW	DN	Lidocaine
DEJGDUW	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMCKYZ5
DEJGDUW	DN	NAB-365
DEJGDUW	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM4IF32
DEJGDUW	DN	Pyrazinamide
DEJGDUW	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMK0O7U
DEJGDUW	DN	Flutamide
DEJGDUW	RN	Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9351907

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMQNWRD
DEJGDUW	DN	Oxaliplatin
DEJGDUW	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMK7F9S
DEJGDUW	DN	Amitriptyline hydrochloride
DEJGDUW	RN	The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28344482

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMNPZL4
DEJGDUW	DN	Dacarbazine
DEJGDUW	RN	Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19954661

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMXYA5K
DEJGDUW	DN	Agomelatine
DEJGDUW	RN	Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2? Drug Des Devel Ther. 2018 Jul 11;12:2169-2172.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30034221

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMFC71L
DEJGDUW	DN	Clozapine
DEJGDUW	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMIFCY2
DEJGDUW	DN	H3B-6545
DEJGDUW	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMSFWT7
DEJGDUW	DN	SHR-1020
DEJGDUW	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DEJGDUW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMEN5KA
DEJGDUW	DN	GTS-21
DEJGDUW	RN	Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiotica. 1999 Jul;29(7):747-62.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456692

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMX2YH7
DEJGDUW	DN	NSC-6113
DEJGDUW	RN	Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
DEJGDUW	RU	https://www.sciencedirect.com/bookseries/side-effects-of-drugs-annual/vol/33/suppl/C

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMVTSM8
DEJGDUW	DN	Acefylline
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMYZJ5B
DEJGDUW	DN	Acriflavinium chloride
DEJGDUW	RN	Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065765

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMY2AH1
DEJGDUW	DN	Aminophenazone
DEJGDUW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM8QXOC
DEJGDUW	DN	Enasidenib
DEJGDUW	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DEJGDUW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM96RD5
DEJGDUW	DN	NSC-38348
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM34V5W
DEJGDUW	DN	Fenethylline
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMGYMW4
DEJGDUW	DN	Guajazulen
DEJGDUW	RN	The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol. 1996 Apr;41(4):311-7.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8730977

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMZKABS
DEJGDUW	DN	Imipramine oxide
DEJGDUW	RN	Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993 May;43(5):827-32.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8502233

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMF57DM
DEJGDUW	DN	Pazopanib
DEJGDUW	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMQY873
DEJGDUW	DN	Pentifylline
DEJGDUW	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM2BO9W
DEJGDUW	DN	BCP-13498
DEJGDUW	RN	Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989 Jun;271(2):270-83.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2729995

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DM5DSFZ
DEJGDUW	DN	Rifampicin
DEJGDUW	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMAI83D
DEJGDUW	DN	Voxilaprevir
DEJGDUW	RN	Management of Unique Populations with HCV Infection
DEJGDUW	RU	https://www.hcvguidelines.org/unique-populations

DEJGDUW	EI	DEJGDUW
DEJGDUW	EN	Cytochrome P450 1A2 (CYP1A2)
DEJGDUW	DI	DMDGCQP
DEJGDUW	DN	Norethindrone acetate
DEJGDUW	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DEJGDUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMIKQH5
DEYGVN4	DN	Hydroxyprogesterone caproate
DEYGVN4	RN	The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos. 2007 Mar;35(3):363-70.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151189

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMDRQZU
DEYGVN4	DN	Ethanol
DEYGVN4	RN	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553666

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJ3I1Q
DEYGVN4	DN	UP-83
DEYGVN4	RN	Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm Res. 2006 Jul;23(7):1502-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783480

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM1SC8M
DEYGVN4	DN	Trimipramine
DEYGVN4	RN	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133892

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMBD4K3
DEYGVN4	DN	Selinexor
DEYGVN4	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DEYGVN4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMOGFIX
DEYGVN4	DN	Eltrombopag olamine
DEYGVN4	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM92AH3
DEYGVN4	DN	Cyproheptadine
DEYGVN4	RN	Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):486-93.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726413

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMCZGRE
DEYGVN4	DN	Dolutegravir sodium
DEYGVN4	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMF28YC
DEYGVN4	DN	Atorvastatin calcium
DEYGVN4	RN	Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17470524

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM7V2LG
DEYGVN4	DN	Chrysin
DEYGVN4	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMDKF3M
DEYGVN4	DN	Raloxifene
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM4KI7O
DEYGVN4	DN	Zidovudine
DEYGVN4	RN	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19628728

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMGVH6N
DEYGVN4	DN	Axitinib
DEYGVN4	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJX6ZG
DEYGVN4	DN	Codeine
DEYGVN4	RN	Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920168

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMQJHR7
DEYGVN4	DN	Indacaterol maleate
DEYGVN4	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM5SICT
DEYGVN4	DN	Phenolphthalein
DEYGVN4	RN	Inhibition of UDP-glucuronyltransferase activity in rat liver microsomes by pyrimidine derivatives. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995 Nov;112(3):321-5.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8838685

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8SXYG
DEYGVN4	DN	Lamotrigine
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMXCM7H
DEYGVN4	DN	Cerivastatin sodium
DEYGVN4	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMQ8JIK
DEYGVN4	DN	Chenodeoxycholic acid
DEYGVN4	RN	Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17058234

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM3S8XC
DEYGVN4	DN	Androstanolone
DEYGVN4	RN	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem. 2007 Nov 16;282(46):33466-74.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17848572

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMPQAGE
DEYGVN4	DN	Mycophenolate mofetil
DEYGVN4	RN	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790558

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMHP21E
DEYGVN4	DN	Hydromorphone
DEYGVN4	RN	Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012 Jan;50(1):1-14.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22148986

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM3KJBC
DEYGVN4	DN	Epinephrine hydrochloride
DEYGVN4	RN	Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J Steroid Biochem Mol Biol. 1991;40(4-6):593-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1835648

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMZREFQ
DEYGVN4	DN	Eslicarbazepine acetate
DEYGVN4	RN	Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21673130

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMFQWNI
DEYGVN4	DN	Clomipramine hydrochloride
DEYGVN4	RN	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133892

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRQD04
DEYGVN4	DN	Tramadol hydrochloride
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8JXPZ
DEYGVN4	DN	Glibenclamide
DEYGVN4	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMD8Q3J
DEYGVN4	DN	Gemfibrozil
DEYGVN4	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMPRI8G
DEYGVN4	DN	Buprenorphine hydrochloride
DEYGVN4	RN	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19841060

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8ZHP1
DEYGVN4	DN	Edaravone
DEYGVN4	RN	A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone. Int J Pharm. 2009 May 8;372(1-2):33-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19166920

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMODJ40
DEYGVN4	DN	Ethinyl estradiol
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMHN027
DEYGVN4	DN	Levothyroxine sodium
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM9OZWQ
DEYGVN4	DN	Lovastatin
DEYGVN4	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM3VFPD
DEYGVN4	DN	Troglitazone
DEYGVN4	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMFYBD0
DEYGVN4	DN	Dexibuprofen
DEYGVN4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM2NUH3
DEYGVN4	DN	Imipramine hydrochloride
DEYGVN4	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMUL5EW
DEYGVN4	DN	Posaconazole
DEYGVN4	RN	Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 Feb;32(2):267-71.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744950

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMKXJZ7
DEYGVN4	DN	Suprofen
DEYGVN4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMSYRBX
DEYGVN4	DN	Atazanavir
DEYGVN4	RN	In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 Nov;33(11):1729-39.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118329

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMLB0EZ
DEYGVN4	DN	Tamoxifen citrate
DEYGVN4	RN	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19244109

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMQPH29
DEYGVN4	DN	Curcumin
DEYGVN4	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8MC6O
DEYGVN4	DN	Estradiol valerate
DEYGVN4	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMAYL0T
DEYGVN4	DN	Phenylbutazone
DEYGVN4	RN	Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys. 2006 Oct 1;454(1):72-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16949544

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMT8J0I
DEYGVN4	DN	GSK-1265744
DEYGVN4	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM7EN8I
DEYGVN4	DN	Diflunisal
DEYGVN4	RN	Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. J Pharmacol Exp Ther. 1987 Sep;242(3):1013-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3656106

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMUNTE3
DEYGVN4	DN	E-3A
DEYGVN4	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8ZXT6
DEYGVN4	DN	Oxymetazoline
DEYGVN4	RN	Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. J Pharm Sci. 2011 Feb;100(2):784-93.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20669329

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMNG35S
DEYGVN4	DN	ABT-751
DEYGVN4	RN	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23670235

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMXNZM4
DEYGVN4	DN	Oxazepam
DEYGVN4	RN	Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19916996

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM7A8TW
DEYGVN4	DN	Ezetimibe
DEYGVN4	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMFORDT
DEYGVN4	DN	ICI-79,280
DEYGVN4	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMTM2IK
DEYGVN4	DN	Mercaptopurine
DEYGVN4	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM0DTF7
DEYGVN4	DN	Zonisamide
DEYGVN4	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DEYGVN4	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMGN4BY
DEYGVN4	DN	Flurbiprofen sodium
DEYGVN4	RN	Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17446261

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMTIVEN
DEYGVN4	DN	Metronidazole
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMB4OLE
DEYGVN4	DN	Propofol
DEYGVN4	RN	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17697043

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMMN36E
DEYGVN4	DN	Abacavir
DEYGVN4	RN	A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMDEXQ0
DEYGVN4	DN	Febuxostat
DEYGVN4	RN	In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18421623

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMK8U72
DEYGVN4	DN	Labetalol
DEYGVN4	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMXBYQR
DEYGVN4	DN	Silymarin
DEYGVN4	RN	Role of UDP-glucuronosyltransferase 1A1 in the metabolism and pharmacokinetics of silymarin flavonolignans in patients with HCV and NAFLD. Molecules. 2017 Jan 15;22(1). pii: E142.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28098838

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMW50NF
DEYGVN4	DN	SN-38
DEYGVN4	RN	Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb;35(2):228-33.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17108060

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMNH3PG
DEYGVN4	DN	Etoposide
DEYGVN4	RN	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151191

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM1P6FR
DEYGVN4	DN	Binimetinib
DEYGVN4	RN	Binimetinib - European Medicines Agency - European Union
DEYGVN4	RU	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-balimek-binimetinib_en.pdf

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRK8OT
DEYGVN4	DN	Candesartan cilexetil
DEYGVN4	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJPSIL
DEYGVN4	DN	TMC-120
DEYGVN4	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DEYGVN4	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM72JXH
DEYGVN4	DN	Losartan potassium
DEYGVN4	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMZ5RGV
DEYGVN4	DN	Naproxen
DEYGVN4	RN	Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18004206

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMV7YFT
DEYGVN4	DN	Darolutamide
DEYGVN4	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM5WDKY
DEYGVN4	DN	TAS-103
DEYGVN4	RN	Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 1;19(7):2084-90.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11283142

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJYCVW
DEYGVN4	DN	Warfarin sodium
DEYGVN4	RN	Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19408964

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMWMPD4
DEYGVN4	DN	Vorinostat
DEYGVN4	RN	A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct;20(10):638-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20729791

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMKSQG0
DEYGVN4	DN	Tiagabine
DEYGVN4	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DEYGVN4	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMFLJHQ
DEYGVN4	DN	LCQ908-NXA
DEYGVN4	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM1UJO0
DEYGVN4	DN	Pitavastatin calcium
DEYGVN4	RN	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519692

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMOB58Q
DEYGVN4	DN	Letermovir
DEYGVN4	RN	Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of letermovir in previously conducted clinical studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31022310

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM672AH
DEYGVN4	DN	Aspirin
DEYGVN4	RN	Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20214591

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMECBWN
DEYGVN4	DN	Riluzole
DEYGVN4	RN	Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997 Sep;282(3):1465-72.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9316860

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM30SGU
DEYGVN4	DN	Simvastatin
DEYGVN4	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMYA50U
DEYGVN4	DN	Phloretin
DEYGVN4	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMYURI6
DEYGVN4	DN	Raltegravir potassium
DEYGVN4	RN	Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact. 2011;26(3):139-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21980965

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM0YZC6
DEYGVN4	DN	Fulvestrant
DEYGVN4	RN	Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol. 2006 Mar;69(3):908-20.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16339389

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMY85QW
DEYGVN4	DN	Bazedoxifene
DEYGVN4	RN	UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene. Pharmazie. 2015 Feb;70(2):94-6.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25997248

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMGTZLW
DEYGVN4	DN	BN-1270
DEYGVN4	RN	Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats. Fundam Clin Pharmacol. 2000 Sep-Oct;14(5):509-18.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11129092

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM9ERH1
DEYGVN4	DN	AG-1549
DEYGVN4	RN	Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15205383

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM1QSM3
DEYGVN4	DN	ENT-1814
DEYGVN4	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMMFWOJ
DEYGVN4	DN	Probenecid
DEYGVN4	RN	Modulation of 3'-azido-3'-deoxythymidine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem Pharmacol. 1991 Sep 12;42(7):1475-80.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1930271

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMKSUOI
DEYGVN4	DN	HMR-1275
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMWVIGP
DEYGVN4	DN	Digitoxin
DEYGVN4	RN	Use of a human liver microsome bank in drug glucuronidation studies. Toxicol In Vitro. 1991;5(5-6):559-62.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20732077

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMG3NFZ
DEYGVN4	DN	BMS-298585
DEYGVN4	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM6WJO9
DEYGVN4	DN	Etodolac
DEYGVN4	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM5SXUV
DEYGVN4	DN	Repaglinide
DEYGVN4	RN	Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175442

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMS3GX2
DEYGVN4	DN	Telmisartan
DEYGVN4	RN	The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011 Sep;21(9):523-30.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21829131

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM7US1H
DEYGVN4	DN	Eugenol
DEYGVN4	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM8IL1U
DEYGVN4	DN	GV-150526
DEYGVN4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMUL45H
DEYGVN4	DN	Naltrexone
DEYGVN4	RN	In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18639530

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMMQ8ZG
DEYGVN4	DN	Furosemide
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMG9B1U
DEYGVN4	DN	Elvitegravir
DEYGVN4	RN	Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24696866

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMSC4A7
DEYGVN4	DN	Indomethacin
DEYGVN4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM4Y1SP
DEYGVN4	DN	YKP-509
DEYGVN4	RN	Carisbamate addon therapy for drugresistant partial epilepsy. The Cochrane Library. John Wiley Sons, Ltd, 2016.
DEYGVN4	RU	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012121/full

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM6IR3P
DEYGVN4	DN	Liothyronine
DEYGVN4	RN	FDA Label of Liothyronine sodium. The 2020 official website of the U.S. Food and Drug Administration.
DEYGVN4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/010379s054lbl.pdf

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMMOFHT
DEYGVN4	DN	Pirprofen
DEYGVN4	RN	Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1981722

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJ0QOW
DEYGVN4	DN	Rilpivirine hydrochloride
DEYGVN4	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM07U2A
DEYGVN4	DN	Estradiol acetate
DEYGVN4	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMWX5CO
DEYGVN4	DN	Nicotine
DEYGVN4	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM27Z5T
DEYGVN4	DN	Estradiol cypionate
DEYGVN4	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMUIE76
DEYGVN4	DN	Acetaminophen
DEYGVN4	RN	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28932176

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMCR1MV
DEYGVN4	DN	Itraconazole
DEYGVN4	RN	Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20304965

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM0T3YH
DEYGVN4	DN	Indinavir sulfate
DEYGVN4	RN	Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R738-43.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19571206

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMJFD2I
DEYGVN4	DN	Delafloxacin
DEYGVN4	RN	Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018 Jun;7(2):197-217.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29605887

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMNP60F
DEYGVN4	DN	Anastrozole
DEYGVN4	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMHTEAO
DEYGVN4	DN	Carvedilol
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRKXPT
DEYGVN4	DN	Ketoprofen
DEYGVN4	RN	Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/30962262

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRMS0L
DEYGVN4	DN	Morphine
DEYGVN4	RN	Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18187562

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMGNYIH
DEYGVN4	DN	Retigabine
DEYGVN4	RN	N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16713428

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMWVCF3
DEYGVN4	DN	CEM-102
DEYGVN4	RN	Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27458210

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM6OC53
DEYGVN4	DN	Belinostat
DEYGVN4	RN	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 2016 Apr;56(4):461-73.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313268

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMA2Z4F
DEYGVN4	DN	Minoxidil
DEYGVN4	RN	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004 Apr;32(4):413-23.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039294

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMCFE9I
DEYGVN4	DN	Valproic acid
DEYGVN4	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMHM93Y
DEYGVN4	DN	Meprobamate
DEYGVN4	RN	Solid-phase synthesis of drug glucuronides by immobilized glucuronosyltransferase. J Med Chem. 1976 May;19(5):679-83.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=818382

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMK7F9S
DEYGVN4	DN	Amitriptyline hydrochloride
DEYGVN4	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMOEM2I
DEYGVN4	DN	Estriol
DEYGVN4	RN	Stimulation of microsomal uridine diphosphate glucuronyltransferase by glucuronic acid derivatives. Biochem J. 1974 Apr;139(1):243-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4219139

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMZA5PQ
DEYGVN4	DN	Glipizide
DEYGVN4	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMMF5IE
DEYGVN4	DN	GS-9883
DEYGVN4	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM6ETS0
DEYGVN4	DN	Deferasirox
DEYGVN4	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMIAPBE
DEYGVN4	DN	Hydrocodone bitartrate
DEYGVN4	RN	Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics. 2003 Nov-Dec;44(6):515-20.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14597688

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMW3QGJ
DEYGVN4	DN	LM-94
DEYGVN4	RN	In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278927

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMVAOME
DEYGVN4	DN	Oleandomycin
DEYGVN4	RN	Inversion of the anomeric configuration of the transferred sugar during inactivation of the macrolide antibiotic oleandomycin catalyzed by a macrolide glycosyltransferase. FEBS Lett. 2000 Jul 7;476(3):186-9.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10913610

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DM2BO9W
DEYGVN4	DN	BCP-13498
DEYGVN4	RN	Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol. 1993 May 5;45(9):1809-14.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8494539

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRQ70X
DEYGVN4	DN	ACMC-1AKLT
DEYGVN4	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMN1YFU
DEYGVN4	DN	Anthraflavic acid
DEYGVN4	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEYGVN4	EI	DEYGVN4
DEYGVN4	EN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DEYGVN4	DI	DMRFTB5
DEYGVN4	DN	Cis-4-hydroxytamoxifen
DEYGVN4	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DEYGVN4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMXTMBJ
DEJVYAZ	DN	Azelastine
DEJVYAZ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMD157S
DEJVYAZ	DN	Montelukast sodium
DEJVYAZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMG6OYJ
DEJVYAZ	DN	Lorcaserin
DEJVYAZ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM28UJG
DEJVYAZ	DN	Dapagliflozin
DEJVYAZ	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM4KI7O
DEJVYAZ	DN	Zidovudine
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM49DUI
DEJVYAZ	DN	Tretinoin
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMCT3I8
DEJVYAZ	DN	Ifosfamide
DEJVYAZ	RN	Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12136253

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMCE985
DEJVYAZ	DN	Antipyrine
DEJVYAZ	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM6F1PU
DEJVYAZ	DN	Vortioxetine hydrobromide
DEJVYAZ	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMQI43G
DEJVYAZ	DN	BMS-650032
DEJVYAZ	RN	Australian Public Assessment Report for asunaprevir.
DEJVYAZ	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMZU5JP
DEJVYAZ	DN	Flunarizine
DEJVYAZ	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMUM7HZ
DEJVYAZ	DN	Fluorouracilo
DEJVYAZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMV9ADG
DEJVYAZ	DN	Pilocarpine
DEJVYAZ	RN	Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J. 2012 May;279(9):1621-31.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22051186

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMUY35B
DEJVYAZ	DN	Progesterone
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMTWS9E
DEJVYAZ	DN	Apremilast
DEJVYAZ	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM2AOTZ
DEJVYAZ	DN	Perazine
DEJVYAZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMLB0EZ
DEJVYAZ	DN	Tamoxifen citrate
DEJVYAZ	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMJ8AUE
DEJVYAZ	DN	Y-100032
DEJVYAZ	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DML0RAE
DEJVYAZ	DN	Methoxyflurane
DEJVYAZ	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DME8FZ9
DEJVYAZ	DN	Methoxsalen
DEJVYAZ	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMAL4G0
DEJVYAZ	DN	Flurazepam
DEJVYAZ	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMCYVDT
DEJVYAZ	DN	Chlorzoxazone
DEJVYAZ	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMTIVEN
DEJVYAZ	DN	Metronidazole
DEJVYAZ	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMB4OLE
DEJVYAZ	DN	Propofol
DEJVYAZ	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMY7PED
DEJVYAZ	DN	Cisapride
DEJVYAZ	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMH07Y3
DEJVYAZ	DN	Letrozole
DEJVYAZ	RN	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30094551

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM4O2Z7
DEJVYAZ	DN	Cyclophosphamide
DEJVYAZ	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMYM974
DEJVYAZ	DN	Arformoterol
DEJVYAZ	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMR27C8
DEJVYAZ	DN	LJPC-0118
DEJVYAZ	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM80OZ5
DEJVYAZ	DN	Halothane
DEJVYAZ	RN	Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology. 2001 Aug;95(2):509-14.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11506127

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM31ZQM
DEJVYAZ	DN	Tegafur
DEJVYAZ	RN	Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:117-20.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16897985

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMSPN58
DEJVYAZ	DN	WY-1485
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMWIO46
DEJVYAZ	DN	BRN-1907611
DEJVYAZ	RN	In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6. Biol Pharm Bull. 2007 Feb;30(2):230-3.
DEJVYAZ	RU	https://pubmed.ncbi.nlm.nih.gov/17268056

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM3VR1L
DEJVYAZ	DN	Selegiline hydrochloride
DEJVYAZ	RN	Variation in CYP2A6 activity and personalized medicine. J Pers Med. 2017 Dec 1;7(4). pii: E18.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29194389

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMPC1J7
DEJVYAZ	DN	Clofibrate
DEJVYAZ	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM6HX9B
DEJVYAZ	DN	Nevirapine
DEJVYAZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMRQAM0
DEJVYAZ	DN	Phenacetin
DEJVYAZ	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM70IK5
DEJVYAZ	DN	Dronabinol
DEJVYAZ	RN	Health control over the feeding of troops on the Western and 3d Belorussian Fronts during the Great Patriotic War years. Voen Med Zh. 1975 Jun;(6):86-8.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1103455

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM7U5QJ
DEJVYAZ	DN	Cinnarizine
DEJVYAZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DME2A8X
DEJVYAZ	DN	HSDB-3466
DEJVYAZ	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMEQH6J
DEJVYAZ	DN	Flavone
DEJVYAZ	RN	Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2019 Jul;49(7):791-802.
DEJVYAZ	RU	https://pubmed.ncbi.nlm.nih.gov/30048196

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMOY7W3
DEJVYAZ	DN	Artemisinin
DEJVYAZ	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMWX5CO
DEJVYAZ	DN	Nicotine
DEJVYAZ	RN	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22869927

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM93L4X
DEJVYAZ	DN	Dexmedetomidine hydrochloride
DEJVYAZ	RN	Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert Rev Clin Pharmacol. 2018 Sep;11(9):917-922.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30092666

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMUIE76
DEJVYAZ	DN	Acetaminophen
DEJVYAZ	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM70BU5
DEJVYAZ	DN	Thalidomide
DEJVYAZ	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMGR5Z3
DEJVYAZ	DN	Flunitrazepam
DEJVYAZ	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMC9O43
DEJVYAZ	DN	Sevoflurane
DEJVYAZ	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DML4ZOT
DEJVYAZ	DN	Lidocaine
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMCFE9I
DEJVYAZ	DN	Valproic acid
DEJVYAZ	RN	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15795555

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMX3O0D
DEJVYAZ	DN	Tegafur-uracil
DEJVYAZ	RN	UFT Capsules (uracil-tegafur).
DEJVYAZ	RU	https://hemonc.org/docs/packageinsert/uraciltegafur.pdf

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMFC71L
DEJVYAZ	DN	Clozapine
DEJVYAZ	RN	Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23297297

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM8KLU9
DEJVYAZ	DN	Cenobamate
DEJVYAZ	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEJVYAZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMM75WZ
DEJVYAZ	DN	Chloroxylenol
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMV3P89
DEJVYAZ	DN	Levoverbenone
DEJVYAZ	RN	Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos. 2003 Aug;31(8):1049-53.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12867494

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM0UGYX
DEJVYAZ	DN	Medifoxamine
DEJVYAZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMO7M2N
DEJVYAZ	DN	Nicotinyl alcohol
DEJVYAZ	RN	Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1396-400.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18559554

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMIZMYQ
DEJVYAZ	DN	Roxatidine
DEJVYAZ	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMDGCQP
DEJVYAZ	DN	Norethindrone acetate
DEJVYAZ	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DMKEG49
DEJVYAZ	DN	Fenthion
DEJVYAZ	RN	The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):343-52.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18845175

DEJVYAZ	EI	DEJVYAZ
DEJVYAZ	EN	Cytochrome P450 2A6 (CYP2A6)
DEJVYAZ	DI	DM4OLRS
DEJVYAZ	DN	Fenthion sulfoxide
DEJVYAZ	RN	The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):343-52.
DEJVYAZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18845175

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMLYGH4
DE6OQ3W	DN	Niraparib
DE6OQ3W	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19873981

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM5T6US
DE6OQ3W	DN	Estrone
DE6OQ3W	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMQUSBT
DE6OQ3W	DN	Daunorubicin
DE6OQ3W	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM4K7GQ
DE6OQ3W	DN	Erythromycin stearate
DE6OQ3W	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMSJDTY
DE6OQ3W	DN	Menadione
DE6OQ3W	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DME4RA8
DE6OQ3W	DN	Amodiaquine
DE6OQ3W	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM8YMWE
DE6OQ3W	DN	Riboflavin
DE6OQ3W	RN	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9512490

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMXBLMP
DE6OQ3W	DN	Riociguat
DE6OQ3W	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMQYUWG
DE6OQ3W	DN	Toremifene citrate
DE6OQ3W	RN	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8204106

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMZU5JP
DE6OQ3W	DN	Flunarizine
DE6OQ3W	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMJ3HQY
DE6OQ3W	DN	GTPL-1666
DE6OQ3W	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMEQL9U
DE6OQ3W	DN	CAM-2028
DE6OQ3W	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMODJ40
DE6OQ3W	DN	Ethinyl estradiol
DE6OQ3W	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMGBPME
DE6OQ3W	DN	NSC-659853
DE6OQ3W	RN	Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Mini Rev Med Chem. 2015;15(5):427-38.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25723461

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM60QMR
DE6OQ3W	DN	MK-595
DE6OQ3W	RN	Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10323333

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM3VFPD
DE6OQ3W	DN	Troglitazone
DE6OQ3W	RN	Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534310

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMUY35B
DE6OQ3W	DN	Progesterone
DE6OQ3W	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM2AOTZ
DE6OQ3W	DN	Perazine
DE6OQ3W	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMLB0EZ
DE6OQ3W	DN	Tamoxifen citrate
DE6OQ3W	RN	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124303

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMQXYRG
DE6OQ3W	DN	NSC-603071
DE6OQ3W	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM4MDJY
DE6OQ3W	DN	Fluvastatin sodium
DE6OQ3W	RN	Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197-204.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937853

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMIK367
DE6OQ3W	DN	Procarbazine
DE6OQ3W	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMUNTE3
DE6OQ3W	DN	E-3A
DE6OQ3W	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMSI5CB
DE6OQ3W	DN	Chloroquine
DE6OQ3W	RN	In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12756207

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMTM2IK
DE6OQ3W	DN	Mercaptopurine
DE6OQ3W	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMKWFBT
DE6OQ3W	DN	Melatonin
DE6OQ3W	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM96SE0
DE6OQ3W	DN	Haloperidol decanoate
DE6OQ3W	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMRJFN9
DE6OQ3W	DN	Theophylline
DE6OQ3W	RN	Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8474022

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMMHSLC
DE6OQ3W	DN	CS-5245
DE6OQ3W	RN	Methods to Assess Pulmonary Metabolism.
DE6OQ3W	RU	https://edoc.unibas.ch/69409/1/110219_Doctoral_Thesis_Yildiz_Yilmaz.pdf

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMECBWN
DE6OQ3W	DN	Riluzole
DE6OQ3W	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMYURI6
DE6OQ3W	DN	Raltegravir potassium
DE6OQ3W	RN	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20926993

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMPC1J7
DE6OQ3W	DN	Clofibrate
DE6OQ3W	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMIUW25
DE6OQ3W	DN	Granisetron hydrochloride
DE6OQ3W	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMUTEX3
DE6OQ3W	DN	Amiodarone hydrochloride
DE6OQ3W	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMC50ME
DE6OQ3W	DN	BS-3952
DE6OQ3W	RN	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023534

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMRQAM0
DE6OQ3W	DN	Phenacetin
DE6OQ3W	RN	Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901704

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM70IK5
DE6OQ3W	DN	Dronabinol
DE6OQ3W	RN	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15714209

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DME2A8X
DE6OQ3W	DN	HSDB-3466
DE6OQ3W	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DM0IO13
DE6OQ3W	DN	CCRIS-1920
DE6OQ3W	RN	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol. 2006 Apr;58(4):449-57.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16597362

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMLOS5R
DE6OQ3W	DN	Copanlisib
DE6OQ3W	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DE6OQ3W	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMF3VXA
DE6OQ3W	DN	Zotepine
DE6OQ3W	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMWX5CO
DE6OQ3W	DN	Nicotine
DE6OQ3W	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMPIHLS
DE6OQ3W	DN	Diclofenac sodium
DE6OQ3W	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMGMF6V
DE6OQ3W	DN	Capsaicin
DE6OQ3W	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMUIE76
DE6OQ3W	DN	Acetaminophen
DE6OQ3W	RN	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8145237

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMCD9YG
DE6OQ3W	DN	Prazosin
DE6OQ3W	RN	Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15627480

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMCKYZ5
DE6OQ3W	DN	NAB-365
DE6OQ3W	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMGNYIH
DE6OQ3W	DN	Retigabine
DE6OQ3W	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMK0O7U
DE6OQ3W	DN	Flutamide
DE6OQ3W	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMQNWRD
DE6OQ3W	DN	Oxaliplatin
DE6OQ3W	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMNPZL4
DE6OQ3W	DN	Dacarbazine
DE6OQ3W	RN	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10473105

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMSFWT7
DE6OQ3W	DN	SHR-1020
DE6OQ3W	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DE6OQ3W	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMYZJ5B
DE6OQ3W	DN	Acriflavinium chloride
DE6OQ3W	RN	Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol. 2002 Jul;62(1):143-53.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065765

DE6OQ3W	EI	DE6OQ3W
DE6OQ3W	EN	Cytochrome P450 1A1 (CYP1A1)
DE6OQ3W	DI	DMC1TEV
DE6OQ3W	DN	Testosterone cypionate
DE6OQ3W	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DE6OQ3W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMCE985
DEZV4AP	DN	Antipyrine
DEZV4AP	RN	Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy. 2000 Feb;20(2):182-90.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10678296

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMLPAOB
DEZV4AP	DN	Allopurinol
DEZV4AP	RN	Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10027663

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMTW3R8
DEZV4AP	DN	Sulfadiazine
DEZV4AP	RN	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843491

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DM79GRO
DEZV4AP	DN	Metamizole sodium
DEZV4AP	RN	N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3037-43.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20884738

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMUI0CH
DEZV4AP	DN	Tobramycin
DEZV4AP	RN	Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1577689

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMHTXSL
DEZV4AP	DN	Arbekacin
DEZV4AP	RN	The novel enzymatic 3''-N-acetylation of arbekacin by an aminoglycoside 3-N-acetyltransferase of Streptomyces origin and the resulting activity. J Antibiot (Tokyo). 1998 Aug;51(8):735-42.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9766465

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMRD1QK
DEZV4AP	DN	Netilmicin
DEZV4AP	RN	Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12709325

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMKBJWP
DEZV4AP	DN	Caffeine
DEZV4AP	RN	A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8354022

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMOL5IU
DEZV4AP	DN	Mesalazine
DEZV4AP	RN	NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18322880

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMTO13J
DEZV4AP	DN	Clonazepam
DEZV4AP	RN	Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356010

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMIUYFH
DEZV4AP	DN	Sulfapyridine
DEZV4AP	RN	Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009 Sep;407(1-2):30-5.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19560446

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMU8JGH
DEZV4AP	DN	Hydralazine hydrochloride
DEZV4AP	RN	Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6111409

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMLQVTJ
DEZV4AP	DN	Octopamine
DEZV4AP	RN	[N-acetylation of biogenic amines in Drosophila virilis]. Genetika. 1997 Jun;33(6):788-92.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9289416

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMZIXU9
DEZV4AP	DN	Dihydralazine
DEZV4AP	RN	The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23 Suppl 1:S74-8.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3842694

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMB08GE
DEZV4AP	DN	Sulfamethoxazole
DEZV4AP	RN	Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17909290

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMNMXR8
DEZV4AP	DN	Procainamide hydrochloride
DEZV4AP	RN	Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1371435

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMEMBJC
DEZV4AP	DN	Folic acid
DEZV4AP	RN	Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1329759

DEZV4AP	EI	DEZV4AP
DEZV4AP	EN	RNA cytidine acetyltransferase (hALP)
DEZV4AP	DI	DMNGW2M
DEZV4AP	DN	Aminobenzoic acid
DEZV4AP	RN	Leukemia inhibitory factor decreases the arylamine N-acetyltransferase activity in human cumulus granulosa cells. J Assist Reprod Genet. 2001 Dec;18(12):660-4.
DEZV4AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11808848

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMIVJ0D
DEYWLRK	DN	Pseudoephedrine
DEYWLRK	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM4V6RL
DEYWLRK	DN	Ritodrine
DEYWLRK	RN	Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res. 2005 Aug;22(8):1406-10.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16078151

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM6LOQU
DEYWLRK	DN	Celecoxib
DEYWLRK	RN	Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17239972

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM3KJBC
DEYWLRK	DN	Epinephrine hydrochloride
DEYWLRK	RN	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16083857

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMBVYDI
DEYWLRK	DN	Benzyl alcohol
DEYWLRK	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM746BZ
DEYWLRK	DN	Clioquinol
DEYWLRK	RN	Clioquinol is sulfated by human jejunum cytosol and SULT1A3, a human-specific dopamine sulfotransferase. Toxicol Lett. 2011 Oct 10;206(2):229-33.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21820498

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMM2NSK
DEYWLRK	DN	Adenosine
DEYWLRK	RN	Regulation of sulfate assimilation in plants: 7. Cysteine inactivation of adenosine 5'-phosphosulfate sulfotransferase in Lemna minor L. Plant Physiol. 1978 Mar;61(3):342-7.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16660289

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMUY35B
DEYWLRK	DN	Progesterone
DEYWLRK	RN	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16879988

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMLB0EZ
DEYWLRK	DN	Tamoxifen citrate
DEYWLRK	RN	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19812351

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMUNTE3
DEYWLRK	DN	E-3A
DEYWLRK	RN	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21669803

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM5I621
DEYWLRK	DN	Methyldopa
DEYWLRK	RN	Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther. 1984 Jan;35(1):55-63.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6580988

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMJYCVW
DEYWLRK	DN	Warfarin sodium
DEYWLRK	RN	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11824526

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM672AH
DEYWLRK	DN	Aspirin
DEYWLRK	RN	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17073578

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMX38HQ
DEYWLRK	DN	Apomorphine
DEYWLRK	RN	Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14660177

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMAQ2LK
DEYWLRK	DN	Teicoplanin
DEYWLRK	RN	The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123867

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMMV0KW
DEYWLRK	DN	Ephedrin
DEYWLRK	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMWVIGP
DEYWLRK	DN	Digitoxin
DEYWLRK	RN	Hydroxysteroid sulfotransferase and a specific UDP-glucuronosyltransferase are involved in the metabolism of digitoxin in man. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):226-33.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1448185

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM7OKQV
DEYWLRK	DN	Cholic acid
DEYWLRK	RN	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20102295

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM6IR3P
DEYWLRK	DN	Liothyronine
DEYWLRK	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMSVOCZ
DEYWLRK	DN	Pantoprazole sodium
DEYWLRK	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMUIE76
DEYWLRK	DN	Acetaminophen
DEYWLRK	RN	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM78XFG
DEYWLRK	DN	Tibolone
DEYWLRK	RN	Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids. 2006 May;71(5):343-51.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16360722

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMA2Z4F
DEYWLRK	DN	Minoxidil
DEYWLRK	RN	Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998 Feb 20;109(1-3):53-67.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9566733

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMJIBAW
DEYWLRK	DN	Budesonide
DEYWLRK	RN	Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11950791

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMNGW2M
DEYWLRK	DN	Aminobenzoic acid
DEYWLRK	RN	Activities of drug metabolizing enzymes in bovine colon epithelial cell cultures. Arch Toxicol. 2003 Nov;77(11):621-9.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14508638

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM3SZ7P
DEYWLRK	DN	CERC-801
DEYWLRK	RN	Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase-1. J Biol Chem. 2008 Oct 10;283(41):27438-43.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18697746

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMP7X6Q
DEYWLRK	DN	Rotigotine
DEYWLRK	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DMVJD1A
DEYWLRK	DN	Triiodo-l-thyronine
DEYWLRK	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM917FE
DEYWLRK	DN	Diiodo-l-thyronine
DEYWLRK	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DEYWLRK	EI	DEYWLRK
DEYWLRK	EN	Sulfotransferase 1A1 (SULT1A1)
DEYWLRK	DI	DM83HWL
DEYWLRK	DN	L-thyroxine
DEYWLRK	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DEYWLRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM13495
DECB0K3	DN	Fesoterodine
DECB0K3	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6W8V5
DECB0K3	DN	Lisdexamfetamine
DECB0K3	RN	Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24594478

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1SC8M
DECB0K3	DN	Trimipramine
DECB0K3	RN	Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16342006

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTNFCQ
DECB0K3	DN	Levobunolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSQZE2
DECB0K3	DN	Asenapine maleate
DECB0K3	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMXTMBJ
DECB0K3	DN	Azelastine
DECB0K3	RN	Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383922

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMW83TP
DECB0K3	DN	Pimozide
DECB0K3	RN	The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25868121

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSW051
DECB0K3	DN	R-58735
DECB0K3	RN	Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Br J Clin Pharmacol. 2001 Feb;51(2):164-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259989

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCXRZF
DECB0K3	DN	LY-2603618
DECB0K3	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOQ81Y
DECB0K3	DN	RSD-1235
DECB0K3	RN	Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18927241

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMT4VSE
DECB0K3	DN	BMY-42569
DECB0K3	RN	Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600718

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOYE70
DECB0K3	DN	HOE-239
DECB0K3	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMINO7Z
DECB0K3	DN	WSM-3978G
DECB0K3	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK1GBJ
DECB0K3	DN	Trazodone hydrochloride
DECB0K3	RN	Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27643409

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMX4GND
DECB0K3	DN	Meperidine
DECB0K3	RN	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319333

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3XYD1
DECB0K3	DN	Tegaserod
DECB0K3	RN	In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560869

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMMG26Z
DECB0K3	DN	Dolasetron mesylate
DECB0K3	RN	Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22427733

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM9BI7M
DECB0K3	DN	Duloxetine hydrochloride
DECB0K3	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMN6DXL
DECB0K3	DN	Risperidone
DECB0K3	RN	Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16321618

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKQTBA
DECB0K3	DN	Diphenhydramine
DECB0K3	RN	Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020955

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMVXFYE
DECB0K3	DN	Vinorelbine tartrate
DECB0K3	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG6OYJ
DECB0K3	DN	Lorcaserin
DECB0K3	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1YBRM
DECB0K3	DN	Cyclobenzaprine
DECB0K3	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMGQF3R
DECB0K3	DN	Remoxipride
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMZFICR
DECB0K3	DN	Bevantolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTUPZ2
DECB0K3	DN	CJ-11974
DECB0K3	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM28UJG
DECB0K3	DN	Dapagliflozin
DECB0K3	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMT2FDC
DECB0K3	DN	Desipramine
DECB0K3	RN	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8880055

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNKG1Z
DECB0K3	DN	Atenolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYJ8Z3
DECB0K3	DN	Alprenolol
DECB0K3	RN	Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25369508

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMM0XGL
DECB0K3	DN	Idarubicin
DECB0K3	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTY9LU
DECB0K3	DN	Piperazine
DECB0K3	RN	Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228152

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBGZI3
DECB0K3	DN	Chlorpromazine hydrochloride
DECB0K3	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNZWL7
DECB0K3	DN	RO-111163
DECB0K3	RN	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7781267

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCRGY4
DECB0K3	DN	BNP-1350
DECB0K3	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMW649X
DECB0K3	DN	Eletriptan hydrobromide
DECB0K3	RN	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814962

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMDJW5K
DECB0K3	DN	Ajmaline
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0NZDT
DECB0K3	DN	CS-505
DECB0K3	RN	Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18524873

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMA4MRX
DECB0K3	DN	Perphenazine
DECB0K3	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNSJFD
DECB0K3	DN	Indoramin
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM65AGJ
DECB0K3	DN	Oxymorphone
DECB0K3	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6L4H2
DECB0K3	DN	Cobicistat
DECB0K3	RN	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
DECB0K3	RU	https://academic.oup.com/jac/article/71/7/1755/1750409

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPWGBR
DECB0K3	DN	Triclabendazole
DECB0K3	RN	FDA Label of Egaten. The 2020 official website of the U.S. Food and Drug Administration.
DECB0K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DME2PY5
DECB0K3	DN	Midodrine
DECB0K3	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJE6KO
DECB0K3	DN	Desvenlafaxine succinate
DECB0K3	RN	Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10233212

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSQDLE
DECB0K3	DN	Flecainide acetate
DECB0K3	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSWYF5
DECB0K3	DN	Quinine sulfate
DECB0K3	RN	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12703961

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJX6ZG
DECB0K3	DN	Codeine
DECB0K3	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLZTP9
DECB0K3	DN	Ipecac
DECB0K3	RN	Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. doi: 10.1002/9781118105955.ch13
DECB0K3	RU	https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118105955.ch13

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM47TSV
DECB0K3	DN	Repinotan
DECB0K3	RN	Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006 Feb;21(1):61-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16547395

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFMDOB
DECB0K3	DN	Carteolol hydrochloride
DECB0K3	RN	Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9413916

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0C9IL
DECB0K3	DN	Ranolazine
DECB0K3	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1NG5W
DECB0K3	DN	Hydrogen peroxide
DECB0K3	RN	Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos. 2006 Dec;34(12):1958-65.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16987939

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCE985
DECB0K3	DN	Antipyrine
DECB0K3	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPWB7T
DECB0K3	DN	Maprotiline hydrochloride
DECB0K3	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM9PLRH
DECB0K3	DN	Doxazosin
DECB0K3	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMV52CP
DECB0K3	DN	MJ-13105
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMMJ1IS
DECB0K3	DN	Fluphenazine decanoate
DECB0K3	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG2X3E
DECB0K3	DN	Pyrantel
DECB0K3	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM42GP9
DECB0K3	DN	DOV-220075
DECB0K3	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6EUL5
DECB0K3	DN	Betaxolol
DECB0K3	RN	Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635183

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG3Y89
DECB0K3	DN	Trabectedin
DECB0K3	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6LOQU
DECB0K3	DN	Celecoxib
DECB0K3	RN	Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30219715

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2L3D5
DECB0K3	DN	Tertatolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6RZ9Q
DECB0K3	DN	Clonidine
DECB0K3	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMZMSCT
DECB0K3	DN	Cilostazol
DECB0K3	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6F1PU
DECB0K3	DN	Vortioxetine hydrobromide
DECB0K3	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM51TYR
DECB0K3	DN	Esmolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCX0K3
DECB0K3	DN	Cinacalcet hydrochloride
DECB0K3	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2ZGAN
DECB0K3	DN	Mesoridazine
DECB0K3	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5L6HI
DECB0K3	DN	Atomoxetine hydrochloride
DECB0K3	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBHMOX
DECB0K3	DN	Palonosetron hydrochloride
DECB0K3	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM79NTF
DECB0K3	DN	Propranolol hydrochloride
DECB0K3	RN	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996013

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHP21E
DECB0K3	DN	Hydromorphone
DECB0K3	RN	Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9067326

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSOURV
DECB0K3	DN	Formoterol
DECB0K3	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7TOWX
DECB0K3	DN	ABT-333
DECB0K3	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7YNV9
DECB0K3	DN	Iclaprim
DECB0K3	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMQI43G
DECB0K3	DN	BMS-650032
DECB0K3	RN	Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015 Dec;54(12):1205-22.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26177803

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSVOZT
DECB0K3	DN	Nifedipine
DECB0K3	RN	Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8751138

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML60TN
DECB0K3	DN	Sotalol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4KDYJ
DECB0K3	DN	Nortriptyline hydrochloride
DECB0K3	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSOX7I
DECB0K3	DN	Cocaine
DECB0K3	RN	Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFQWNI
DECB0K3	DN	Clomipramine hydrochloride
DECB0K3	RN	The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 Jun;277(3):1659-64.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8667235

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSZQAK
DECB0K3	DN	Amphetamine
DECB0K3	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMZU5JP
DECB0K3	DN	Flunarizine
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMA8FS5
DECB0K3	DN	Dronedarone hydrochloride
DECB0K3	RN	Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28942006

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHZJCG
DECB0K3	DN	Pentamidine isethionate
DECB0K3	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMRQD04
DECB0K3	DN	Tramadol hydrochloride
DECB0K3	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMO946V
DECB0K3	DN	Ticlopidine
DECB0K3	RN	Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28496987

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5QF9V
DECB0K3	DN	Tamsulosin
DECB0K3	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBVYDI
DECB0K3	DN	Benzyl alcohol
DECB0K3	RN	Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717179

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBW7VH
DECB0K3	DN	Methyprylon
DECB0K3	RN	Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-94.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12016549

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3NXRU
DECB0K3	DN	Timolol maleate
DECB0K3	RN	Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27534869

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJYDVK
DECB0K3	DN	Cariprazine hydrochloride
DECB0K3	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMA8DPN
DECB0K3	DN	Dexchlorpheniramine maleate
DECB0K3	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML53ZJ
DECB0K3	DN	Mirtazapine
DECB0K3	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF3AN7
DECB0K3	DN	Loratadine
DECB0K3	RN	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11502723

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPRI8G
DECB0K3	DN	Buprenorphine hydrochloride
DECB0K3	RN	Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684471

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6MDCF
DECB0K3	DN	TRV-130
DECB0K3	RN	First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24122908

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJ3HQY
DECB0K3	DN	GTPL-1666
DECB0K3	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPI98T
DECB0K3	DN	Doxepin hydrochloride
DECB0K3	RN	Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15520506

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMEQL9U
DECB0K3	DN	CAM-2028
DECB0K3	RN	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012553

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5PVQE
DECB0K3	DN	Paroxetine hydrochloride
DECB0K3	RN	Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25974703

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK0GHV
DECB0K3	DN	Encainide
DECB0K3	RN	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000 Feb;38(2):111-80.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709776

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLK2QH
DECB0K3	DN	Nateglinide
DECB0K3	RN	Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005635

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF93U1
DECB0K3	DN	TV-1203
DECB0K3	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DECB0K3	RU	http://www.ncbi.nlm.nih.gov/pubmed/14555336

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMW51AX
DECB0K3	DN	Q-100648
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOH8VY
DECB0K3	DN	Dacomitinib
DECB0K3	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2NUH3
DECB0K3	DN	Imipramine hydrochloride
DECB0K3	RN	QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15687478

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUY35B
DECB0K3	DN	Progesterone
DECB0K3	RN	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15469888

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCT2YF
DECB0K3	DN	Q-100155
DECB0K3	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6VP9U
DECB0K3	DN	INN-00835
DECB0K3	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DECB0K3	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2AOTZ
DECB0K3	DN	Perazine
DECB0K3	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLB0EZ
DECB0K3	DN	Tamoxifen citrate
DECB0K3	RN	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20425602

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOMK1V
DECB0K3	DN	Halofantrine
DECB0K3	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCMBHA
DECB0K3	DN	Erlotinib hydrochloride
DECB0K3	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5UGDK
DECB0K3	DN	Mephenytoin
DECB0K3	RN	Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499174

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML0RAE
DECB0K3	DN	Methoxyflurane
DECB0K3	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1XT4N
DECB0K3	DN	Tafenoquine
DECB0K3	RN	Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27528800

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMVP5YE
DECB0K3	DN	Doxorubicin
DECB0K3	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCA7LN
DECB0K3	DN	Oxycodone hydrochloride
DECB0K3	RN	Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26227254

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMQ52JG
DECB0K3	DN	Phenformin
DECB0K3	RN	Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4MDJY
DECB0K3	DN	Fluvastatin sodium
DECB0K3	RN	Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368292

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMN3E57
DECB0K3	DN	Levodopa
DECB0K3	RN	Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433806

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFK9HG
DECB0K3	DN	Escitalopram
DECB0K3	RN	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24302953

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4KLPT
DECB0K3	DN	Terfenadine
DECB0K3	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK1ZOR
DECB0K3	DN	Vincamine
DECB0K3	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFA5MY
DECB0K3	DN	Metoclopramide hydrochloride
DECB0K3	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCYVDT
DECB0K3	DN	Chlorzoxazone
DECB0K3	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSI5CB
DECB0K3	DN	Chloroquine
DECB0K3	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMW4M97
DECB0K3	DN	Clevidipine
DECB0K3	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMAFBCY
DECB0K3	DN	Mequitazine
DECB0K3	RN	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9454781

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKITQE
DECB0K3	DN	Amoxapine
DECB0K3	RN	Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24294487

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWGRQD
DECB0K3	DN	LU-AE58054
DECB0K3	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHZCPO
DECB0K3	DN	Ibrutinib
DECB0K3	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIKFEL
DECB0K3	DN	Levomepromazine
DECB0K3	RN	Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25369508

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUDJZM
DECB0K3	DN	Dextromethorphan hydrobromide
DECB0K3	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTW6IU
DECB0K3	DN	Methadone
DECB0K3	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYWQ0O
DECB0K3	DN	Tetrabenazine
DECB0K3	RN	Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
DECB0K3	RU	http://www.ncbi.nlm.nih.gov/pubmed/20442355

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSPJG2
DECB0K3	DN	Ropivacaine hydrochloride
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM15F0X
DECB0K3	DN	Gefitinib
DECB0K3	RN	Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176119

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM32GSJ
DECB0K3	DN	Umeclidinium bromide
DECB0K3	RN	The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24004659

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4PRFC
DECB0K3	DN	Bupivacaine hydrochloride
DECB0K3	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLMXE0
DECB0K3	DN	Amprenavir
DECB0K3	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMB4OLE
DECB0K3	DN	Propofol
DECB0K3	RN	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9764927

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSREPX
DECB0K3	DN	Levobetaxolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK8U72
DECB0K3	DN	Labetalol
DECB0K3	RN	Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1613128

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMQ4TJK
DECB0K3	DN	Dutasteride
DECB0K3	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1F42Z
DECB0K3	DN	KW-4354
DECB0K3	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBDPY0
DECB0K3	DN	KW-5338
DECB0K3	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7RJXL
DECB0K3	DN	Imatinib mesylate
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM53SRA
DECB0K3	DN	Prochlorperazine
DECB0K3	RN	Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15025745

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKBJWP
DECB0K3	DN	Caffeine
DECB0K3	RN	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9617978

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7NPJS
DECB0K3	DN	Paliperidone
DECB0K3	RN	Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15767244

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5URA2
DECB0K3	DN	Chlorpheniramine
DECB0K3	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0GUSX
DECB0K3	DN	Ranitidine
DECB0K3	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5I621
DECB0K3	DN	Methyldopa
DECB0K3	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSHPW8
DECB0K3	DN	Tolterodine tartrate
DECB0K3	RN	Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20530222

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHKJ5I
DECB0K3	DN	GW-1000
DECB0K3	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG0EL7
DECB0K3	DN	Methoxybufotenin
DECB0K3	RN	Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010 Oct;11(8):659-66.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20942780

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTW79H
DECB0K3	DN	Aminobutyric acid
DECB0K3	RN	Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14563706

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOJZQ9
DECB0K3	DN	Loperamide hydrochloride
DECB0K3	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKI7RB
DECB0K3	DN	Enclomiphene
DECB0K3	RN	CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445989

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM96SE0
DECB0K3	DN	Haloperidol decanoate
DECB0K3	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYM974
DECB0K3	DN	Arformoterol
DECB0K3	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM23HCX
DECB0K3	DN	Dextropropoxyphene
DECB0K3	RN	Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9143866

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPUOXF
DECB0K3	DN	G-33040
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM80OZ5
DECB0K3	DN	Halothane
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMX0K3Q
DECB0K3	DN	Epinastine
DECB0K3	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUPFLI
DECB0K3	DN	Deutetrabenazine
DECB0K3	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DECB0K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM8HJX6
DECB0K3	DN	Tipranavir
DECB0K3	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM20VSK
DECB0K3	DN	Istradefylline
DECB0K3	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYVU47
DECB0K3	DN	CCRIS-9277
DECB0K3	RN	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228154

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMVHJLX
DECB0K3	DN	M-813
DECB0K3	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMRJFN9
DECB0K3	DN	Theophylline
DECB0K3	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJ7YDS
DECB0K3	DN	Dexfenfluramine
DECB0K3	RN	Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics. 1998 Oct;8(5):423-32.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9825834

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMEKAYI
DECB0K3	DN	R-1124
DECB0K3	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3NF5G
DECB0K3	DN	Delavirdine mesylate
DECB0K3	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMZKYIV
DECB0K3	DN	Amsacrine
DECB0K3	RN	Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10955788

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYGJQO
DECB0K3	DN	Ponatinib hydrochloride
DECB0K3	RN	Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28882992

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM30SGU
DECB0K3	DN	Simvastatin
DECB0K3	RN	Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15285699

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3NUMH
DECB0K3	DN	Aripiprazole lauroxil
DECB0K3	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJCP1Y
DECB0K3	DN	Yohimbine
DECB0K3	RN	Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008 Aug;20(8):891-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18433425

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMV6KFY
DECB0K3	DN	Dapoxetine
DECB0K3	RN	Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23024705

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIFYLX
DECB0K3	DN	Bopindolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1N62C
DECB0K3	DN	Quetiapine fumarate
DECB0K3	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0TI4U
DECB0K3	DN	Acebutolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM458UM
DECB0K3	DN	Captopril
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOJ0V6
DECB0K3	DN	Metoprolol succinate
DECB0K3	RN	The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30248178

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMICMXE
DECB0K3	DN	SSR-97193
DECB0K3	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPK34E
DECB0K3	DN	P-459
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKYD5N
DECB0K3	DN	Zuclopenthixol
DECB0K3	RN	Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26514968

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSM2KE
DECB0K3	DN	Nitrofural
DECB0K3	RN	Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):1008-16.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10939229

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMVO1C0
DECB0K3	DN	Valbenazine
DECB0K3	RN	Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018 Apr;18(4):323-332.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557243

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMTEQ0G
DECB0K3	DN	CGP-11305A
DECB0K3	RN	Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol. 1993;45(3):265-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8276052

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPIBJK
DECB0K3	DN	Propafenone hydrochloride
DECB0K3	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3VR1L
DECB0K3	DN	Selegiline hydrochloride
DECB0K3	RN	Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease. Rinsho Shinkeigaku. 2005 Nov;45(11):895-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16447756

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPC1J7
DECB0K3	DN	Clofibrate
DECB0K3	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIUW25
DECB0K3	DN	Granisetron hydrochloride
DECB0K3	RN	Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12943486

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUIBV8
DECB0K3	DN	NE-10064
DECB0K3	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSRZAO
DECB0K3	DN	Eliglustat tartrate
DECB0K3	RN	Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25239269

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNSJ7V
DECB0K3	DN	Tropisetron
DECB0K3	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1WXA6
DECB0K3	DN	Lofexidine
DECB0K3	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DECB0K3	RU	https://www.fda.gov/media/111903/download

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0FB1J
DECB0K3	DN	Sertraline hydrochloride
DECB0K3	RN	Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15199661

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMMP5SI
DECB0K3	DN	Revefenacin
DECB0K3	RN	A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29096627

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3UZ95
DECB0K3	DN	Bisoprolol
DECB0K3	RN	Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14732961

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMXLSH3
DECB0K3	DN	Tapentadol
DECB0K3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2NA4K
DECB0K3	DN	Ciclesonide
DECB0K3	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMOTQ1I
DECB0K3	DN	Ondansetron
DECB0K3	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWK9BX
DECB0K3	DN	SQ-109
DECB0K3	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMGLZ26
DECB0K3	DN	Practolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG592Q
DECB0K3	DN	Solifenacin succinate
DECB0K3	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJMVKI
DECB0K3	DN	Metipranolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUTEX3
DECB0K3	DN	Amiodarone hydrochloride
DECB0K3	RN	Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688833

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLQVTJ
DECB0K3	DN	Octopamine
DECB0K3	RN	Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998 Aug 28;249(3):838-43.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9731223

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG3NFZ
DECB0K3	DN	BMS-298585
DECB0K3	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJKROX
DECB0K3	DN	Fluvoxamine maleate
DECB0K3	RN	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10774624

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6AUFY
DECB0K3	DN	Iloperidone
DECB0K3	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM48QOT
DECB0K3	DN	Artemether
DECB0K3	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMC50ME
DECB0K3	DN	BS-3952
DECB0K3	RN	Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726636

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0YROF
DECB0K3	DN	Ethylmorphine
DECB0K3	RN	A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal. 2002 Aug 22;30(1):113-24.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12151071

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM8WI3R
DECB0K3	DN	Alogliptin
DECB0K3	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIYG7Z
DECB0K3	DN	Donepezil hydrochloride
DECB0K3	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0659E
DECB0K3	DN	Cannabidiol
DECB0K3	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6HX9B
DECB0K3	DN	Nevirapine
DECB0K3	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMRQAM0
DECB0K3	DN	Phenacetin
DECB0K3	RN	Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10189256

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUDWP9
DECB0K3	DN	Mepindolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMAI7ZV
DECB0K3	DN	Diltiazem hydrochloride
DECB0K3	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMMP65N
DECB0K3	DN	Sertindole
DECB0K3	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHG57U
DECB0K3	DN	Brexpiprazole
DECB0K3	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMR6QH0
DECB0K3	DN	Venlafaxine hydrochloride
DECB0K3	RN	The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30485867

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2QDX1
DECB0K3	DN	Oxamniquine
DECB0K3	RN	Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7621845

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIT8LX
DECB0K3	DN	Fluphenazine enanthate
DECB0K3	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPM4SK
DECB0K3	DN	Metamfetamine
DECB0K3	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMY3JWO
DECB0K3	DN	WR-6026
DECB0K3	RN	Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25870069

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7U5QJ
DECB0K3	DN	Cinnarizine
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWSMND
DECB0K3	DN	Cevimeline hydrochloride
DECB0K3	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMGX5Q0
DECB0K3	DN	Org-33062
DECB0K3	RN	Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15057659

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMVKA4O
DECB0K3	DN	Mianserin
DECB0K3	RN	Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15779673

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMA9CSG
DECB0K3	DN	Methoxyamphetamine beta
DECB0K3	RN	Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9264312

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMEO794
DECB0K3	DN	Galantamine hydrobromide
DECB0K3	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIG5W8
DECB0K3	DN	RD-4593
DECB0K3	RN	Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):127-33.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17574934

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNO38U
DECB0K3	DN	Bortezomib
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCDYW7
DECB0K3	DN	Nicardipine hydrochloride
DECB0K3	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSWLM5
DECB0K3	DN	CP-122721
DECB0K3	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWOSKJ
DECB0K3	DN	Zolpidem tartrate
DECB0K3	RN	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12469329

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMS7T13
DECB0K3	DN	Meclizine
DECB0K3	RN	Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21903894

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6I5GR
DECB0K3	DN	Promethazine
DECB0K3	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMMIHVP
DECB0K3	DN	Dextroamphetamine
DECB0K3	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF3VXA
DECB0K3	DN	Zotepine
DECB0K3	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMB0FWL
DECB0K3	DN	Dihydrocodeine
DECB0K3	RN	The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12665158

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPGUCF
DECB0K3	DN	Dopamine hydrochloride
DECB0K3	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWX5CO
DECB0K3	DN	Nicotine
DECB0K3	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM3PD2C
DECB0K3	DN	Fluoxetine hydrochloride
DECB0K3	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM702MU
DECB0K3	DN	ITX-5061
DECB0K3	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM35M8J
DECB0K3	DN	Thioridazine
DECB0K3	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBS632
DECB0K3	DN	Buspirone
DECB0K3	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMGMF6V
DECB0K3	DN	Capsaicin
DECB0K3	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM8AI9U
DECB0K3	DN	Loxapine succinate
DECB0K3	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUIE76
DECB0K3	DN	Acetaminophen
DECB0K3	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMNMXR8
DECB0K3	DN	Procainamide hydrochloride
DECB0K3	RN	Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10634131

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBCM8L
DECB0K3	DN	Nicergoline
DECB0K3	RN	Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol. 1996 Dec;42(6):707-11.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8971425

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPFN6Y
DECB0K3	DN	Olanzapine
DECB0K3	RN	[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11704898

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0T3YH
DECB0K3	DN	Indinavir sulfate
DECB0K3	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBXWU8
DECB0K3	DN	AC-1802
DECB0K3	RN	Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16508157

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4ES8F
DECB0K3	DN	Penbutolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0EP7M
DECB0K3	DN	Minaprine
DECB0K3	RN	Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642599

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHTEAO
DECB0K3	DN	Carvedilol
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5TVS3
DECB0K3	DN	Vinblastine sulfate
DECB0K3	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMRMS0L
DECB0K3	DN	Morphine
DECB0K3	RN	Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600248

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG814N
DECB0K3	DN	Saquinavir mesylate
DECB0K3	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCTE9R
DECB0K3	DN	Mexiletine hydrochloride
DECB0K3	RN	Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12937870

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMA2GHJ
DECB0K3	DN	AV-650
DECB0K3	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM51OQW
DECB0K3	DN	CCRIS-4201
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML4ZOT
DECB0K3	DN	Lidocaine
DECB0K3	RN	Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901707

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5PCS7
DECB0K3	DN	Bupropion
DECB0K3	RN	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/27836670

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMS1GYT
DECB0K3	DN	Mirabegron
DECB0K3	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4LECQ
DECB0K3	DN	Vilazodone hydrochloride
DECB0K3	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM4ZS8M
DECB0K3	DN	Nefazodone
DECB0K3	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCME17
DECB0K3	DN	Lisuride
DECB0K3	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWVCF3
DECB0K3	DN	CEM-102
DECB0K3	RN	The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027845

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMPB36I
DECB0K3	DN	YMB-1002
DECB0K3	RN	N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45(4):298-304.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10755318

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML1Y49
DECB0K3	DN	TS-702
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2HN6Q
DECB0K3	DN	Astemizole
DECB0K3	RN	Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259984

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM0RKS4
DECB0K3	DN	Bepridil hydrochloride
DECB0K3	RN	Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26195225

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWXLYZ
DECB0K3	DN	Darifenacin hydrobromide
DECB0K3	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2G9AE
DECB0K3	DN	Citalopram hydrobromide
DECB0K3	RN	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968657

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK7F9S
DECB0K3	DN	Amitriptyline hydrochloride
DECB0K3	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFC71L
DECB0K3	DN	Clozapine
DECB0K3	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM7F1PA
DECB0K3	DN	Nebivolol hydrochloride
DECB0K3	RN	Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16961165

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMD5JU8
DECB0K3	DN	Cefalexin
DECB0K3	RN	Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289959

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIFCY2
DECB0K3	DN	H3B-6545
DECB0K3	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMC68DF
DECB0K3	DN	GTPL7557
DECB0K3	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19902987

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMG1OPF
DECB0K3	DN	Buflomedil
DECB0K3	RN	DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10909680

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM1FBZ7
DECB0K3	DN	Tiotropium Bromide
DECB0K3	RN	Tiotropium rromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016 Feb;41(2):97-102.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26908999

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMH7MUV
DECB0K3	DN	Zalcitabine
DECB0K3	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMU764S
DECB0K3	DN	Ritonavir
DECB0K3	RN	Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002 Sep-Oct;25(5):251-3.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12410055

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMFG5ST
DECB0K3	DN	Almotriptan malate
DECB0K3	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMY2AH1
DECB0K3	DN	Aminophenazone
DECB0K3	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DML1VXW
DECB0K3	DN	Arotinolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMV15JC
DECB0K3	DN	Befunolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF7EXL
DECB0K3	DN	Benzatropine
DECB0K3	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMHKZX1
DECB0K3	DN	Benzethonium
DECB0K3	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMJSC07
DECB0K3	DN	Bufuralol
DECB0K3	RN	Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol. 2015 Apr;87(4):733-9.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25657337

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMUT9IQ
DECB0K3	DN	Bupranolol
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM9X2FV
DECB0K3	DN	Butyrfentanyl
DECB0K3	RN	Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017 Jul;9(7):1085-1092.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27736030

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMYTGW0
DECB0K3	DN	Celiprolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMM75WZ
DECB0K3	DN	Chloroxylenol
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6C4YJ
DECB0K3	DN	Chlorphenamine
DECB0K3	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMBG0N4
DECB0K3	DN	Cibenzoline
DECB0K3	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMH7GKB
DECB0K3	DN	Cloranolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM6093Y
DECB0K3	DN	NSC-172130
DECB0K3	RN	Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17471183

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMKEGI3
DECB0K3	DN	Esmirtazapine
DECB0K3	RN	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011 May;215(2):321-32.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21246188

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMR9YL6
DECB0K3	DN	Etilamfetamine
DECB0K3	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLYXBF
DECB0K3	DN	Guanoxan
DECB0K3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIAPBE
DECB0K3	DN	Hydrocodone bitartrate
DECB0K3	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2R496
DECB0K3	DN	Indenolol
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMU86DM
DECB0K3	DN	ONO-1101
DECB0K3	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMK5J9M
DECB0K3	DN	Lorpiprazole
DECB0K3	RN	[Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22232986

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMO2JBC
DECB0K3	DN	Methamphetamine hydrochloride
DECB0K3	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMN8HRU
DECB0K3	DN	Methoxyphenamine
DECB0K3	RN	Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica. 1995 Sep;25(9):895-906.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8553683

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF4I1V
DECB0K3	DN	FT-0710230
DECB0K3	RN	Interpretation of opiate urine drug screens.
DECB0K3	RU	https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMF57DM
DECB0K3	DN	Pazopanib
DECB0K3	RN	Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21395357

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIVMR3
DECB0K3	DN	Prajmaline
DECB0K3	RN	Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr. 1985 Nov 15;63(22):1180-6.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4079282

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM2BO9W
DECB0K3	DN	BCP-13498
DECB0K3	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMLPICK
DECB0K3	DN	Quinidine
DECB0K3	RN	Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. J Inorg Biochem. 2012 May;110:46-50.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22459173

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM5DSFZ
DECB0K3	DN	Rifampicin
DECB0K3	RN	Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20035023

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMIZMYQ
DECB0K3	DN	Roxatidine
DECB0K3	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMSWJ5X
DECB0K3	DN	Sildenafil citrate
DECB0K3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMWCIMG
DECB0K3	DN	Sparteine
DECB0K3	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DM8T2OI
DECB0K3	DN	Upadacitinib
DECB0K3	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DECB0K3	EI	DECB0K3
DECB0K3	EN	Cytochrome P450 2D6 (CYP2D6)
DECB0K3	DI	DMCOJPS
DECB0K3	DN	Vonoprazan
DECB0K3	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DECB0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DEMF740	EI	DEMF740
DEMF740	EN	Cytochrome P450 4B1 (CYP4B1)
DEMF740	DI	DMUY35B
DEMF740	DN	Progesterone
DEMF740	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DEMF740	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DEMF740	EI	DEMF740
DEMF740	EN	Cytochrome P450 4B1 (CYP4B1)
DEMF740	DI	DMXOELT
DEMF740	DN	Midazolam hydrochloride
DEMF740	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEMF740	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEMF740	EI	DEMF740
DEMF740	EN	Cytochrome P450 4B1 (CYP4B1)
DEMF740	DI	DMC1TEV
DEMF740	DN	Testosterone cypionate
DEMF740	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DEMF740	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMOLNHF
DE4ZHS1	DN	Melphalan
DE4ZHS1	RN	Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15840383

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMBD4K3
DE4ZHS1	DN	Selinexor
DE4ZHS1	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DE4ZHS1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMIZKOP
DE4ZHS1	DN	Thiotepa
DE4ZHS1	RN	Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys. 1999 Jun 1;366(1):89-94.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10334868

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMVGPMX
DE4ZHS1	DN	Fosfomycin
DE4ZHS1	RN	Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother. 1988 Oct;32(10):1552-6.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3056239

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMXZRW0
DE4ZHS1	DN	Carmustine
DE4ZHS1	RN	Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16874663

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMJKO05
DE4ZHS1	DN	AI3-25184
DE4ZHS1	RN	Subunit specificity and organ distribution of glutathione transferase-catalysed S-nitrosoglutathione formation from alkyl nitrites in the rat. Biochem Pharmacol. 1997 Jan 10;53(1):117-20.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8960071

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMG3Y89
DE4ZHS1	DN	Trabectedin
DE4ZHS1	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DM60QMR
DE4ZHS1	DN	MK-595
DE4ZHS1	RN	Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15826502

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMOMN31
DE4ZHS1	DN	BP-12941
DE4ZHS1	RN	Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS J. 2014 Jul;16(4):705-13.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24821055

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMUY35B
DE4ZHS1	DN	Progesterone
DE4ZHS1	RN	Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11418619

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMXYJ9C
DE4ZHS1	DN	Busulfan
DE4ZHS1	RN	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15142875

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMNOKBV
DE4ZHS1	DN	Phenytoin
DE4ZHS1	RN	Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2890493

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DM51FY6
DE4ZHS1	DN	Tacrine hydrochloride
DE4ZHS1	RN	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10801254

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMBI4JG
DE4ZHS1	DN	Isosorbide dinitrate
DE4ZHS1	RN	Nitroglycerin and isosorbide dinitrate stimulation of glutathione disulfide efflux from perfused rat liver. Biochem Pharmacol. 1989 Nov 1;38(21):3807-10.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2512927

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMPC1J7
DE4ZHS1	DN	Clofibrate
DE4ZHS1	RN	Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7720514

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMOY7W3
DE4ZHS1	DN	Artemisinin
DE4ZHS1	RN	Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11807801

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMRHGI9
DE4ZHS1	DN	Cisplatin
DE4ZHS1	RN	Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18852128

DE4ZHS1	EI	DE4ZHS1
DE4ZHS1	EN	Glutathione S-transferase alpha-1 (GSTA1)
DE4ZHS1	DI	DMUIE76
DE4ZHS1	DN	Acetaminophen
DE4ZHS1	RN	Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
DE4ZHS1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16157696

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIKQH5
DEIBDNY	DN	Hydroxyprogesterone caproate
DEIBDNY	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMXTMBJ
DEIBDNY	DN	Azelastine
DEIBDNY	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMW83TP
DEIBDNY	DN	Pimozide
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOYE70
DEIBDNY	DN	HOE-239
DEIBDNY	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMK1GBJ
DEIBDNY	DN	Trazodone hydrochloride
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM5T6US
DEIBDNY	DN	Estrone
DEIBDNY	RN	16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9635876

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMN6DXL
DEIBDNY	DN	Risperidone
DEIBDNY	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMLW57T
DEIBDNY	DN	Teniposide
DEIBDNY	RN	O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8114683

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM1IQRP
DEIBDNY	DN	DA-8159
DEIBDNY	RN	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011 Dec;21(12):820-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21934637

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DML83IW
DEIBDNY	DN	LY-450139
DEIBDNY	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF28YC
DEIBDNY	DN	Atorvastatin calcium
DEIBDNY	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMTUPZ2
DEIBDNY	DN	CJ-11974
DEIBDNY	RN	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950851

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM471KJ
DEIBDNY	DN	Omeprazole
DEIBDNY	RN	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19139162

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGVH6N
DEIBDNY	DN	Axitinib
DEIBDNY	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZO10Y
DEIBDNY	DN	Testosterone undecanoate
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM49DUI
DEIBDNY	DN	Tretinoin
DEIBDNY	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMPAZHC
DEIBDNY	DN	Cabazitaxel
DEIBDNY	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DEIBDNY	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6A0X7
DEIBDNY	DN	Pravastatin
DEIBDNY	RN	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb;27(2):173-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9929499

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCT3I8
DEIBDNY	DN	Ifosfamide
DEIBDNY	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6L4H2
DEIBDNY	DN	Cobicistat
DEIBDNY	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4K7GQ
DEIBDNY	DN	Erythromycin stearate
DEIBDNY	RN	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMICA9H
DEIBDNY	DN	Sulfasalazine
DEIBDNY	RN	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9117175

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSWYF5
DEIBDNY	DN	Quinine sulfate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMXCM7H
DEIBDNY	DN	Cerivastatin sodium
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGW1ID
DEIBDNY	DN	Sirolimus
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6RZ9Q
DEIBDNY	DN	Clonidine
DEIBDNY	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZMSCT
DEIBDNY	DN	Cilostazol
DEIBDNY	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6F1PU
DEIBDNY	DN	Vortioxetine hydrobromide
DEIBDNY	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4F29C
DEIBDNY	DN	Crizotinib
DEIBDNY	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMPQAGE
DEIBDNY	DN	Mycophenolate mofetil
DEIBDNY	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM79NTF
DEIBDNY	DN	Propranolol hydrochloride
DEIBDNY	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQI43G
DEIBDNY	DN	BMS-650032
DEIBDNY	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZOLBI
DEIBDNY	DN	Carbamazepine
DEIBDNY	RN	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSVOZT
DEIBDNY	DN	Nifedipine
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMVR628
DEIBDNY	DN	Lilly-112531
DEIBDNY	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DEIBDNY	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCOZJY
DEIBDNY	DN	Tenapanor
DEIBDNY	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DEIBDNY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4KDYJ
DEIBDNY	DN	Nortriptyline hydrochloride
DEIBDNY	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSOX7I
DEIBDNY	DN	Cocaine
DEIBDNY	RN	Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8617431

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMA8FS5
DEIBDNY	DN	Dronedarone hydrochloride
DEIBDNY	RN	Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26490246

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMHZJCG
DEIBDNY	DN	Pentamidine isethionate
DEIBDNY	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM8JXPZ
DEIBDNY	DN	Glibenclamide
DEIBDNY	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMJZHT1
DEIBDNY	DN	Tadalafil
DEIBDNY	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF3AN7
DEIBDNY	DN	Loratadine
DEIBDNY	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMPRI8G
DEIBDNY	DN	Buprenorphine hydrochloride
DEIBDNY	RN	Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30531584

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZ7XNQ
DEIBDNY	DN	Tacrolimus
DEIBDNY	RN	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635182

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMLK2QH
DEIBDNY	DN	Nateglinide
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM5GFIK
DEIBDNY	DN	BPI-2009
DEIBDNY	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMUY35B
DEIBDNY	DN	Progesterone
DEIBDNY	RN	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10403825

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMP6SC2
DEIBDNY	DN	Irinotecan hydrochloride
DEIBDNY	RN	Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16271446

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSYRBX
DEIBDNY	DN	Atazanavir
DEIBDNY	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM08E9O
DEIBDNY	DN	Diazepam
DEIBDNY	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMLB0EZ
DEIBDNY	DN	Tamoxifen citrate
DEIBDNY	RN	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15596297

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOMK1V
DEIBDNY	DN	Halofantrine
DEIBDNY	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCMBHA
DEIBDNY	DN	Erlotinib hydrochloride
DEIBDNY	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM5UGDK
DEIBDNY	DN	Mephenytoin
DEIBDNY	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMFI46A
DEIBDNY	DN	Argatroban
DEIBDNY	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM8MC6O
DEIBDNY	DN	Estradiol valerate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMVP5YE
DEIBDNY	DN	Doxorubicin
DEIBDNY	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCA7LN
DEIBDNY	DN	Oxycodone hydrochloride
DEIBDNY	RN	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039299

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM3BH1Y
DEIBDNY	DN	Lapatinib ditosylate
DEIBDNY	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4MDJY
DEIBDNY	DN	Fluvastatin sodium
DEIBDNY	RN	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004 Aug;14(8):523-5.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284534

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMWV3TZ
DEIBDNY	DN	Finasteride
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMUNTE3
DEIBDNY	DN	E-3A
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4KLPT
DEIBDNY	DN	Terfenadine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMN4ZKC
DEIBDNY	DN	Paraoxon
DEIBDNY	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM0ZOGX
DEIBDNY	DN	DUP-996
DEIBDNY	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGFWSM
DEIBDNY	DN	Zaleplon
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSI5CB
DEIBDNY	DN	Chloroquine
DEIBDNY	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZ4P3A
DEIBDNY	DN	Telithromycin
DEIBDNY	RN	Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15598962

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMMTW9K
DEIBDNY	DN	SCH-417690
DEIBDNY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMHZCPO
DEIBDNY	DN	Ibrutinib
DEIBDNY	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMXNZM4
DEIBDNY	DN	Oxazepam
DEIBDNY	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMUDJZM
DEIBDNY	DN	Dextromethorphan hydrobromide
DEIBDNY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM7GCVW
DEIBDNY	DN	Acalabrutinib
DEIBDNY	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DEIBDNY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMINOX3
DEIBDNY	DN	Vincristine sulfate
DEIBDNY	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSFK9V
DEIBDNY	DN	Daclatasvir dihydrochloride
DEIBDNY	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM0PHEW
DEIBDNY	DN	Erythromycin salnacedin
DEIBDNY	RN	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM15F0X
DEIBDNY	DN	Gefitinib
DEIBDNY	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM0DTF7
DEIBDNY	DN	Zonisamide
DEIBDNY	RN	Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9626925

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMLMXE0
DEIBDNY	DN	Amprenavir
DEIBDNY	RN	Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584153

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM21C09
DEIBDNY	DN	BRN-0498823
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMTIVEN
DEIBDNY	DN	Metronidazole
DEIBDNY	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQ4TJK
DEIBDNY	DN	Dutasteride
DEIBDNY	RN	Product monograph: Avodart (dutasteride capsules).
DEIBDNY	RU	https://ca.gsk.com/media/588688/avodart.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMICDLV
DEIBDNY	DN	Lorlatinib
DEIBDNY	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DEIBDNY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMBDPY0
DEIBDNY	DN	KW-5338
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM7RJXL
DEIBDNY	DN	Imatinib mesylate
DEIBDNY	RN	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16122278

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM7NPJS
DEIBDNY	DN	Paliperidone
DEIBDNY	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMNH3PG
DEIBDNY	DN	Etoposide
DEIBDNY	RN	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319341

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM5URA2
DEIBDNY	DN	Chlorpheniramine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMY7PED
DEIBDNY	DN	Cisapride
DEIBDNY	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMHKJ5I
DEIBDNY	DN	GW-1000
DEIBDNY	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMTBGW8
DEIBDNY	DN	Vardenafil hydrochloride
DEIBDNY	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6QHDJ
DEIBDNY	DN	RO-7-0207
DEIBDNY	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM96SE0
DEIBDNY	DN	Haloperidol decanoate
DEIBDNY	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQ8FR2
DEIBDNY	DN	Prednisolone
DEIBDNY	RN	Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10533695

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMAYTRK
DEIBDNY	DN	H3B-6527
DEIBDNY	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIGX84
DEIBDNY	DN	ABT-773
DEIBDNY	RN	CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004 Jun;75(6):516-28.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15179406

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMJPSIL
DEIBDNY	DN	TMC-120
DEIBDNY	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DEIBDNY	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM72JXH
DEIBDNY	DN	Losartan potassium
DEIBDNY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM8WAHT
DEIBDNY	DN	Fentanyl citrate
DEIBDNY	RN	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMNOKBV
DEIBDNY	DN	Phenytoin
DEIBDNY	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMJV2EK
DEIBDNY	DN	Dasatinib
DEIBDNY	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMS104F
DEIBDNY	DN	Temsirolimus
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMDNJHG
DEIBDNY	DN	Aztreonam
DEIBDNY	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM31ZQM
DEIBDNY	DN	Tegafur
DEIBDNY	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM20VSK
DEIBDNY	DN	Istradefylline
DEIBDNY	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM3WP0N
DEIBDNY	DN	Al3-818
DEIBDNY	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMAOJBX
DEIBDNY	DN	CBT-1
DEIBDNY	RN	CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol. 2016 Jul;90(7):1737-48.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26302866

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMVO0UB
DEIBDNY	DN	Alfentanil
DEIBDNY	RN	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17554244

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM3NF5G
DEIBDNY	DN	Delavirdine mesylate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQH1NV
DEIBDNY	DN	MKC-442
DEIBDNY	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMYGJQO
DEIBDNY	DN	Ponatinib hydrochloride
DEIBDNY	RN	Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986642

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM30SGU
DEIBDNY	DN	Simvastatin
DEIBDNY	RN	In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9321523

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM3NUMH
DEIBDNY	DN	Aripiprazole lauroxil
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM1N62C
DEIBDNY	DN	Quetiapine fumarate
DEIBDNY	RN	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24240480

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMTQLIJ
DEIBDNY	DN	Amlodipine besylate
DEIBDNY	RN	Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep. 2017 Apr;15(4):1593-1600.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28259948

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM9S2JW
DEIBDNY	DN	BRN-3224996
DEIBDNY	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM89JLN
DEIBDNY	DN	Apixaban
DEIBDNY	RN	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23016247

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMMWZET
DEIBDNY	DN	Dexamethasone acetate
DEIBDNY	RN	Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12538830

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIUW25
DEIBDNY	DN	Granisetron hydrochloride
DEIBDNY	RN	Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7888294

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGB035
DEIBDNY	DN	Armodafinil
DEIBDNY	RN	Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12537513

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMUIBV8
DEIBDNY	DN	NE-10064
DEIBDNY	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOTQ1I
DEIBDNY	DN	Ondansetron
DEIBDNY	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGXENV
DEIBDNY	DN	Saxagliptin hydrochloride
DEIBDNY	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQMBZ1
DEIBDNY	DN	Rivaroxaban
DEIBDNY	RN	Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23645472

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGEMB7
DEIBDNY	DN	Hydrocortisone
DEIBDNY	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIEU69
DEIBDNY	DN	Salmeterol xinafoate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMT5GNL
DEIBDNY	DN	Romidepsin
DEIBDNY	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19228751

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMC7XDN
DEIBDNY	DN	Alprazolam
DEIBDNY	RN	Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15903124

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMLQVTJ
DEIBDNY	DN	Octopamine
DEIBDNY	RN	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOU1PK
DEIBDNY	DN	Praziquantel
DEIBDNY	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGCSVF
DEIBDNY	DN	Fluticasone furoate
DEIBDNY	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCYANK
DEIBDNY	DN	Doxapram hydrochloride
DEIBDNY	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6AUFY
DEIBDNY	DN	Iloperidone
DEIBDNY	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM48QOT
DEIBDNY	DN	Artemether
DEIBDNY	RN	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 3;16(1):267.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28673292

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4LT8A
DEIBDNY	DN	Dapsone
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOL54H
DEIBDNY	DN	Clopidogrel bisulfate
DEIBDNY	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM0659E
DEIBDNY	DN	Cannabidiol
DEIBDNY	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMU8L7C
DEIBDNY	DN	CBL-0102
DEIBDNY	RN	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16581945

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6HX9B
DEIBDNY	DN	Nevirapine
DEIBDNY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMDI269
DEIBDNY	DN	Docetaxel
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF8Y74
DEIBDNY	DN	Hydroxyzine
DEIBDNY	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DEIBDNY	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMAI7ZV
DEIBDNY	DN	Diltiazem hydrochloride
DEIBDNY	RN	Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27149910

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMPWSEM
DEIBDNY	DN	TJN-324
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMHIDUE
DEIBDNY	DN	Phenelzine
DEIBDNY	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMX0E5B
DEIBDNY	DN	Bimatoprost
DEIBDNY	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DEIBDNY	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF0NQR
DEIBDNY	DN	Eplerenone
DEIBDNY	RN	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31408697

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMDZ9LT
DEIBDNY	DN	Ethosuximide
DEIBDNY	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMA7PEW
DEIBDNY	DN	Verapamil hydrochloride
DEIBDNY	RN	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15689501

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCBJSR
DEIBDNY	DN	Sunitinib malate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM215WE
DEIBDNY	DN	Doravirine
DEIBDNY	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF2KLU
DEIBDNY	DN	Oxybutynin chloride
DEIBDNY	RN	Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica. 2007 Jan;37(1):59-73.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178634

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMBPN7T
DEIBDNY	DN	Rupatadine
DEIBDNY	RN	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):117-24.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25427746

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM7ISKJ
DEIBDNY	DN	Nisoldipine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMWOSKJ
DEIBDNY	DN	Zolpidem tartrate
DEIBDNY	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
DEIBDNY	RU	https://www.pharmgkb.org/vip/PA166170041/relationships

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMF3VXA
DEIBDNY	DN	Zotepine
DEIBDNY	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM07U2A
DEIBDNY	DN	Estradiol acetate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM8M2N3
DEIBDNY	DN	BRN-0077922
DEIBDNY	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM52HUD
DEIBDNY	DN	CR-2017
DEIBDNY	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM3PD2C
DEIBDNY	DN	Fluoxetine hydrochloride
DEIBDNY	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM702MU
DEIBDNY	DN	ITX-5061
DEIBDNY	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM27Z5T
DEIBDNY	DN	Estradiol cypionate
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMBS632
DEIBDNY	DN	Buspirone
DEIBDNY	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMJDYNQ
DEIBDNY	DN	Perampanel
DEIBDNY	RN	FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
DEIBDNY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMETYK5
DEIBDNY	DN	Triazolam
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMUIE76
DEIBDNY	DN	Acetaminophen
DEIBDNY	RN	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620348

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMXOELT
DEIBDNY	DN	Midazolam hydrochloride
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM70BU5
DEIBDNY	DN	Thalidomide
DEIBDNY	RN	Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20443640

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMU1LXS
DEIBDNY	DN	AK-602
DEIBDNY	RN	Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25629144

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIM5AP
DEIBDNY	DN	TAK-875
DEIBDNY	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMBSHMF
DEIBDNY	DN	Boceprevir
DEIBDNY	RN	Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23140245

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM0T3YH
DEIBDNY	DN	Indinavir sulfate
DEIBDNY	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMNP60F
DEIBDNY	DN	Anastrozole
DEIBDNY	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGM2Z6
DEIBDNY	DN	EBP-994
DEIBDNY	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMS8IFC
DEIBDNY	DN	Sorafenib
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMZC1HS
DEIBDNY	DN	Ivacaftor
DEIBDNY	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM5TVS3
DEIBDNY	DN	Vinblastine sulfate
DEIBDNY	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMG814N
DEIBDNY	DN	Saquinavir mesylate
DEIBDNY	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOSW35
DEIBDNY	DN	Felodipine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DML4ZOT
DEIBDNY	DN	Lidocaine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMG8K57
DEIBDNY	DN	Cortisone acetate
DEIBDNY	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCL2OK
DEIBDNY	DN	Disulfiram
DEIBDNY	RN	Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9756035

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMQ0RKZ
DEIBDNY	DN	Nimodipine
DEIBDNY	RN	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501176

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMK0O7U
DEIBDNY	DN	Flutamide
DEIBDNY	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM2HN6Q
DEIBDNY	DN	Astemizole
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMCFE9I
DEIBDNY	DN	Valproic acid
DEIBDNY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMK7F9S
DEIBDNY	DN	Amitriptyline hydrochloride
DEIBDNY	RN	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14637191

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMXZOCG
DEIBDNY	DN	Phenobarbital
DEIBDNY	RN	Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10696073

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM4M1SG
DEIBDNY	DN	Clarithromycin
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMOEARH
DEIBDNY	DN	AZD-2014
DEIBDNY	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMGZQEF
DEIBDNY	DN	Mifepristone
DEIBDNY	RN	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16684709

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMJBXO3
DEIBDNY	DN	VX-661
DEIBDNY	RN	Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 2019 May;12(3):267-275.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30694595

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMIFCY2
DEIBDNY	DN	H3B-6545
DEIBDNY	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSFWT7
DEIBDNY	DN	SHR-1020
DEIBDNY	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DEIBDNY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMH7MUV
DEIBDNY	DN	Zalcitabine
DEIBDNY	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMU764S
DEIBDNY	DN	Ritonavir
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMWNP6B
DEIBDNY	DN	Benidipine
DEIBDNY	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM8KLU9
DEIBDNY	DN	Cenobamate
DEIBDNY	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEIBDNY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM6C4YJ
DEIBDNY	DN	Chlorphenamine
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMAZJFX
DEIBDNY	DN	Ciclosporin
DEIBDNY	RN	CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25976223

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM429AE
DEIBDNY	DN	Levomethadyl acetate hydrochloride
DEIBDNY	RN	Drug Interactions Flockhart Table
DEIBDNY	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMFX6G8
DEIBDNY	DN	Nelfinavir mesylate
DEIBDNY	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMSWJ5X
DEIBDNY	DN	Sildenafil citrate
DEIBDNY	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMC1TEV
DEIBDNY	DN	Testosterone cypionate
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMB6871
DEIBDNY	DN	Testosterone enanthate
DEIBDNY	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DMDGCQP
DEIBDNY	DN	Norethindrone acetate
DEIBDNY	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DEIBDNY	EI	DEIBDNY
DEIBDNY	EN	Cytochrome P450 3A5 (CYP3A5)
DEIBDNY	DI	DM7LRKD
DEIBDNY	DN	Triamcinolone diacetate
DEIBDNY	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DEIBDNY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMDRQZU
DEVDYN7	DN	Ethanol
DEVDYN7	RN	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12707490

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM5T6US
DEVDYN7	DN	Estrone
DEVDYN7	RN	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640505

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMYPEX3
DEVDYN7	DN	AC1L9GJA
DEVDYN7	RN	Drug Interactions Flockhart Table
DEVDYN7	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM6VOWQ
DEVDYN7	DN	Fomepizole
DEVDYN7	RN	Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole. Open Access Emerg Med. 2010 Aug 24;2:67-75.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27147840

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMNXDGQ
DEVDYN7	DN	Thiram
DEVDYN7	RN	Effect of cytochrome P450 inducers on the metabolism and toxicity of thiram in rats. Vet Hum Toxicol. 2002 Dec;44(6):331-3.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12458634

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMSJDTY
DEVDYN7	DN	Menadione
DEVDYN7	RN	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 2004 Feb;39(2):444-55.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14767997

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMCE985
DEVDYN7	DN	Antipyrine
DEVDYN7	RN	Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801065

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMG3Y89
DEVDYN7	DN	Trabectedin
DEVDYN7	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DML2NIB
DEVDYN7	DN	Aminophylline
DEVDYN7	RN	Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786569

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM1V5ZS
DEVDYN7	DN	Felbamate
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMTW3R8
DEVDYN7	DN	Sulfadiazine
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMBVYDI
DEVDYN7	DN	Benzyl alcohol
DEVDYN7	RN	The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15129551

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMA17D0
DEVDYN7	DN	Dorzolamide hydrochloride
DEVDYN7	RN	In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos. 1994 Nov-Dec;22(6):916-21.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895610

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMJ3HQY
DEVDYN7	DN	GTPL-1666
DEVDYN7	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMEQL9U
DEVDYN7	DN	CAM-2028
DEVDYN7	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM7YPM1
DEVDYN7	DN	Enfuvirtide
DEVDYN7	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMYNJHI
DEVDYN7	DN	ARC-029
DEVDYN7	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMHDF7B
DEVDYN7	DN	Thiamylal
DEVDYN7	RN	Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):181-3.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16445592

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMUPE07
DEVDYN7	DN	N-547
DEVDYN7	RN	Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab Dispos. 2013 Mar;41(3):550-3.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23418369

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM8RZ9H
DEVDYN7	DN	Eszopiclone
DEVDYN7	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM2AOTZ
DEVDYN7	DN	Perazine
DEVDYN7	RN	Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol. 2001 Nov-Dec;53(6):615-21.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11985335

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMLB0EZ
DEVDYN7	DN	Tamoxifen citrate
DEVDYN7	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM4ZLFD
DEVDYN7	DN	Glucosamine
DEVDYN7	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMJ8AUE
DEVDYN7	DN	Y-100032
DEVDYN7	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DML0RAE
DEVDYN7	DN	Methoxyflurane
DEVDYN7	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMK1ZOR
DEVDYN7	DN	Vincamine
DEVDYN7	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMN4ZKC
DEVDYN7	DN	Paraoxon
DEVDYN7	RN	Interaction of ethanol and the organophosphorus insecticide parathion. Biochem Pharmacol. 1995 Nov 27;50(11):1925-32.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8615874

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMM0PDO
DEVDYN7	DN	Dalfampridine
DEVDYN7	RN	Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22764324

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMCYVDT
DEVDYN7	DN	Chlorzoxazone
DEVDYN7	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMW4M97
DEVDYN7	DN	Clevidipine
DEVDYN7	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMR5ZUP
DEVDYN7	DN	Paramethadione
DEVDYN7	RN	Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 Jun;25(3):165-75.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10886461

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM1794O
DEVDYN7	DN	HSDB-1516
DEVDYN7	RN	Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21133409

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM5JVS3
DEVDYN7	DN	Isoniazid
DEVDYN7	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMBFE4K
DEVDYN7	DN	SR-4233
DEVDYN7	RN	Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br J Cancer. 1995 Apr;71(4):780-5.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7710944

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMB4OLE
DEVDYN7	DN	Propofol
DEVDYN7	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM0YJSB
DEVDYN7	DN	Enflurane
DEVDYN7	RN	Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos. 1995 Dec;23(12):1426-30.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8689955

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMKBJWP
DEVDYN7	DN	Caffeine
DEVDYN7	RN	CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 1;459(1):59-69.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17222385

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMNH3PG
DEVDYN7	DN	Etoposide
DEVDYN7	RN	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732391

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM80OZ5
DEVDYN7	DN	Halothane
DEVDYN7	RN	Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiol Scand. 2003 Jul;47(6):765-70.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12803597

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMY6T31
DEVDYN7	DN	Isoflurane
DEVDYN7	RN	Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology. 1999 Mar;90(3):766-71.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10078678

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DML6O4N
DEVDYN7	DN	N,N-dimethylformamide
DEVDYN7	RN	Association between CYP2E1 and GOT2 gene polymorphisms and susceptibility and low-dose N,N-dimethylformamide occupational exposure-induced liver injury. Int Arch Occup Environ Health. 2019 Oct;92(7):967-975.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30993423

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM8DUZT
DEVDYN7	DN	EGYT-3886
DEVDYN7	RN	Role of CYP2E1 in deramciclane metabolism. Drug Metab Dispos. 2005 Nov;33(11):1717-22.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15932955

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM4SJ5Y
DEVDYN7	DN	INS-260
DEVDYN7	RN	Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J Biol Chem. 1999 Aug 20;274(34):23833-40.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10446146

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM31ZQM
DEVDYN7	DN	Tegafur
DEVDYN7	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMRJFN9
DEVDYN7	DN	Theophylline
DEVDYN7	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMJBOCR
DEVDYN7	DN	Levocarnitine
DEVDYN7	RN	Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. Biol Pharm Bull. 1993 Dec;16(12):1240-3.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8130774

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMM8D3F
DEVDYN7	DN	SC-15090
DEVDYN7	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM0FB1J
DEVDYN7	DN	Sertraline hydrochloride
DEVDYN7	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166181117)
DEVDYN7	RU	https://www.pharmgkb.org/pathway/PA166181117

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMOTQ1I
DEVDYN7	DN	Ondansetron
DEVDYN7	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM1QSM3
DEVDYN7	DN	ENT-1814
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMJKROX
DEVDYN7	DN	Fluvoxamine maleate
DEVDYN7	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM4LT8A
DEVDYN7	DN	Dapsone
DEVDYN7	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM3B654
DEVDYN7	DN	FO-611
DEVDYN7	RN	CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med. 2006 Jul;73(4):657-72.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16878272

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMRQAM0
DEVDYN7	DN	Phenacetin
DEVDYN7	RN	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421611

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMBL79I
DEVDYN7	DN	Proguanil
DEVDYN7	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMMQ8ZG
DEVDYN7	DN	Furosemide
DEVDYN7	RN	Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009 Jan;61(1):47-54.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19126296

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMDZ9LT
DEVDYN7	DN	Ethosuximide
DEVDYN7	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DME2A8X
DEVDYN7	DN	HSDB-3466
DEVDYN7	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMA7PEW
DEVDYN7	DN	Verapamil hydrochloride
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMM39BF
DEVDYN7	DN	Mitoxantrone
DEVDYN7	RN	FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
DEVDYN7	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMJ2AH4
DEVDYN7	DN	NSC-122758
DEVDYN7	RN	The role of inflammatory cells and cytochrome P450 in the potentiation of CCl4-induced liver injury by a single dose of retinol. Toxicol Appl Pharmacol. 1996 Dec;141(2):507-19.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8975775

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMCDYW7
DEVDYN7	DN	Nicardipine hydrochloride
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMWX5CO
DEVDYN7	DN	Nicotine
DEVDYN7	RN	Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20233178

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM3PD2C
DEVDYN7	DN	Fluoxetine hydrochloride
DEVDYN7	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM93L4X
DEVDYN7	DN	Dexmedetomidine hydrochloride
DEVDYN7	RN	Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20020418

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMYQDBO
DEVDYN7	DN	Ademetionine
DEVDYN7	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM0Q8MZ
DEVDYN7	DN	Trimethadione
DEVDYN7	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMGMF6V
DEVDYN7	DN	Capsaicin
DEVDYN7	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMRHGI9
DEVDYN7	DN	Cisplatin
DEVDYN7	RN	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12675844

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMUIE76
DEVDYN7	DN	Acetaminophen
DEVDYN7	RN	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20166895

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM70BU5
DEVDYN7	DN	Thalidomide
DEVDYN7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMC9O43
DEVDYN7	DN	Sevoflurane
DEVDYN7	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMHTEAO
DEVDYN7	DN	Carvedilol
DEVDYN7	RN	In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9280405

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMCTE9R
DEVDYN7	DN	Mexiletine hydrochloride
DEVDYN7	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM5PCS7
DEVDYN7	DN	Bupropion
DEVDYN7	RN	Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222-30.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997944

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMCL2OK
DEVDYN7	DN	Disulfiram
DEVDYN7	RN	Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther. 1999 Oct;291(1):213-9.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490907

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMQNWRD
DEVDYN7	DN	Oxaliplatin
DEVDYN7	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMHM93Y
DEVDYN7	DN	Meprobamate
DEVDYN7	RN	Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther. 2002 Jan;300(1):273-81.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752126

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM2G9AE
DEVDYN7	DN	Citalopram hydrobromide
DEVDYN7	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMK7F9S
DEVDYN7	DN	Amitriptyline hydrochloride
DEVDYN7	RN	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9549641

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMXZOCG
DEVDYN7	DN	Phenobarbital
DEVDYN7	RN	Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. Eur J Pharmacol. 2006 Dec 15;552(1-3):151-8.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17049344

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMNPZL4
DEVDYN7	DN	Dacarbazine
DEVDYN7	RN	Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11751525

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMEMBJC
DEVDYN7	DN	Folic acid
DEVDYN7	RN	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15705656

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMPI6Z0
DEVDYN7	DN	Zopiclone
DEVDYN7	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMY40UB
DEVDYN7	DN	Chloroben
DEVDYN7	RN	Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse, and human liver microsomes. Chem Biol Interact. 1998 Aug 14;115(1):53-70.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9817075

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMFG5ST
DEVDYN7	DN	Almotriptan malate
DEVDYN7	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM8KLU9
DEVDYN7	DN	Cenobamate
DEVDYN7	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEVDYN7	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMM75WZ
DEVDYN7	DN	Chloroxylenol
DEVDYN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM2BO9W
DEVDYN7	DN	BCP-13498
DEVDYN7	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMLPICK
DEVDYN7	DN	Quinidine
DEVDYN7	RN	In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther. 1999 Apr;289(1):31-7.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10086984

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DM5DSFZ
DEVDYN7	DN	Rifampicin
DEVDYN7	RN	Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786635

DEVDYN7	EI	DEVDYN7
DEVDYN7	EN	Cytochrome P450 2E1 (CYP2E1)
DEVDYN7	DI	DMSWJ5X
DEVDYN7	DN	Sildenafil citrate
DEVDYN7	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DEVDYN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM7NKEV
DEFQ8VO	DN	BW-5071
DEFQ8VO	RN	Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21086934

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM3KJBC
DEFQ8VO	DN	Epinephrine hydrochloride
DEFQ8VO	RN	Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6859813

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM78IME
DEFQ8VO	DN	Histamine
DEFQ8VO	RN	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19538200

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMXJ7O8
DEFQ8VO	DN	Ascorbic acid
DEFQ8VO	RN	Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9054258

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMLB0EZ
DEFQ8VO	DN	Tamoxifen citrate
DEFQ8VO	RN	Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15288375

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMMZSXQ
DEFQ8VO	DN	Azathioprine
DEFQ8VO	RN	Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20726808

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMN3E57
DEFQ8VO	DN	Levodopa
DEFQ8VO	RN	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19676096

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMUNTE3
DEFQ8VO	DN	E-3A
DEFQ8VO	RN	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8055052

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMPDYFR
DEFQ8VO	DN	Cefazolin
DEFQ8VO	RN	Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228189

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMTM2IK
DEFQ8VO	DN	Mercaptopurine
DEFQ8VO	RN	The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20130603

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM5I621
DEFQ8VO	DN	Methyldopa
DEFQ8VO	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM458UM
DEFQ8VO	DN	Captopril
DEFQ8VO	RN	S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6344869

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMK7MEY
DEFQ8VO	DN	ICI-46399
DEFQ8VO	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DM2TEOL
DEFQ8VO	DN	Methotrexate
DEFQ8VO	RN	Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16438485

DEFQ8VO	EI	DEFQ8VO
DEFQ8VO	EN	Thiopurine methyltransferase (TPMT)
DEFQ8VO	DI	DMYQDBO
DEFQ8VO	DN	Ademetionine
DEFQ8VO	RN	Evolution of putrescine N-methyltransferase from spermidine synthase demanded alterations in substrate binding. FEBS Lett. 2009 Oct 20;583(20):3367-74.
DEFQ8VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19796640

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMW83TP
DERD86B	DN	Pimozide
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMK1GBJ
DERD86B	DN	Trazodone hydrochloride
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMF28YC
DERD86B	DN	Atorvastatin calcium
DERD86B	RN	Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
DERD86B	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMZO10Y
DERD86B	DN	Testosterone undecanoate
DERD86B	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM49DUI
DERD86B	DN	Tretinoin
DERD86B	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMCT3I8
DERD86B	DN	Ifosfamide
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6L4H2
DERD86B	DN	Cobicistat
DERD86B	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM4K7GQ
DERD86B	DN	Erythromycin stearate
DERD86B	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMSWYF5
DERD86B	DN	Quinine sulfate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMJX6ZG
DERD86B	DN	Codeine
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMXCM7H
DERD86B	DN	Cerivastatin sodium
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMGW1ID
DERD86B	DN	Sirolimus
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMZMSCT
DERD86B	DN	Cilostazol
DERD86B	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM79NTF
DERD86B	DN	Propranolol hydrochloride
DERD86B	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMZOLBI
DERD86B	DN	Carbamazepine
DERD86B	RN	CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos. 2003 Apr;31(4):432-8.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642469

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMVR628
DERD86B	DN	Lilly-112531
DERD86B	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DERD86B	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMSOX7I
DERD86B	DN	Cocaine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM8JXPZ
DERD86B	DN	Glibenclamide
DERD86B	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMPRI8G
DERD86B	DN	Buprenorphine hydrochloride
DERD86B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMLK2QH
DERD86B	DN	Nateglinide
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM2NUH3
DERD86B	DN	Imipramine hydrochloride
DERD86B	RN	Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534316

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMUY35B
DERD86B	DN	Progesterone
DERD86B	RN	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8424894

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMP6SC2
DERD86B	DN	Irinotecan hydrochloride
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMSYRBX
DERD86B	DN	Atazanavir
DERD86B	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM08E9O
DERD86B	DN	Diazepam
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMLB0EZ
DERD86B	DN	Tamoxifen citrate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM8MC6O
DERD86B	DN	Estradiol valerate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMCA7LN
DERD86B	DN	Oxycodone hydrochloride
DERD86B	RN	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039299

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMWV3TZ
DERD86B	DN	Finasteride
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMUNTE3
DERD86B	DN	E-3A
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM4KLPT
DERD86B	DN	Terfenadine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM0ZOGX
DERD86B	DN	DUP-996
DERD86B	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMGFWSM
DERD86B	DN	Zaleplon
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMXNZM4
DERD86B	DN	Oxazepam
DERD86B	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMUDJZM
DERD86B	DN	Dextromethorphan hydrobromide
DERD86B	RN	Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8043020

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMTW6IU
DERD86B	DN	Methadone
DERD86B	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMINOX3
DERD86B	DN	Vincristine sulfate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMSFK9V
DERD86B	DN	Daclatasvir dihydrochloride
DERD86B	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM0PHEW
DERD86B	DN	Erythromycin salnacedin
DERD86B	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM0DTF7
DERD86B	DN	Zonisamide
DERD86B	RN	Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9555064

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM21C09
DERD86B	DN	BRN-0498823
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMTIVEN
DERD86B	DN	Metronidazole
DERD86B	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMICDLV
DERD86B	DN	Lorlatinib
DERD86B	RN	Product characteristics of Lorviqua.
DERD86B	RU	https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMBDPY0
DERD86B	DN	KW-5338
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM7RJXL
DERD86B	DN	Imatinib mesylate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM5URA2
DERD86B	DN	Chlorpheniramine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMY7PED
DERD86B	DN	Cisapride
DERD86B	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM4O2Z7
DERD86B	DN	Cyclophosphamide
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6QHDJ
DERD86B	DN	RO-7-0207
DERD86B	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM96SE0
DERD86B	DN	Haloperidol decanoate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM8WAHT
DERD86B	DN	Fentanyl citrate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMNOKBV
DERD86B	DN	Phenytoin
DERD86B	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMS104F
DERD86B	DN	Temsirolimus
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMDNJHG
DERD86B	DN	Aztreonam
DERD86B	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMVO0UB
DERD86B	DN	Alfentanil
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM3NF5G
DERD86B	DN	Delavirdine mesylate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM3NUMH
DERD86B	DN	Aripiprazole lauroxil
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM1N62C
DERD86B	DN	Quetiapine fumarate
DERD86B	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMMWZET
DERD86B	DN	Dexamethasone acetate
DERD86B	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM67VKL
DERD86B	DN	Dehydroepiandrosterone
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMOTQ1I
DERD86B	DN	Ondansetron
DERD86B	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMGEMB7
DERD86B	DN	Hydrocortisone
DERD86B	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMIEU69
DERD86B	DN	Salmeterol xinafoate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMC7XDN
DERD86B	DN	Alprazolam
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMOU1PK
DERD86B	DN	Praziquantel
DERD86B	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMGCSVF
DERD86B	DN	Fluticasone furoate
DERD86B	RN	Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16565171

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6AUFY
DERD86B	DN	Iloperidone
DERD86B	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM4LT8A
DERD86B	DN	Dapsone
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM0YROF
DERD86B	DN	Ethylmorphine
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6HX9B
DERD86B	DN	Nevirapine
DERD86B	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMDI269
DERD86B	DN	Docetaxel
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMAI7ZV
DERD86B	DN	Diltiazem hydrochloride
DERD86B	RN	FDA Drug Development and Drug Interactions
DERD86B	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMPWSEM
DERD86B	DN	TJN-324
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6K1OA
DERD86B	DN	Clotiapine
DERD86B	RN	Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000 May;38(5):393-414.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10843459

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMDZ9LT
DERD86B	DN	Ethosuximide
DERD86B	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMA7PEW
DERD86B	DN	Verapamil hydrochloride
DERD86B	RN	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744949

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMCBJSR
DERD86B	DN	Sunitinib malate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM7ISKJ
DERD86B	DN	Nisoldipine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMWOSKJ
DERD86B	DN	Zolpidem tartrate
DERD86B	RN	Principles of Clinical Pharmacology (Third Edition). 2012, Pages 417-436
DERD86B	RU	https://doi.org/10.1016/B978-0-12-385471-1.00025-8

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM07U2A
DERD86B	DN	Estradiol acetate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM8M2N3
DERD86B	DN	BRN-0077922
DERD86B	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM27Z5T
DERD86B	DN	Estradiol cypionate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMBS632
DERD86B	DN	Buspirone
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMETYK5
DERD86B	DN	Triazolam
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMXOELT
DERD86B	DN	Midazolam hydrochloride
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM0T3YH
DERD86B	DN	Indinavir sulfate
DERD86B	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMS8IFC
DERD86B	DN	Sorafenib
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMG814N
DERD86B	DN	Saquinavir mesylate
DERD86B	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMOSW35
DERD86B	DN	Felodipine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DML4ZOT
DERD86B	DN	Lidocaine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMG8K57
DERD86B	DN	Cortisone acetate
DERD86B	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM2HN6Q
DERD86B	DN	Astemizole
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMXZOCG
DERD86B	DN	Phenobarbital
DERD86B	RN	Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 1993 Nov;18(5):1254-62.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8225233

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMOEM2I
DERD86B	DN	Estriol
DERD86B	RN	Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003 Jan;31(1):1-6.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485945

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMH7MUV
DERD86B	DN	Zalcitabine
DERD86B	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMU764S
DERD86B	DN	Ritonavir
DERD86B	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMY2AH1
DERD86B	DN	Aminophenazone
DERD86B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM6C4YJ
DERD86B	DN	Chlorphenamine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMAZJFX
DERD86B	DN	Ciclosporin
DERD86B	RN	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008 Dec;30(6):689-99.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18978522

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM429AE
DERD86B	DN	Levomethadyl acetate hydrochloride
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMFX6G8
DERD86B	DN	Nelfinavir mesylate
DERD86B	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMWRYUH
DERD86B	DN	Prasterone sulfate
DERD86B	RN	CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int. 2007 Mar;80(3):154-9.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17334880

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMLPICK
DERD86B	DN	Quinidine
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMSWJ5X
DERD86B	DN	Sildenafil citrate
DERD86B	RN	Drug Interactions Flockhart Table
DERD86B	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMC1TEV
DERD86B	DN	Testosterone cypionate
DERD86B	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMB6871
DERD86B	DN	Testosterone enanthate
DERD86B	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DMDGCQP
DERD86B	DN	Norethindrone acetate
DERD86B	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DERD86B	EI	DERD86B
DERD86B	EN	Cytochrome P450 3A7 (CYP3A7)
DERD86B	DI	DM7LRKD
DERD86B	DN	Triamcinolone diacetate
DERD86B	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DERD86B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DED5AT3	EI	DED5AT3
DED5AT3	EN	Cytochrome P450 2F1 (CYP2F1)
DED5AT3	DI	DM0YJSB
DED5AT3	DN	Enflurane
DED5AT3	RN	Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther. 1994 Apr;55(4):434-40.
DED5AT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8162670

DED5AT3	EI	DED5AT3
DED5AT3	EN	Cytochrome P450 2F1 (CYP2F1)
DED5AT3	DI	DM1QSM3
DED5AT3	DN	ENT-1814
DED5AT3	RN	Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite. Toxicol Lett. 2001 Dec 15;125(1-3):117-23.
DED5AT3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11701230

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM471KJ
DEZMWRE	DN	Omeprazole
DEZMWRE	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM49DUI
DEZMWRE	DN	Tretinoin
DEZMWRE	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMA4MRX
DEZMWRE	DN	Perphenazine
DEZMWRE	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMCT3I8
DEZMWRE	DN	Ifosfamide
DEZMWRE	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMCE985
DEZMWRE	DN	Antipyrine
DEZMWRE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMPRI8G
DEZMWRE	DN	Buprenorphine hydrochloride
DEZMWRE	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMJ3HQY
DEZMWRE	DN	GTPL-1666
DEZMWRE	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM02AWV
DEZMWRE	DN	Tolbutamide
DEZMWRE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM2NUH3
DEZMWRE	DN	Imipramine hydrochloride
DEZMWRE	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM08E9O
DEZMWRE	DN	Diazepam
DEZMWRE	RN	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9028867

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM5UGDK
DEZMWRE	DN	Mephenytoin
DEZMWRE	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMTW6IU
DEZMWRE	DN	Methadone
DEZMWRE	RN	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8839037

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMB4OLE
DEZMWRE	DN	Propofol
DEZMWRE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM4O2Z7
DEZMWRE	DN	Cyclophosphamide
DEZMWRE	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMJYCVW
DEZMWRE	DN	Warfarin sodium
DEZMWRE	RN	Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9014207

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMNOKBV
DEZMWRE	DN	Phenytoin
DEZMWRE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM20VSK
DEZMWRE	DN	Istradefylline
DEZMWRE	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM4LT8A
DEZMWRE	DN	Dapsone
DEZMWRE	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMA7PEW
DEZMWRE	DN	Verapamil hydrochloride
DEZMWRE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM59AZT
DEZMWRE	DN	Clotiazepam
DEZMWRE	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMW1OQ0
DEZMWRE	DN	Clobazam
DEZMWRE	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMPIHLS
DEZMWRE	DN	Diclofenac sodium
DEZMWRE	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM70BU5
DEZMWRE	DN	Thalidomide
DEZMWRE	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DML4ZOT
DEZMWRE	DN	Lidocaine
DEZMWRE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMXZOCG
DEZMWRE	DN	Phenobarbital
DEZMWRE	RN	Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181490

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMY2AH1
DEZMWRE	DN	Aminophenazone
DEZMWRE	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DM8TNX3
DEZMWRE	DN	Etizolam
DEZMWRE	RN	Etizolam (INN) Pre-Review Report.
DEZMWRE	RU	https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf

DEZMWRE	EI	DEZMWRE
DEZMWRE	EN	Cytochrome P450 2C18 (CYP2C18)
DEZMWRE	DI	DMXYLQ3
DEZMWRE	DN	Lansoprazole
DEZMWRE	RN	Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
DEZMWRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7870052

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTK234
DES5XRU	DN	Piroxicam
DES5XRU	RN	Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9 J Pain Res. 2017 Jul 6;10:1581-1589.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28740425

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTP1DC
DES5XRU	DN	Irbesartan
DES5XRU	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXTMBJ
DES5XRU	DN	Azelastine
DES5XRU	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMOGFIX
DES5XRU	DN	Eltrombopag olamine
DES5XRU	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMD157S
DES5XRU	DN	Montelukast sodium
DES5XRU	RN	Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18413310

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM7HXWT
DES5XRU	DN	Nilotinib
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMI6HUW
DES5XRU	DN	Terbinafine hydrochloride
DES5XRU	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM56YN7
DES5XRU	DN	Desloratadine
DES5XRU	RN	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCMETN
DES5XRU	DN	Ixazomib
DES5XRU	RN	Ninlaro- European Medicines Agency - European Union
DES5XRU	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMF28YC
DES5XRU	DN	Atorvastatin calcium
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTIQF3
DES5XRU	DN	Treprostinil
DES5XRU	RN	FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021272s026lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM471KJ
DES5XRU	DN	Omeprazole
DES5XRU	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4KI7O
DES5XRU	DN	Zidovudine
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMZO10Y
DES5XRU	DN	Testosterone undecanoate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCRGY4
DES5XRU	DN	BNP-1350
DES5XRU	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM49DUI
DES5XRU	DN	Tretinoin
DES5XRU	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMA4MRX
DES5XRU	DN	Perphenazine
DES5XRU	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPAZHC
DES5XRU	DN	Cabazitaxel
DES5XRU	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DES5XRU	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCT3I8
DES5XRU	DN	Ifosfamide
DES5XRU	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMV26S8
DES5XRU	DN	Levomilnacipran
DES5XRU	RN	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26572745

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCDZ15
DES5XRU	DN	LY-2484595
DES5XRU	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMSWYF5
DES5XRU	DN	Quinine sulfate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMEV954
DES5XRU	DN	Sulfinpyrazone
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMAPO0T
DES5XRU	DN	ADD-3878
DES5XRU	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCE985
DES5XRU	DN	Antipyrine
DES5XRU	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXCM7H
DES5XRU	DN	Cerivastatin sodium
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMKJ485
DES5XRU	DN	Pioglitazone hydrochloride
DES5XRU	RN	The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19614891

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM6LOQU
DES5XRU	DN	Celecoxib
DES5XRU	RN	Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19761371

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM6F1PU
DES5XRU	DN	Vortioxetine hydrobromide
DES5XRU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMHY3IP
DES5XRU	DN	CKD-501
DES5XRU	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMM3L6Z
DES5XRU	DN	Ketobemidone
DES5XRU	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM02A65
DES5XRU	DN	Temazepam
DES5XRU	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPQAGE
DES5XRU	DN	Mycophenolate mofetil
DES5XRU	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM7TOWX
DES5XRU	DN	ABT-333
DES5XRU	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMZOLBI
DES5XRU	DN	Carbamazepine
DES5XRU	RN	Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10907977

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DME4RA8
DES5XRU	DN	Amodiaquine
DES5XRU	RN	Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361129

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPNTDL
DES5XRU	DN	ABT-001
DES5XRU	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXBLMP
DES5XRU	DN	Riociguat
DES5XRU	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMHNQOG
DES5XRU	DN	Zafirlukast
DES5XRU	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMHZJCG
DES5XRU	DN	Pentamidine isethionate
DES5XRU	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMK7HFI
DES5XRU	DN	Mefenamic acid
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMUM7HZ
DES5XRU	DN	Fluorouracilo
DES5XRU	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTW3R8
DES5XRU	DN	Sulfadiazine
DES5XRU	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMBVYDI
DES5XRU	DN	Benzyl alcohol
DES5XRU	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMX6OE3
DES5XRU	DN	Dabrafenib mesylate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM3P5DA
DES5XRU	DN	Rofecoxib
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DML53ZJ
DES5XRU	DN	Mirtazapine
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMF3AN7
DES5XRU	DN	Loratadine
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPRI8G
DES5XRU	DN	Buprenorphine hydrochloride
DES5XRU	RN	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16010532

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMOL793
DES5XRU	DN	Trifarotene
DES5XRU	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMODJ40
DES5XRU	DN	Ethinyl estradiol
DES5XRU	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM02AWV
DES5XRU	DN	Tolbutamide
DES5XRU	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM9OZWQ
DES5XRU	DN	Lovastatin
DES5XRU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM3VFPD
DES5XRU	DN	Troglitazone
DES5XRU	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMFYBD0
DES5XRU	DN	Dexibuprofen
DES5XRU	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM8RZ9H
DES5XRU	DN	Eszopiclone
DES5XRU	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM08E9O
DES5XRU	DN	Diazepam
DES5XRU	RN	Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10771285

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMOMK1V
DES5XRU	DN	Halofantrine
DES5XRU	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM5UGDK
DES5XRU	DN	Mephenytoin
DES5XRU	RN	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8110777

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM8MC6O
DES5XRU	DN	Estradiol valerate
DES5XRU	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM3BH1Y
DES5XRU	DN	Lapatinib ditosylate
DES5XRU	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4MDJY
DES5XRU	DN	Fluvastatin sodium
DES5XRU	RN	Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15998357

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMRD5SP
DES5XRU	DN	LAU-7b
DES5XRU	RN	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21054342

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMBY31K
DES5XRU	DN	CS-011
DES5XRU	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM7W94S
DES5XRU	DN	Brigatinib
DES5XRU	RN	Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28597393

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMUNTE3
DES5XRU	DN	E-3A
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMN4ZKC
DES5XRU	DN	Paraoxon
DES5XRU	RN	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16757081

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMSI5CB
DES5XRU	DN	Chloroquine
DES5XRU	RN	Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005 Dec;10(12):1271-3.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16359408

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTW6IU
DES5XRU	DN	Methadone
DES5XRU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMB4OLE
DES5XRU	DN	Propofol
DES5XRU	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMICDLV
DES5XRU	DN	Lorlatinib
DES5XRU	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMM7CHK
DES5XRU	DN	Trimethoprim
DES5XRU	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMBDPY0
DES5XRU	DN	KW-5338
DES5XRU	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM7RJXL
DES5XRU	DN	Imatinib mesylate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMKBJWP
DES5XRU	DN	Caffeine
DES5XRU	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMTG18I
DES5XRU	DN	R-1439
DES5XRU	RN	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: an analysis of the AleCardio trial. Diabetes Obes Metab. 2020 Jan;22(1):30-38.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31468659

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMY7PED
DES5XRU	DN	Cisapride
DES5XRU	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM8SMD1
DES5XRU	DN	Tazarotene
DES5XRU	RN	Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642475

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMOJZQ9
DES5XRU	DN	Loperamide hydrochloride
DES5XRU	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4O2Z7
DES5XRU	DN	Cyclophosphamide
DES5XRU	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMF98Q0
DES5XRU	DN	CYT-387
DES5XRU	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMI4EL5
DES5XRU	DN	Ketorolac
DES5XRU	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM72JXH
DES5XRU	DN	Losartan potassium
DES5XRU	RN	Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25424246

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMZ5RGV
DES5XRU	DN	Naproxen
DES5XRU	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMJYCVW
DES5XRU	DN	Warfarin sodium
DES5XRU	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMNOKBV
DES5XRU	DN	Phenytoin
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXBHR6
DES5XRU	DN	DRF-2593
DES5XRU	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM31ZQM
DES5XRU	DN	Tegafur
DES5XRU	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM20VSK
DES5XRU	DN	Istradefylline
DES5XRU	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMVHJLX
DES5XRU	DN	M-813
DES5XRU	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMRNGD2
DES5XRU	DN	GSK-1278863
DES5XRU	RN	Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26643993

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4Y95F
DES5XRU	DN	Cefaloridine
DES5XRU	RN	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004 Oct;311(1):228-36.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15194707

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM1UJO0
DES5XRU	DN	Pitavastatin calcium
DES5XRU	RN	Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22472908

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM2AR7L
DES5XRU	DN	Meloxicam
DES5XRU	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMZ6YPV
DES5XRU	DN	Cyamemazine
DES5XRU	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM30SGU
DES5XRU	DN	Simvastatin
DES5XRU	RN	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178259

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM89JLN
DES5XRU	DN	Apixaban
DES5XRU	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMG3F94
DES5XRU	DN	Mestranol
DES5XRU	RN	Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012 Oct;20(4):331-44.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960808

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM3VR1L
DES5XRU	DN	Selegiline hydrochloride
DES5XRU	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM1EO3G
DES5XRU	DN	MK-0822
DES5XRU	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXKJ6C
DES5XRU	DN	Torasemide
DES5XRU	RN	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304522

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM9ERH1
DES5XRU	DN	AG-1549
DES5XRU	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMEGFYD
DES5XRU	DN	LAS-17177
DES5XRU	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMUTEX3
DES5XRU	DN	Amiodarone hydrochloride
DES5XRU	RN	Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15716363

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMNQ869
DES5XRU	DN	Ombitasvir
DES5XRU	RN	Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179128

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMG3NFZ
DES5XRU	DN	BMS-298585
DES5XRU	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4LT8A
DES5XRU	DN	Dapsone
DES5XRU	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM7HLFD
DES5XRU	DN	ML-3000
DES5XRU	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMAHSU0
DES5XRU	DN	Selexipag
DES5XRU	RN	FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s005lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM5SXUV
DES5XRU	DN	Repaglinide
DES5XRU	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMAI7ZV
DES5XRU	DN	Diltiazem hydrochloride
DES5XRU	RN	Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9223567

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMDO279
DES5XRU	DN	Phenprocoumon
DES5XRU	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMA7PEW
DES5XRU	DN	Verapamil hydrochloride
DES5XRU	RN	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12972955

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM8VCBE
DES5XRU	DN	Ibuprofen
DES5XRU	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMB08GE
DES5XRU	DN	Sulfamethoxazole
DES5XRU	RN	Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17442935

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMSB068
DES5XRU	DN	Glasdegib
DES5XRU	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMT81LZ
DES5XRU	DN	Apalutamide
DES5XRU	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMJ2AH4
DES5XRU	DN	NSC-122758
DES5XRU	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMCDYW7
DES5XRU	DN	Nicardipine hydrochloride
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM07U2A
DES5XRU	DN	Estradiol acetate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMWX5CO
DES5XRU	DN	Nicotine
DES5XRU	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPIHLS
DES5XRU	DN	Diclofenac sodium
DES5XRU	RN	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15581350

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM27Z5T
DES5XRU	DN	Estradiol cypionate
DES5XRU	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMKB79O
DES5XRU	DN	Bromfenac
DES5XRU	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMGDKXN
DES5XRU	DN	Sitagliptin
DES5XRU	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM0Q8MZ
DES5XRU	DN	Trimethadione
DES5XRU	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMGMF6V
DES5XRU	DN	Capsaicin
DES5XRU	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM70BU5
DES5XRU	DN	Thalidomide
DES5XRU	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMNP60F
DES5XRU	DN	Anastrozole
DES5XRU	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMH7IPW
DES5XRU	DN	EMD-128130
DES5XRU	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMS8IFC
DES5XRU	DN	Sorafenib
DES5XRU	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMRMS0L
DES5XRU	DN	Morphine
DES5XRU	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPMDTH
DES5XRU	DN	AZD-9496
DES5XRU	RN	Complete substrate inhibition of cytochrome P450 2C8 by AZD9496, an oral selective estrogen receptor degrader. Drug Metab Dispos. 2018 Sep;46(9):1268-1276.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29921707

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DML4ZOT
DES5XRU	DN	Lidocaine
DES5XRU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMN3UXQ
DES5XRU	DN	Diethylstilbestrol
DES5XRU	RN	Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21553654

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMK7F9S
DES5XRU	DN	Amitriptyline hydrochloride
DES5XRU	RN	The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136296

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXZOCG
DES5XRU	DN	Phenobarbital
DES5XRU	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM4V8WF
DES5XRU	DN	TAK-652
DES5XRU	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DES5XRU	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMFC71L
DES5XRU	DN	Clozapine
DES5XRU	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMOEARH
DES5XRU	DN	AZD-2014
DES5XRU	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMIFCY2
DES5XRU	DN	H3B-6545
DES5XRU	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMPI6Z0
DES5XRU	DN	Zopiclone
DES5XRU	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMFG5ST
DES5XRU	DN	Almotriptan malate
DES5XRU	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMY2AH1
DES5XRU	DN	Aminophenazone
DES5XRU	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DML634R
DES5XRU	DN	Beraprost
DES5XRU	RN	Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18827466

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DM8QXOC
DES5XRU	DN	Enasidenib
DES5XRU	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMXYLQ3
DES5XRU	DN	Lansoprazole
DES5XRU	RN	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627562

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMF57DM
DES5XRU	DN	Pazopanib
DES5XRU	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMLPICK
DES5XRU	DN	Quinidine
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMZI4OV
DES5XRU	DN	QLT-091001
DES5XRU	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMY6EAO
DES5XRU	DN	Rosiglitazone
DES5XRU	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMC1TEV
DES5XRU	DN	Testosterone cypionate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMB6871
DES5XRU	DN	Testosterone enanthate
DES5XRU	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DES5XRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMGF8ZQ
DES5XRU	DN	Velpatasvir
DES5XRU	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DES5XRU	EI	DES5XRU
DES5XRU	EN	Cytochrome P450 2C8 (CYP2C8)
DES5XRU	DI	DMAI83D
DES5XRU	DN	Voxilaprevir
DES5XRU	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DES5XRU	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPHZQE
DE5IED8	DN	Chlorpropamide
DE5IED8	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMQ314B
DE5IED8	DN	VA-10872
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM1SC8M
DE5IED8	DN	Trimipramine
DE5IED8	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTK234
DE5IED8	DN	Piroxicam
DE5IED8	RN	Functional characterization of human CYP2C9 allelic variants in COS-7 cells. Front Pharmacol. 2016 Apr 25;7:98.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27199745

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTP1DC
DE5IED8	DN	Irbesartan
DE5IED8	RN	Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol. 2003 Jun;9(6):1342-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12800253

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXTMBJ
DE5IED8	DN	Azelastine
DE5IED8	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZAL7W
DE5IED8	DN	Promazine
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMD157S
DE5IED8	DN	Montelukast sodium
DE5IED8	RN	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26374173

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMMG26Z
DE5IED8	DN	Dolasetron mesylate
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5T6US
DE5IED8	DN	Estrone
DE5IED8	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9BI7M
DE5IED8	DN	Duloxetine hydrochloride
DE5IED8	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMI6HUW
DE5IED8	DN	Terbinafine hydrochloride
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKQTBA
DE5IED8	DN	Diphenhydramine
DE5IED8	RN	Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/25185985

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM28UJG
DE5IED8	DN	Dapagliflozin
DE5IED8	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTIQF3
DE5IED8	DN	Treprostinil
DE5IED8	RN	Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133511

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMM0XGL
DE5IED8	DN	Idarubicin
DE5IED8	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM471KJ
DE5IED8	DN	Omeprazole
DE5IED8	RN	Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258107

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM4KI7O
DE5IED8	DN	Zidovudine
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMNZWL7
DE5IED8	DN	RO-111163
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZO10Y
DE5IED8	DN	Testosterone undecanoate
DE5IED8	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMC4GEI
DE5IED8	DN	Ospemifene
DE5IED8	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM49DUI
DE5IED8	DN	Tretinoin
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMW649X
DE5IED8	DN	Eletriptan hydrobromide
DE5IED8	RN	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27582896

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMA4MRX
DE5IED8	DN	Perphenazine
DE5IED8	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6A0X7
DE5IED8	DN	Pravastatin
DE5IED8	RN	In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8737761

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMFQCB1
DE5IED8	DN	Dicumarol
DE5IED8	RN	Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25866574

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMCT3I8
DE5IED8	DN	Ifosfamide
DE5IED8	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPWGBR
DE5IED8	DN	Triclabendazole
DE5IED8	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSWYF5
DE5IED8	DN	Quinine sulfate
DE5IED8	RN	Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968357

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5IXKQ
DE5IED8	DN	Vismodegib
DE5IED8	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMCE985
DE5IED8	DN	Antipyrine
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9PLRH
DE5IED8	DN	Doxazosin
DE5IED8	RN	Product monograph: CARDURA (Doxazosin mesylate).
DE5IED8	RU	https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMY4D87
DE5IED8	DN	Quazepam
DE5IED8	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKJ485
DE5IED8	DN	Pioglitazone hydrochloride
DE5IED8	RN	Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013 Nov 26;4:147.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24324437

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMG3Y89
DE5IED8	DN	Trabectedin
DE5IED8	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6LOQU
DE5IED8	DN	Celecoxib
DE5IED8	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6F1PU
DE5IED8	DN	Vortioxetine hydrobromide
DE5IED8	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM0N8ZM
DE5IED8	DN	Coumarin
DE5IED8	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMGPF0N
DE5IED8	DN	Estrone sulfate
DE5IED8	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMM3L6Z
DE5IED8	DN	Ketobemidone
DE5IED8	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM02A65
DE5IED8	DN	Temazepam
DE5IED8	RN	Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol. 1998 Mar 15;55(6):889-96.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9586962

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMQ8R4E
DE5IED8	DN	Naftopidil
DE5IED8	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9SX6Y
DE5IED8	DN	E-7070
DE5IED8	RN	PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther. 2008 Jun;83(6):829-39.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17851564

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMHP21E
DE5IED8	DN	Hydromorphone
DE5IED8	RN	Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15268978

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSOURV
DE5IED8	DN	Formoterol
DE5IED8	RN	FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM7YNV9
DE5IED8	DN	Iclaprim
DE5IED8	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMQI43G
DE5IED8	DN	BMS-650032
DE5IED8	RN	Australian Public Assessment Report for asunaprevir.
DE5IED8	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMJPR2B
DE5IED8	DN	BRN-0592109
DE5IED8	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPNTDL
DE5IED8	DN	ABT-001
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM78IME
DE5IED8	DN	Histamine
DE5IED8	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM62B78
DE5IED8	DN	Olodaterol hydrochloride
DE5IED8	RN	FDA Label of Olodaterol. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203108s006lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM1S4AG
DE5IED8	DN	Lumiracoxib
DE5IED8	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZU5JP
DE5IED8	DN	Flunarizine
DE5IED8	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMAT2XH
DE5IED8	DN	Nabumetone
DE5IED8	RN	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull. 2011;34(5):734-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21532165

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMHNQOG
DE5IED8	DN	Zafirlukast
DE5IED8	RN	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370959

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMMQYL9
DE5IED8	DN	CC-223
DE5IED8	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMK7HFI
DE5IED8	DN	Mefenamic acid
DE5IED8	RN	Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014 Dec 15;27(12):2071-81.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25372302

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMH75KV
DE5IED8	DN	G-23350
DE5IED8	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTW3R8
DE5IED8	DN	Sulfadiazine
DE5IED8	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM8JXPZ
DE5IED8	DN	Glibenclamide
DE5IED8	RN	Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20437462

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVM6QR
DE5IED8	DN	Lacosamide
DE5IED8	RN	Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009 Sep-Oct;9(5):133-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19826503

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMA17D0
DE5IED8	DN	Dorzolamide hydrochloride
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM3P5DA
DE5IED8	DN	Rofecoxib
DE5IED8	RN	Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118328

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DML53ZJ
DE5IED8	DN	Mirtazapine
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMF3AN7
DE5IED8	DN	Loratadine
DE5IED8	RN	In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10597902

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPRI8G
DE5IED8	DN	Buprenorphine hydrochloride
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM27U4Y
DE5IED8	DN	Desogestrel
DE5IED8	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPI98T
DE5IED8	DN	Doxepin hydrochloride
DE5IED8	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOL793
DE5IED8	DN	Trifarotene
DE5IED8	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DML2A03
DE5IED8	DN	Alosetron hydrochloride
DE5IED8	RN	Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001 Apr;41(4):455-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304903

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMB0EUX
DE5IED8	DN	Gliquidone
DE5IED8	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMHDF7B
DE5IED8	DN	Thiamylal
DE5IED8	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMODJ40
DE5IED8	DN	Ethinyl estradiol
DE5IED8	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM02AWV
DE5IED8	DN	Tolbutamide
DE5IED8	RN	Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 2001 Feb;29(2):141-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159803

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMLK2QH
DE5IED8	DN	Nateglinide
DE5IED8	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMREUQ6
DE5IED8	DN	Valsartan
DE5IED8	RN	In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000 May;56(2):135-40.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10877007

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOH8VY
DE5IED8	DN	Dacomitinib
DE5IED8	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM3VFPD
DE5IED8	DN	Troglitazone
DE5IED8	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMFYBD0
DE5IED8	DN	Dexibuprofen
DE5IED8	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKXJZ7
DE5IED8	DN	Suprofen
DE5IED8	RN	Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14570769

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUY35B
DE5IED8	DN	Progesterone
DE5IED8	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM2R86O
DE5IED8	DN	BAF-312
DE5IED8	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM2F8XZ
DE5IED8	DN	ANW-43703
DE5IED8	RN	Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25840124

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSYRBX
DE5IED8	DN	Atazanavir
DE5IED8	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM7MT6E
DE5IED8	DN	Prasugrel hydrochloride
DE5IED8	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM08E9O
DE5IED8	DN	Diazepam
DE5IED8	RN	Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12708941

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM2AOTZ
DE5IED8	DN	Perazine
DE5IED8	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMLB0EZ
DE5IED8	DN	Tamoxifen citrate
DE5IED8	RN	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17024799

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5UGDK
DE5IED8	DN	Mephenytoin
DE5IED8	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DML0RAE
DE5IED8	DN	Methoxyflurane
DE5IED8	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM8MC6O
DE5IED8	DN	Estradiol valerate
DE5IED8	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMAYL0T
DE5IED8	DN	Phenylbutazone
DE5IED8	RN	Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11302937

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMR6N7H
DE5IED8	DN	Acetohexamide
DE5IED8	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM4MDJY
DE5IED8	DN	Fluvastatin sodium
DE5IED8	RN	Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 1;6(2):94-101.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22594566

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUNTE3
DE5IED8	DN	E-3A
DE5IED8	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMR8ONJ
DE5IED8	DN	Leflunomide
DE5IED8	RN	Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004 Jan;36(1):82-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14971821

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM4KLPT
DE5IED8	DN	Terfenadine
DE5IED8	RN	Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab Pharmacokinet. 2002;17(6):522-31.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618707

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMIHRNA
DE5IED8	DN	Tolazamide
DE5IED8	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMR5ZUP
DE5IED8	DN	Paramethadione
DE5IED8	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMMTW9K
DE5IED8	DN	SCH-417690
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVRIC2
DE5IED8	DN	Zileuton
DE5IED8	RN	Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654206

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOWZ6B
DE5IED8	DN	Fluconazole
DE5IED8	RN	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10952477

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6A4NW
DE5IED8	DN	Etoricoxib
DE5IED8	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUDJZM
DE5IED8	DN	Dextromethorphan hydrobromide
DE5IED8	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTW6IU
DE5IED8	DN	Methadone
DE5IED8	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMCS6M5
DE5IED8	DN	Voxelotor
DE5IED8	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXLT8C
DE5IED8	DN	J-005528
DE5IED8	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMLMXE0
DE5IED8	DN	Amprenavir
DE5IED8	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMGN4BY
DE5IED8	DN	Flurbiprofen sodium
DE5IED8	RN	Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25144335

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMTIVEN
DE5IED8	DN	Metronidazole
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMB4OLE
DE5IED8	DN	Propofol
DE5IED8	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVXLOD
DE5IED8	DN	Imrecoxib
DE5IED8	RN	Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019 Oct 31;9(1):15774.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31673051

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKWFBT
DE5IED8	DN	Melatonin
DE5IED8	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMM7CHK
DE5IED8	DN	Trimethoprim
DE5IED8	RN	Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002 Jun;30(6):631-5.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12019187

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM7RJXL
DE5IED8	DN	Imatinib mesylate
DE5IED8	RN	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27749579

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5FSJA
DE5IED8	DN	Glimepiride
DE5IED8	RN	Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006 May;72(2):148-54.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16325295

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKBJWP
DE5IED8	DN	Caffeine
DE5IED8	RN	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23679834

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMY7PED
DE5IED8	DN	Cisapride
DE5IED8	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMGV8QU
DE5IED8	DN	Etravirine
DE5IED8	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSHPW8
DE5IED8	DN	Tolterodine tartrate
DE5IED8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUR64T
DE5IED8	DN	Lesinurad
DE5IED8	RN	FDA Label of Lesinurad. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMHKJ5I
DE5IED8	DN	GW-1000
DE5IED8	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSEPK8
DE5IED8	DN	Brivaracetam
DE5IED8	RN	Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22538270

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM4O2Z7
DE5IED8	DN	Cyclophosphamide
DE5IED8	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM96SE0
DE5IED8	DN	Haloperidol decanoate
DE5IED8	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMRK8OT
DE5IED8	DN	Candesartan cilexetil
DE5IED8	RN	Product Monograph of Atacand.
DE5IED8	RU	https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/ATACAND%20-%20Product-Monograph_001.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMF98Q0
DE5IED8	DN	CYT-387
DE5IED8	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM80OZ5
DE5IED8	DN	Halothane
DE5IED8	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM72JXH
DE5IED8	DN	Losartan potassium
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZ5RGV
DE5IED8	DN	Naproxen
DE5IED8	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMJYCVW
DE5IED8	DN	Warfarin sodium
DE5IED8	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMNOKBV
DE5IED8	DN	Phenytoin
DE5IED8	RN	Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21358975

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DME5Y64
DE5IED8	DN	Tranilast
DE5IED8	RN	Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos. 2007 Apr;35(4):583-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17220234

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM20VSK
DE5IED8	DN	Istradefylline
DE5IED8	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM1UJO0
DE5IED8	DN	Pitavastatin calcium
DE5IED8	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMEKAYI
DE5IED8	DN	R-1124
DE5IED8	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM2AR7L
DE5IED8	DN	Meloxicam
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZ6YPV
DE5IED8	DN	Cyamemazine
DE5IED8	RN	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17951033

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM672AH
DE5IED8	DN	Aspirin
DE5IED8	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUOQZD
DE5IED8	DN	Arachidonic acid
DE5IED8	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM89JLN
DE5IED8	DN	Apixaban
DE5IED8	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVAZP9
DE5IED8	DN	Tenoxicam
DE5IED8	RN	CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004 Jul;76(1):18-26.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15229460

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMICMXE
DE5IED8	DN	SSR-97193
DE5IED8	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMIYDT4
DE5IED8	DN	Cabozantinib
DE5IED8	RN	FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMG3F94
DE5IED8	DN	Mestranol
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM3VR1L
DE5IED8	DN	Selegiline hydrochloride
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPC1J7
DE5IED8	DN	Clofibrate
DE5IED8	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOX3LB
DE5IED8	DN	Fosphenytoin sodium
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXKJ6C
DE5IED8	DN	Torasemide
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMJAGXQ
DE5IED8	DN	Niclosamide
DE5IED8	RN	Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557374

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMMIQ7G
DE5IED8	DN	Rosuvastatin
DE5IED8	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMABRJL
DE5IED8	DN	Ximelagatran
DE5IED8	RN	Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372822

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMNSJ7V
DE5IED8	DN	Tropisetron
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM0FB1J
DE5IED8	DN	Sertraline hydrochloride
DE5IED8	RN	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15547048

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXLSH3
DE5IED8	DN	Tapentadol
DE5IED8	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DML6HP3
DE5IED8	DN	HSP-990
DE5IED8	RN	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015 Feb 17;112(4):650-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25625276

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOTQ1I
DE5IED8	DN	Ondansetron
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9ERH1
DE5IED8	DN	AG-1549
DE5IED8	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUTEX3
DE5IED8	DN	Amiodarone hydrochloride
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMAY7H4
DE5IED8	DN	Valdecoxib
DE5IED8	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMC7XDN
DE5IED8	DN	Alprazolam
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMN6QO5
DE5IED8	DN	Gliclazide
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMG3NFZ
DE5IED8	DN	BMS-298585
DE5IED8	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM48QOT
DE5IED8	DN	Artemether
DE5IED8	RN	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23441978

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9UB0P
DE5IED8	DN	Oxaprozin
DE5IED8	RN	Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9115051

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM4LT8A
DE5IED8	DN	Dapsone
DE5IED8	RN	Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15130760

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOBIKY
DE5IED8	DN	Bexarotene
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMOL54H
DE5IED8	DN	Clopidogrel bisulfate
DE5IED8	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM7HLFD
DE5IED8	DN	ML-3000
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6WJO9
DE5IED8	DN	Etodolac
DE5IED8	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMAOL2S
DE5IED8	DN	Voriconazole
DE5IED8	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMIYG7Z
DE5IED8	DN	Donepezil hydrochloride
DE5IED8	RN	Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26603528

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMI782S
DE5IED8	DN	Erdafitinib
DE5IED8	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM0659E
DE5IED8	DN	Cannabidiol
DE5IED8	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM6HX9B
DE5IED8	DN	Nevirapine
DE5IED8	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMRQAM0
DE5IED8	DN	Phenacetin
DE5IED8	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMAI7ZV
DE5IED8	DN	Diltiazem hydrochloride
DE5IED8	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMT70RC
DE5IED8	DN	Piperaquine
DE5IED8	RN	Eurartesim - European Medicines Agency
DE5IED8	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM70IK5
DE5IED8	DN	Dronabinol
DE5IED8	RN	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16112652

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMR6QH0
DE5IED8	DN	Venlafaxine hydrochloride
DE5IED8	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMBL79I
DE5IED8	DN	Proguanil
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM7U5QJ
DE5IED8	DN	Cinnarizine
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMMUCG4
DE5IED8	DN	SC-411
DE5IED8	RN	CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21945326

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMDO279
DE5IED8	DN	Phenprocoumon
DE5IED8	RN	Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica. 2004 Sep;34(9):847-59.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15742978

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMA7PEW
DE5IED8	DN	Verapamil hydrochloride
DE5IED8	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM8VCBE
DE5IED8	DN	Ibuprofen
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSC4A7
DE5IED8	DN	Indomethacin
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMB08GE
DE5IED8	DN	Sulfamethoxazole
DE5IED8	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMBPN7T
DE5IED8	DN	Rupatadine
DE5IED8	RN	Product Monograph of Xtandi Rupatadine (as rupatadine fumarate).
DE5IED8	RU	http://www.pedia-pharm.com/en/wp-content/uploads/sites/3/2017/02/RUPALL-monograph-EN.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMNO38U
DE5IED8	DN	Bortezomib
DE5IED8	RN	Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443666

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMLFSTR
DE5IED8	DN	Tienilic acid
DE5IED8	RN	Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23(3-4):235-42.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9112234

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKM5HB
DE5IED8	DN	Sitaxentan
DE5IED8	RN	Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest. 2009 Jun;39 Suppl 2:14-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19335742

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMWOSKJ
DE5IED8	DN	Zolpidem tartrate
DE5IED8	RN	The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30178440

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPGUCF
DE5IED8	DN	Dopamine hydrochloride
DE5IED8	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM07U2A
DE5IED8	DN	Estradiol acetate
DE5IED8	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMWX5CO
DE5IED8	DN	Nicotine
DE5IED8	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZDF0B
DE5IED8	DN	Aceclofenac
DE5IED8	RN	Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996 Aug;24(8):834-41.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8869816

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPIHLS
DE5IED8	DN	Diclofenac sodium
DE5IED8	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM52HUD
DE5IED8	DN	CR-2017
DE5IED8	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVU687
DE5IED8	DN	JNJ-54135419
DE5IED8	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM3PD2C
DE5IED8	DN	Fluoxetine hydrochloride
DE5IED8	RN	Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19442216

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM27Z5T
DE5IED8	DN	Estradiol cypionate
DE5IED8	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMKB79O
DE5IED8	DN	Bromfenac
DE5IED8	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMIOGBU
DE5IED8	DN	Bosentan
DE5IED8	RN	Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12603176

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM0Q8MZ
DE5IED8	DN	Trimethadione
DE5IED8	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMGMF6V
DE5IED8	DN	Capsaicin
DE5IED8	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUIE76
DE5IED8	DN	Acetaminophen
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM0WX6I
DE5IED8	DN	Primidone
DE5IED8	RN	Prescribrt's digital referenve - Primidone - Drug Summary.
DE5IED8	RU	https://www.pdr.net/drug-summary/Mysoline-primidone-775

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM70BU5
DE5IED8	DN	Thalidomide
DE5IED8	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMYZFXN
DE5IED8	DN	Lornoxicam
DE5IED8	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMT5HA4
DE5IED8	DN	Ketamine
DE5IED8	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMUTYR2
DE5IED8	DN	Epoprostenol
DE5IED8	RN	Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):321-6.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15569819

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMGR5Z3
DE5IED8	DN	Flunitrazepam
DE5IED8	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMH7IPW
DE5IED8	DN	EMD-128130
DE5IED8	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMHTEAO
DE5IED8	DN	Carvedilol
DE5IED8	RN	The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25476996

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMRKXPT
DE5IED8	DN	Ketoprofen
DE5IED8	RN	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21516380

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DML4ZOT
DE5IED8	DN	Lidocaine
DE5IED8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5PCS7
DE5IED8	DN	Bupropion
DE5IED8	RN	Product Monograph of Wellbutrin SR(Bupropion Hydrochloride).
DE5IED8	RU	https://pdf.hres.ca/dpd_pm/00038603.PDF

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMCFE9I
DE5IED8	DN	Valproic acid
DE5IED8	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMK7F9S
DE5IED8	DN	Amitriptyline hydrochloride
DE5IED8	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXZOCG
DE5IED8	DN	Phenobarbital
DE5IED8	RN	Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb;308(2):495-501.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600250

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMFC71L
DE5IED8	DN	Clozapine
DE5IED8	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMC3YUA
DE5IED8	DN	Benzbromarone
DE5IED8	RN	Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry. 2004 Jun 8;43(22):6948-58.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15170332

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMZA5PQ
DE5IED8	DN	Glipizide
DE5IED8	RN	Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15637526

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMIFCY2
DE5IED8	DN	H3B-6545
DE5IED8	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMH7MUV
DE5IED8	DN	Zalcitabine
DE5IED8	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMPI6Z0
DE5IED8	DN	Zopiclone
DE5IED8	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMY2AH1
DE5IED8	DN	Aminophenazone
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMH6B9J
DE5IED8	DN	BZ-55
DE5IED8	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM8QXOC
DE5IED8	DN	Enasidenib
DE5IED8	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DE5IED8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMXYLQ3
DE5IED8	DN	Lansoprazole
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM82JP0
DE5IED8	DN	Lynestrenol
DE5IED8	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMLPICK
DE5IED8	DN	Quinidine
DE5IED8	RN	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10594487

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM5DSFZ
DE5IED8	DN	Rifampicin
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMY6EAO
DE5IED8	DN	Rosiglitazone
DE5IED8	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMSWJ5X
DE5IED8	DN	Sildenafil citrate
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMVCMUJ
DE5IED8	DN	Siponimod
DE5IED8	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMC1TEV
DE5IED8	DN	Testosterone cypionate
DE5IED8	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DMB6871
DE5IED8	DN	Testosterone enanthate
DE5IED8	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DE5IED8	EI	DE5IED8
DE5IED8	EN	Cytochrome P450 2C9 (CYP2C9)
DE5IED8	DI	DM9RJH7
DE5IED8	DN	Zaltoprofen
DE5IED8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE5IED8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMK5I07
DEPKLMQ	DN	AN-16649
DEPKLMQ	RN	Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006 Jun;13(6):598-605.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16410820

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMOYE70
DEPKLMQ	DN	HOE-239
DEPKLMQ	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMINO7Z
DEPKLMQ	DN	WSM-3978G
DEPKLMQ	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMX4GND
DEPKLMQ	DN	Meperidine
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM5T6US
DEPKLMQ	DN	Estrone
DEPKLMQ	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMG6OYJ
DEPKLMQ	DN	Lorcaserin
DEPKLMQ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCMETN
DEPKLMQ	DN	Ixazomib
DEPKLMQ	RN	NINLARO- European Medicines Agency - European Union
DEPKLMQ	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMT2FDC
DEPKLMQ	DN	Desipramine
DEPKLMQ	RN	Drugs that may have potential CYP2B6 interactions.
DEPKLMQ	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMZO10Y
DEPKLMQ	DN	Testosterone undecanoate
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMC4GEI
DEPKLMQ	DN	Ospemifene
DEPKLMQ	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM49DUI
DEPKLMQ	DN	Tretinoin
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCT3I8
DEPKLMQ	DN	Ifosfamide
DEPKLMQ	RN	A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12571232

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCE985
DEPKLMQ	DN	Antipyrine
DEPKLMQ	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM6F1PU
DEPKLMQ	DN	Vortioxetine hydrobromide
DEPKLMQ	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMM3L6Z
DEPKLMQ	DN	Ketobemidone
DEPKLMQ	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM02A65
DEPKLMQ	DN	Temazepam
DEPKLMQ	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMQI43G
DEPKLMQ	DN	BMS-650032
DEPKLMQ	RN	Australian Public Assessment Report for asunaprevir.
DEPKLMQ	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMZOLBI
DEPKLMQ	DN	Carbamazepine
DEPKLMQ	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMPNTDL
DEPKLMQ	DN	ABT-001
DEPKLMQ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMSH108
DEPKLMQ	DN	CYC-202
DEPKLMQ	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMRQD04
DEPKLMQ	DN	Tramadol hydrochloride
DEPKLMQ	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMF3AN7
DEPKLMQ	DN	Loratadine
DEPKLMQ	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMOL793
DEPKLMQ	DN	Trifarotene
DEPKLMQ	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM2NUH3
DEPKLMQ	DN	Imipramine hydrochloride
DEPKLMQ	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMP6SC2
DEPKLMQ	DN	Irinotecan hydrochloride
DEPKLMQ	RN	Drugs that may have potential CYP2B6 interactions.
DEPKLMQ	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMC0GSJ
DEPKLMQ	DN	Efavirenz
DEPKLMQ	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM7MT6E
DEPKLMQ	DN	Prasugrel hydrochloride
DEPKLMQ	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM08E9O
DEPKLMQ	DN	Diazepam
DEPKLMQ	RN	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMLB0EZ
DEPKLMQ	DN	Tamoxifen citrate
DEPKLMQ	RN	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023523

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM5UGDK
DEPKLMQ	DN	Mephenytoin
DEPKLMQ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DML0RAE
DEPKLMQ	DN	Methoxyflurane
DEPKLMQ	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMDSWAG
DEPKLMQ	DN	DEA-2250
DEPKLMQ	RN	Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284537

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMUDJZM
DEPKLMQ	DN	Dextromethorphan hydrobromide
DEPKLMQ	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMTW6IU
DEPKLMQ	DN	Methadone
DEPKLMQ	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMSPJG2
DEPKLMQ	DN	Ropivacaine hydrochloride
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCS6M5
DEPKLMQ	DN	Voxelotor
DEPKLMQ	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMB4OLE
DEPKLMQ	DN	Propofol
DEPKLMQ	RN	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620218

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMBDPY0
DEPKLMQ	DN	KW-5338
DEPKLMQ	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMY7PED
DEPKLMQ	DN	Cisapride
DEPKLMQ	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMOJZQ9
DEPKLMQ	DN	Loperamide hydrochloride
DEPKLMQ	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMSEPK8
DEPKLMQ	DN	Brivaracetam
DEPKLMQ	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM4O2Z7
DEPKLMQ	DN	Cyclophosphamide
DEPKLMQ	RN	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065440

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM80OZ5
DEPKLMQ	DN	Halothane
DEPKLMQ	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMY6T31
DEPKLMQ	DN	Isoflurane
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMX0K3Q
DEPKLMQ	DN	Epinastine
DEPKLMQ	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMNOKBV
DEPKLMQ	DN	Phenytoin
DEPKLMQ	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM20VSK
DEPKLMQ	DN	Istradefylline
DEPKLMQ	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMSPN58
DEPKLMQ	DN	WY-1485
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMTQLIJ
DEPKLMQ	DN	Amlodipine besylate
DEPKLMQ	RN	Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules. Biochemistry. 2012 Sep 18;51(37):7225-38.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22909231

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM3VR1L
DEPKLMQ	DN	Selegiline hydrochloride
DEPKLMQ	RN	Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25656918

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMPC1J7
DEPKLMQ	DN	Clofibrate
DEPKLMQ	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM0FB1J
DEPKLMQ	DN	Sertraline hydrochloride
DEPKLMQ	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMXZ84M
DEPKLMQ	DN	Malathion
DEPKLMQ	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMZ0Q1G
DEPKLMQ	DN	Permethrin
DEPKLMQ	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMT5GNL
DEPKLMQ	DN	Romidepsin
DEPKLMQ	RN	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM48QOT
DEPKLMQ	DN	Artemether
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMOL54H
DEPKLMQ	DN	Clopidogrel bisulfate
DEPKLMQ	RN	Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20440227

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM0YROF
DEPKLMQ	DN	Ethylmorphine
DEPKLMQ	RN	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM6HX9B
DEPKLMQ	DN	Nevirapine
DEPKLMQ	RN	RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003847

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM7U5QJ
DEPKLMQ	DN	Cinnarizine
DEPKLMQ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMA7PEW
DEPKLMQ	DN	Verapamil hydrochloride
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM59AZT
DEPKLMQ	DN	Clotiazepam
DEPKLMQ	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMVKA4O
DEPKLMQ	DN	Mianserin
DEPKLMQ	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMOY7W3
DEPKLMQ	DN	Artemisinin
DEPKLMQ	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMW1OQ0
DEPKLMQ	DN	Clobazam
DEPKLMQ	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM6I5GR
DEPKLMQ	DN	Promethazine
DEPKLMQ	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMIJATC
DEPKLMQ	DN	Benzphetamine
DEPKLMQ	RN	Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19144770

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMF3VXA
DEPKLMQ	DN	Zotepine
DEPKLMQ	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMWX5CO
DEPKLMQ	DN	Nicotine
DEPKLMQ	RN	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16174803

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMPIHLS
DEPKLMQ	DN	Diclofenac sodium
DEPKLMQ	RN	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10449188

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM52HUD
DEPKLMQ	DN	CR-2017
DEPKLMQ	RN	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16236040

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMVU687
DEPKLMQ	DN	JNJ-54135419
DEPKLMQ	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM3PD2C
DEPKLMQ	DN	Fluoxetine hydrochloride
DEPKLMQ	RN	Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537573

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMGMF6V
DEPKLMQ	DN	Capsaicin
DEPKLMQ	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMXOELT
DEPKLMQ	DN	Midazolam hydrochloride
DEPKLMQ	RN	Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732386

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM70BU5
DEPKLMQ	DN	Thalidomide
DEPKLMQ	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMT5HA4
DEPKLMQ	DN	Ketamine
DEPKLMQ	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMGR5Z3
DEPKLMQ	DN	Flunitrazepam
DEPKLMQ	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMC9O43
DEPKLMQ	DN	Sevoflurane
DEPKLMQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCTE9R
DEPKLMQ	DN	Mexiletine hydrochloride
DEPKLMQ	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DML4ZOT
DEPKLMQ	DN	Lidocaine
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM5PCS7
DEPKLMQ	DN	Bupropion
DEPKLMQ	RN	Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30916845

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMHB2C3
DEPKLMQ	DN	Z-4828
DEPKLMQ	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCFE9I
DEPKLMQ	DN	Valproic acid
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMK7F9S
DEPKLMQ	DN	Amitriptyline hydrochloride
DEPKLMQ	RN	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259560

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMXZOCG
DEPKLMQ	DN	Phenobarbital
DEPKLMQ	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMWLFGO
DEPKLMQ	DN	Methyltestosterone
DEPKLMQ	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMIFCY2
DEPKLMQ	DN	H3B-6545
DEPKLMQ	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMU764S
DEPKLMQ	DN	Ritonavir
DEPKLMQ	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM8KLU9
DEPKLMQ	DN	Cenobamate
DEPKLMQ	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM8QXOC
DEPKLMQ	DN	Enasidenib
DEPKLMQ	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMIAPBE
DEPKLMQ	DN	Hydrocodone bitartrate
DEPKLMQ	RN	FDA label of Hydrocodone bitartrate. The 2020 official website of the U.S. Food and Drug Administration.
DEPKLMQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMV3P89
DEPKLMQ	DN	Levoverbenone
DEPKLMQ	RN	Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos. 2003 Aug;31(8):1049-53.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12867494

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DM5DSFZ
DEPKLMQ	DN	Rifampicin
DEPKLMQ	RN	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16815319

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMC1TEV
DEPKLMQ	DN	Testosterone cypionate
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMB6871
DEPKLMQ	DN	Testosterone enanthate
DEPKLMQ	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMGF8ZQ
DEPKLMQ	DN	Velpatasvir
DEPKLMQ	RN	Epclusa- European Medicines Agency - European Union
DEPKLMQ	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_de.pdf

DEPKLMQ	EI	DEPKLMQ
DEPKLMQ	EN	Cytochrome P450 2B6 (CYP2B6)
DEPKLMQ	DI	DMCOJPS
DEPKLMQ	DN	Vonoprazan
DEPKLMQ	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DEPKLMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPHZQE
DEGTFWK	DN	Chlorpropamide
DEGTFWK	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMQ314B
DEGTFWK	DN	VA-10872
DEGTFWK	RN	Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality. 2007 Jul;19(7):550-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17487889

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM1SC8M
DEGTFWK	DN	Trimipramine
DEGTFWK	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMXTMBJ
DEGTFWK	DN	Azelastine
DEGTFWK	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMYZ57N
DEGTFWK	DN	Albendazole
DEGTFWK	RN	Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26048912

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMGP8AX
DEGTFWK	DN	Thiopental
DEGTFWK	RN	Lerman J. (2014). Neonatal Anesthesia. Springer.
DEGTFWK	RU	https://link.springer.com/book/10.1007%2F978-1-4419-6041-2

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMZAL7W
DEGTFWK	DN	Promazine
DEGTFWK	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMOYE70
DEGTFWK	DN	HOE-239
DEGTFWK	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMX4GND
DEGTFWK	DN	Meperidine
DEGTFWK	RN	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30902024

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMI6HUW
DEGTFWK	DN	Terbinafine hydrochloride
DEGTFWK	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMLW57T
DEGTFWK	DN	Teniposide
DEGTFWK	RN	Drug Interactions Flockhart Table
DEGTFWK	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMKQTBA
DEGTFWK	DN	Diphenhydramine
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMG6OYJ
DEGTFWK	DN	Lorcaserin
DEGTFWK	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMT2FDC
DEGTFWK	DN	Desipramine
DEGTFWK	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM471KJ
DEGTFWK	DN	Omeprazole
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4KI7O
DEGTFWK	DN	Zidovudine
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMGVH6N
DEGTFWK	DN	Axitinib
DEGTFWK	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMNZWL7
DEGTFWK	DN	RO-111163
DEGTFWK	RN	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11309556

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMZO10Y
DEGTFWK	DN	Testosterone undecanoate
DEGTFWK	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMC4GEI
DEGTFWK	DN	Ospemifene
DEGTFWK	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMA4MRX
DEGTFWK	DN	Perphenazine
DEGTFWK	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMCT3I8
DEGTFWK	DN	Ifosfamide
DEGTFWK	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPWGBR
DEGTFWK	DN	Triclabendazole
DEGTFWK	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMMSDOY
DEGTFWK	DN	Stiripentol
DEGTFWK	RN	FDA Label of Diacomit. The 2020 official website of the U.S. Food and Drug Administration.
DEGTFWK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMH1DYU
DEGTFWK	DN	AS-703026
DEGTFWK	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSWYF5
DEGTFWK	DN	Quinine sulfate
DEGTFWK	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159893

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMCE985
DEGTFWK	DN	Antipyrine
DEGTFWK	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM9PLRH
DEGTFWK	DN	Doxazosin
DEGTFWK	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMY4D87
DEGTFWK	DN	Quazepam
DEGTFWK	RN	In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15801544

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMG3Y89
DEGTFWK	DN	Trabectedin
DEGTFWK	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPW5SB
DEGTFWK	DN	BAY-8697661
DEGTFWK	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMZMSCT
DEGTFWK	DN	Cilostazol
DEGTFWK	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM6F1PU
DEGTFWK	DN	Vortioxetine hydrobromide
DEGTFWK	RN	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29189941

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMM3L6Z
DEGTFWK	DN	Ketobemidone
DEGTFWK	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM02A65
DEGTFWK	DN	Temazepam
DEGTFWK	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM5L6HI
DEGTFWK	DN	Atomoxetine hydrochloride
DEGTFWK	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMQ8R4E
DEGTFWK	DN	Naftopidil
DEGTFWK	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DME7KRM
DEGTFWK	DN	Oxiconazole
DEGTFWK	RN	In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21177487

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM9SX6Y
DEGTFWK	DN	E-7070
DEGTFWK	RN	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17504998

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM79NTF
DEGTFWK	DN	Propranolol hydrochloride
DEGTFWK	RN	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11678778

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSOURV
DEGTFWK	DN	Formoterol
DEGTFWK	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMQI43G
DEGTFWK	DN	BMS-650032
DEGTFWK	RN	Australian Public Assessment Report for asunaprevir.
DEGTFWK	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPNTDL
DEGTFWK	DN	ABT-001
DEGTFWK	RN	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010637

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4KDYJ
DEGTFWK	DN	Nortriptyline hydrochloride
DEGTFWK	RN	In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9867310

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM1S4AG
DEGTFWK	DN	Lumiracoxib
DEGTFWK	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFQWNI
DEGTFWK	DN	Clomipramine hydrochloride
DEGTFWK	RN	Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28470111

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHZJCG
DEGTFWK	DN	Pentamidine isethionate
DEGTFWK	RN	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21299635

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMH75KV
DEGTFWK	DN	G-23350
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMO946V
DEGTFWK	DN	Ticlopidine
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8JXPZ
DEGTFWK	DN	Glibenclamide
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMVM6QR
DEGTFWK	DN	Lacosamide
DEGTFWK	RN	Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23942540

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMWR1JC
DEGTFWK	DN	Carisoprodol
DEGTFWK	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM3NXRU
DEGTFWK	DN	Timolol maleate
DEGTFWK	RN	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21385322

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMF3AN7
DEGTFWK	DN	Loratadine
DEGTFWK	RN	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27460981

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM27U4Y
DEGTFWK	DN	Desogestrel
DEGTFWK	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPI98T
DEGTFWK	DN	Doxepin hydrochloride
DEGTFWK	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMEQL9U
DEGTFWK	DN	CAM-2028
DEGTFWK	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM7YPM1
DEGTFWK	DN	Enfuvirtide
DEGTFWK	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM5PVQE
DEGTFWK	DN	Paroxetine hydrochloride
DEGTFWK	RN	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20007670

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMODJ40
DEGTFWK	DN	Ethinyl estradiol
DEGTFWK	RN	The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12895199

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM02AWV
DEGTFWK	DN	Tolbutamide
DEGTFWK	RN	CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681382

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM9OZWQ
DEGTFWK	DN	Lovastatin
DEGTFWK	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM3VFPD
DEGTFWK	DN	Troglitazone
DEGTFWK	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFYBD0
DEGTFWK	DN	Dexibuprofen
DEGTFWK	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM1DBV5
DEGTFWK	DN	Dexlansoprazole
DEGTFWK	RN	Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26932927

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM2NUH3
DEGTFWK	DN	Imipramine hydrochloride
DEGTFWK	RN	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228186

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMUY35B
DEGTFWK	DN	Progesterone
DEGTFWK	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM6VP9U
DEGTFWK	DN	INN-00835
DEGTFWK	RN	Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
DEGTFWK	RU	https://books.google.com/books?id=Ue3uCAAAQBAJ&pg=PA574&lpg=PA574&dq=Nemifitide+metabolism&source=bl&ots=GQLQ8gSF2U&sig=ACfU3U27jlKMS_W2CDicejY8jKnpE1dFaw&hl=zh-CN&sa=X&ved=2ahUKEwiL7fCx8rTnAhXK-GEKHc_aD0UQ6AEwAHoECAkQAQ#v=onepage&q=Nemifitide%20metabolism&f=false

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM7MT6E
DEGTFWK	DN	Prasugrel hydrochloride
DEGTFWK	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM08E9O
DEGTFWK	DN	Diazepam
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM2AOTZ
DEGTFWK	DN	Perazine
DEGTFWK	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMLB0EZ
DEGTFWK	DN	Tamoxifen citrate
DEGTFWK	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4ZLFD
DEGTFWK	DN	Glucosamine
DEGTFWK	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM5UGDK
DEGTFWK	DN	Mephenytoin
DEGTFWK	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8MC6O
DEGTFWK	DN	Estradiol valerate
DEGTFWK	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM3BH1Y
DEGTFWK	DN	Lapatinib ditosylate
DEGTFWK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM6L5VO
DEGTFWK	DN	Methsuximide
DEGTFWK	RN	The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7640152

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMUNTE3
DEGTFWK	DN	E-3A
DEGTFWK	RN	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18521743

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFK9HG
DEGTFWK	DN	Escitalopram
DEGTFWK	RN	Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313485

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMDSWAG
DEGTFWK	DN	DEA-2250
DEGTFWK	RN	A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499191

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMUDJZM
DEGTFWK	DN	Dextromethorphan hydrobromide
DEGTFWK	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMTW6IU
DEGTFWK	DN	Methadone
DEGTFWK	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMCS6M5
DEGTFWK	DN	Voxelotor
DEGTFWK	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DEGTFWK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0DTF7
DEGTFWK	DN	Zonisamide
DEGTFWK	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4PRFC
DEGTFWK	DN	Bupivacaine hydrochloride
DEGTFWK	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMB4OLE
DEGTFWK	DN	Propofol
DEGTFWK	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMK8U72
DEGTFWK	DN	Labetalol
DEGTFWK	RN	Drug Interactions Flockhart Table
DEGTFWK	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMICDLV
DEGTFWK	DN	Lorlatinib
DEGTFWK	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DEGTFWK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMKWFBT
DEGTFWK	DN	Melatonin
DEGTFWK	RN	The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003850

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0GUSX
DEGTFWK	DN	Ranitidine
DEGTFWK	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMY7PED
DEGTFWK	DN	Cisapride
DEGTFWK	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMGV8QU
DEGTFWK	DN	Etravirine
DEGTFWK	RN	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22269145

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSHPW8
DEGTFWK	DN	Tolterodine tartrate
DEGTFWK	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHKJ5I
DEGTFWK	DN	GW-1000
DEGTFWK	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM7BN0X
DEGTFWK	DN	Esomeprazole
DEGTFWK	RN	Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027194

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSEPK8
DEGTFWK	DN	Brivaracetam
DEGTFWK	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4O2Z7
DEGTFWK	DN	Cyclophosphamide
DEGTFWK	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM96SE0
DEGTFWK	DN	Haloperidol decanoate
DEGTFWK	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMYM974
DEGTFWK	DN	Arformoterol
DEGTFWK	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMT2EJP
DEGTFWK	DN	Podophyllotoxin
DEGTFWK	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMF98Q0
DEGTFWK	DN	CYT-387
DEGTFWK	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMJ8NMC
DEGTFWK	DN	Barbital
DEGTFWK	RN	Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22331680

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMY9TCW
DEGTFWK	DN	Bromazepam
DEGTFWK	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMJYCVW
DEGTFWK	DN	Warfarin sodium
DEGTFWK	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMNOKBV
DEGTFWK	DN	Phenytoin
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMBHO9Y
DEGTFWK	DN	Adinazolam
DEGTFWK	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMBS370
DEGTFWK	DN	Tofacitinib citrate
DEGTFWK	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8HJX6
DEGTFWK	DN	Tipranavir
DEGTFWK	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFNH7L
DEGTFWK	DN	Pentobarbital
DEGTFWK	RN	CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805060

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMUYNEI
DEGTFWK	DN	Amoxicillin
DEGTFWK	RN	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14696516

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSPN58
DEGTFWK	DN	WY-1485
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMG6TS2
DEGTFWK	DN	GW-873140
DEGTFWK	RN	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18070967

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM053KT
DEGTFWK	DN	Aprepitant
DEGTFWK	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM672AH
DEGTFWK	DN	Aspirin
DEGTFWK	RN	Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621391

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM30SGU
DEGTFWK	DN	Simvastatin
DEGTFWK	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM1N62C
DEGTFWK	DN	Quetiapine fumarate
DEGTFWK	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMOJ0V6
DEGTFWK	DN	Metoprolol succinate
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM89JLN
DEGTFWK	DN	Apixaban
DEGTFWK	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMICMXE
DEGTFWK	DN	SSR-97193
DEGTFWK	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM3VR1L
DEGTFWK	DN	Selegiline hydrochloride
DEGTFWK	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMOX3LB
DEGTFWK	DN	Fosphenytoin sodium
DEGTFWK	RN	CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19617466

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM1WXA6
DEGTFWK	DN	Lofexidine
DEGTFWK	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DEGTFWK	RU	https://www.fda.gov/media/111903/download

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMRL3AB
DEGTFWK	DN	Famotidine
DEGTFWK	RN	Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112810

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0FB1J
DEGTFWK	DN	Sertraline hydrochloride
DEGTFWK	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMWK9BX
DEGTFWK	DN	SQ-109
DEGTFWK	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMMZXIW
DEGTFWK	DN	Rabeprazole sodium
DEGTFWK	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMUTEX3
DEGTFWK	DN	Amiodarone hydrochloride
DEGTFWK	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMOU1PK
DEGTFWK	DN	Praziquantel
DEGTFWK	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMN6QO5
DEGTFWK	DN	Gliclazide
DEGTFWK	RN	The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18541345

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMG3NFZ
DEGTFWK	DN	BMS-298585
DEGTFWK	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM48QOT
DEGTFWK	DN	Artemether
DEGTFWK	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4LT8A
DEGTFWK	DN	Dapsone
DEGTFWK	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMOL54H
DEGTFWK	DN	Clopidogrel bisulfate
DEGTFWK	RN	Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28164572

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMV50R1
DEGTFWK	DN	HE-3235
DEGTFWK	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DEGTFWK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMAOL2S
DEGTFWK	DN	Voriconazole
DEGTFWK	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0659E
DEGTFWK	DN	Cannabidiol
DEGTFWK	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMRQAM0
DEGTFWK	DN	Phenacetin
DEGTFWK	RN	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10548449

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMAI7ZV
DEGTFWK	DN	Diltiazem hydrochloride
DEGTFWK	RN	Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560871

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMT70RC
DEGTFWK	DN	Piperaquine
DEGTFWK	RN	Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25267661

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM70IK5
DEGTFWK	DN	Dronabinol
DEGTFWK	RN	Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8730919

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMR6QH0
DEGTFWK	DN	Venlafaxine hydrochloride
DEGTFWK	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMBL79I
DEGTFWK	DN	Proguanil
DEGTFWK	RN	Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol. 2002 Nov;58(8):543-5.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451432

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHIDUE
DEGTFWK	DN	Phenelzine
DEGTFWK	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMA7PEW
DEGTFWK	DN	Verapamil hydrochloride
DEGTFWK	RN	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8750925

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8VCBE
DEGTFWK	DN	Ibuprofen
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSC4A7
DEGTFWK	DN	Indomethacin
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM59AZT
DEGTFWK	DN	Clotiazepam
DEGTFWK	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMP79A1
DEGTFWK	DN	Macitentan
DEGTFWK	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM70DTN
DEGTFWK	DN	Flibanserin
DEGTFWK	RN	Flibanserin therapy and CYP2C19 genotype.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31550099

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMW1OQ0
DEGTFWK	DN	Clobazam
DEGTFWK	RN	A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15533655

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMNO38U
DEGTFWK	DN	Bortezomib
DEGTFWK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFN07X
DEGTFWK	DN	Nilutamide
DEGTFWK	RN	Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1785203

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMWOSKJ
DEGTFWK	DN	Zolpidem tartrate
DEGTFWK	RN	Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17515707

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMF3VXA
DEGTFWK	DN	Zotepine
DEGTFWK	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMJ0QOW
DEGTFWK	DN	Rilpivirine hydrochloride
DEGTFWK	RN	Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27799217

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSVOCZ
DEGTFWK	DN	Pantoprazole sodium
DEGTFWK	RN	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29620484

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPGUCF
DEGTFWK	DN	Dopamine hydrochloride
DEGTFWK	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM07U2A
DEGTFWK	DN	Estradiol acetate
DEGTFWK	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMWX5CO
DEGTFWK	DN	Nicotine
DEGTFWK	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMPIHLS
DEGTFWK	DN	Diclofenac sodium
DEGTFWK	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMNQXV8
DEGTFWK	DN	Encorafenib
DEGTFWK	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMVU687
DEGTFWK	DN	JNJ-54135419
DEGTFWK	RN	Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017 Feb 20;2(1):2-10.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/30483613

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM3PD2C
DEGTFWK	DN	Fluoxetine hydrochloride
DEGTFWK	RN	Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11730569

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM702MU
DEGTFWK	DN	ITX-5061
DEGTFWK	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM7IW9J
DEGTFWK	DN	Ramelteon
DEGTFWK	RN	Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23861638

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM27Z5T
DEGTFWK	DN	Estradiol cypionate
DEGTFWK	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM35M8J
DEGTFWK	DN	Thioridazine
DEGTFWK	RN	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23959307

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMKB79O
DEGTFWK	DN	Bromfenac
DEGTFWK	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0Q8MZ
DEGTFWK	DN	Trimethadione
DEGTFWK	RN	Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11896285

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMGMF6V
DEGTFWK	DN	Capsaicin
DEGTFWK	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM0WX6I
DEGTFWK	DN	Primidone
DEGTFWK	RN	Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10380060

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM70BU5
DEGTFWK	DN	Thalidomide
DEGTFWK	RN	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642692

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMGR5Z3
DEGTFWK	DN	Flunitrazepam
DEGTFWK	RN	The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12640218

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMA2GHJ
DEGTFWK	DN	AV-650
DEGTFWK	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMD1QXW
DEGTFWK	DN	Ambrisentan
DEGTFWK	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4LECQ
DEGTFWK	DN	Vilazodone hydrochloride
DEGTFWK	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFXEWT
DEGTFWK	DN	Chloramphenicol
DEGTFWK	RN	Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14576103

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMK0O7U
DEGTFWK	DN	Flutamide
DEGTFWK	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMCFE9I
DEGTFWK	DN	Valproic acid
DEGTFWK	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHM93Y
DEGTFWK	DN	Meprobamate
DEGTFWK	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM2G9AE
DEGTFWK	DN	Citalopram hydrobromide
DEGTFWK	RN	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10494454

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMK7F9S
DEGTFWK	DN	Amitriptyline hydrochloride
DEGTFWK	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMXZOCG
DEGTFWK	DN	Phenobarbital
DEGTFWK	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFC71L
DEGTFWK	DN	Clozapine
DEGTFWK	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM7F1PA
DEGTFWK	DN	Nebivolol hydrochloride
DEGTFWK	RN	Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27538917

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM4M1SG
DEGTFWK	DN	Clarithromycin
DEGTFWK	RN	Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15952098

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMZA5PQ
DEGTFWK	DN	Glipizide
DEGTFWK	RN	Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10208645

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMIFCY2
DEGTFWK	DN	H3B-6545
DEGTFWK	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMC68DF
DEGTFWK	DN	GTPL7557
DEGTFWK	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMG1OPF
DEGTFWK	DN	Buflomedil
DEGTFWK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFG5ST
DEGTFWK	DN	Almotriptan malate
DEGTFWK	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMY2AH1
DEGTFWK	DN	Aminophenazone
DEGTFWK	RN	Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11853173

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMF7EXL
DEGTFWK	DN	Benzatropine
DEGTFWK	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHKZX1
DEGTFWK	DN	Benzethonium
DEGTFWK	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8KLU9
DEGTFWK	DN	Cenobamate
DEGTFWK	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEGTFWK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8QXOC
DEGTFWK	DN	Enasidenib
DEGTFWK	RN	Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29770715

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM8TNX3
DEGTFWK	DN	Etizolam
DEGTFWK	RN	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635335

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DML2DCR
DEGTFWK	DN	Fedratinib hydrochloride
DEGTFWK	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DEGTFWK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMXYLQ3
DEGTFWK	DN	Lansoprazole
DEGTFWK	RN	Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752376

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM82JP0
DEGTFWK	DN	Lynestrenol
DEGTFWK	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMNKSX3
DEGTFWK	DN	Medazepam
DEGTFWK	RN	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18175099

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMFX6G8
DEGTFWK	DN	Nelfinavir mesylate
DEGTFWK	RN	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol. 2015 Aug;80(2):267-75.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25752914

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMHAWYQ
DEGTFWK	DN	Nordazepam
DEGTFWK	RN	Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999 Dec;66(6):642-6.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10613621

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DM5DSFZ
DEGTFWK	DN	Rifampicin
DEGTFWK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMSWJ5X
DEGTFWK	DN	Sildenafil citrate
DEGTFWK	RN	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11298070

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMC1TEV
DEGTFWK	DN	Testosterone cypionate
DEGTFWK	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMB6871
DEGTFWK	DN	Testosterone enanthate
DEGTFWK	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMCOJPS
DEGTFWK	DN	Vonoprazan
DEGTFWK	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DEGTFWK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DEGTFWK	EI	DEGTFWK
DEGTFWK	EN	Mephenytoin 4-hydroxylase (CYP2C19)
DEGTFWK	DI	DMDGCQP
DEGTFWK	DN	Norethindrone acetate
DEGTFWK	RN	Drug Interactions Flockhart Table
DEGTFWK	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DEO1IE3	EI	DEO1IE3
DEO1IE3	EN	Cytochrome P450 3A43 (CYP3A43)
DEO1IE3	DI	DMXNZM4
DEO1IE3	DN	Oxazepam
DEO1IE3	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DEO1IE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DEO1IE3	EI	DEO1IE3
DEO1IE3	EN	Cytochrome P450 3A43 (CYP3A43)
DEO1IE3	DI	DMOU1PK
DEO1IE3	DN	Praziquantel
DEO1IE3	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DEO1IE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DEO1IE3	EI	DEO1IE3
DEO1IE3	EN	Cytochrome P450 3A43 (CYP3A43)
DEO1IE3	DI	DMDZ9LT
DEO1IE3	DN	Ethosuximide
DEO1IE3	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DEO1IE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DEO1IE3	EI	DEO1IE3
DEO1IE3	EN	Cytochrome P450 3A43 (CYP3A43)
DEO1IE3	DI	DMH7MUV
DEO1IE3	DN	Zalcitabine
DEO1IE3	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DEO1IE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DEO1IE3	EI	DEO1IE3
DEO1IE3	EN	Cytochrome P450 3A43 (CYP3A43)
DEO1IE3	DI	DMC1TEV
DEO1IE3	DN	Testosterone cypionate
DEO1IE3	RN	cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
DEO1IE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160876

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DM5T6US
DE9QHP6	DN	Estrone
DE9QHP6	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DM4K7GQ
DE9QHP6	DN	Erythromycin stearate
DE9QHP6	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DM1NG5W
DE9QHP6	DN	Hydrogen peroxide
DE9QHP6	RN	NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. J Steroid Biochem Mol Biol. 2000 Sep;74(1-2):11-8.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11074351

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DME4RA8
DE9QHP6	DN	Amodiaquine
DE9QHP6	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMUY35B
DE9QHP6	DN	Progesterone
DE9QHP6	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMEDGKO
DE9QHP6	DN	Dibutylphthalate
DE9QHP6	RN	Inhibition of human cytochrome p450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture. J Biochem Mol Toxicol. 2007;21(3):101-9.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17623886

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMIK367
DE9QHP6	DN	Procarbazine
DE9QHP6	RN	Tumour cytochrome P450 and drug activation. Curr Pharm Des. 2002;8(15):1335-47.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12052211

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMUNTE3
DE9QHP6	DN	E-3A
DE9QHP6	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMKWFBT
DE9QHP6	DN	Melatonin
DE9QHP6	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMKBJWP
DE9QHP6	DN	Caffeine
DE9QHP6	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMRJFN9
DE9QHP6	DN	Theophylline
DE9QHP6	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMMIQ7G
DE9QHP6	DN	Rosuvastatin
DE9QHP6	RN	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691987

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DME2A8X
DE9QHP6	DN	HSDB-3466
DE9QHP6	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMJ2AH4
DE9QHP6	DN	NSC-122758
DE9QHP6	RN	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258110

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMK0O7U
DE9QHP6	DN	Flutamide
DE9QHP6	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMQNWRD
DE9QHP6	DN	Oxaliplatin
DE9QHP6	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DE9QHP6	EI	DE9QHP6
DE9QHP6	EN	Cytochrome P450 1B1 (CYP1B1)
DE9QHP6	DI	DMC1TEV
DE9QHP6	DN	Testosterone cypionate
DE9QHP6	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DE9QHP6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DEX2KIA	EI	DEX2KIA
DEX2KIA	EN	Steroid 17-alpha-monooxygenase (CYP17A1)
DEX2KIA	DI	DM3S8XC
DEX2KIA	DN	Androstanolone
DEX2KIA	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DEX2KIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DEX2KIA	EI	DEX2KIA
DEX2KIA	EN	Steroid 17-alpha-monooxygenase (CYP17A1)
DEX2KIA	DI	DMLZIT2
DEX2KIA	DN	GTPL-463
DEX2KIA	RN	In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol. 1997 Sep 1;54(5):605-11.
DEX2KIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9337077

DEX2KIA	EI	DEX2KIA
DEX2KIA	EN	Steroid 17-alpha-monooxygenase (CYP17A1)
DEX2KIA	DI	DM1G4S9
DEX2KIA	DN	INS-339(II)
DEX2KIA	RN	Transcriptional complexes at the CYP17 CRS. Endocr Res. 2002 Nov;28(4):551-8.
DEX2KIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12530662

DEX2KIA	EI	DEX2KIA
DEX2KIA	EN	Steroid 17-alpha-monooxygenase (CYP17A1)
DEX2KIA	DI	DMY2AH1
DEX2KIA	DN	Aminophenazone
DEX2KIA	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DEX2KIA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMTYOPD
DE3GT9C	DN	Dinoprostone
DE3GT9C	RN	Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11370662

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DM5JVAN
DE3GT9C	DN	Fingolimod
DE3GT9C	RN	CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMFKOR9
DE3GT9C	DN	DB-289
DE3GT9C	RN	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17709372

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMUOQZD
DE3GT9C	DN	Arachidonic acid
DE3GT9C	RN	Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta. 2011 Jan;1814(1):210-22.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20869469

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMJPXZ4
DE3GT9C	DN	Fingolimod hydrochloride
DE3GT9C	RN	Product information - Gilenya.
DE3GT9C	RU	http://www.medsafe.govt.nz/profs/datasheet/g/gilenyacap.pdf

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMQRX24
DE3GT9C	DN	Ebastine
DE3GT9C	RN	cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162645

DE3GT9C	EI	DE3GT9C
DE3GT9C	EN	Cytochrome P450 4F2 (CYP4F2)
DE3GT9C	DI	DMBIJZ6
DE3GT9C	DN	Tocopherol
DE3GT9C	RN	Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004 Dec;1031:13-21.
DE3GT9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15753130

DEBS639	EI	DEBS639
DEBS639	EN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DEBS639	DI	DM6FG1P
DEBS639	DN	Doxercalciferol
DEBS639	RN	Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4. Indian J Nephrol. 2013 Jul;23(4):271-5.
DEBS639	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960343

DEBS639	EI	DEBS639
DEBS639	EN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DEBS639	DI	DM1237M
DEBS639	DN	Alfacalcidol
DEBS639	RN	Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development. Biochim Biophys Acta. 2002 Feb 28;1580(2-3):133-44.
DEBS639	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11880238

DEBS639	EI	DEBS639
DEBS639	EN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DEBS639	DI	DMWQUC9
DEBS639	DN	Vitamin D
DEBS639	RN	Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis. 2005;22(3):265-73.
DEBS639	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16158254

DEBS639	EI	DEBS639
DEBS639	EN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DEBS639	DI	DMMJOZD
DEBS639	DN	ANW-32821
DEBS639	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DEBS639	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DEPE0RD	EI	DEPE0RD
DEPE0RD	EN	Steroid 11-beta-hydroxylase (CYP11B1)
DEPE0RD	DI	DMW6YLS
DEPE0RD	DN	Desoxycortone
DEPE0RD	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DEPE0RD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DEPE0RD	EI	DEPE0RD
DEPE0RD	EN	Steroid 11-beta-hydroxylase (CYP11B1)
DEPE0RD	DI	DM9S2JW
DEPE0RD	DN	BRN-3224996
DEPE0RD	RN	Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002 Dec;147(6):795-802.
DEPE0RD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12457455

DEPE0RD	EI	DEPE0RD
DEPE0RD	EN	Steroid 11-beta-hydroxylase (CYP11B1)
DEPE0RD	DI	DMGEMB7
DEPE0RD	DN	Hydrocortisone
DEPE0RD	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DEPE0RD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMUY35B
DEKP5HX	DN	Progesterone
DEKP5HX	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DEKP5HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMUDJZM
DEKP5HX	DN	Dextromethorphan hydrobromide
DEKP5HX	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DEKP5HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMRQAM0
DEKP5HX	DN	Phenacetin
DEKP5HX	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DEKP5HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMPIHLS
DEKP5HX	DN	Diclofenac sodium
DEKP5HX	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DEKP5HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMC1TEV
DEKP5HX	DN	Testosterone cypionate
DEKP5HX	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DEKP5HX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DEKP5HX	EI	DEKP5HX
DEKP5HX	EN	Cholesterol 24-hydroxylase (CYP46A1)
DEKP5HX	DI	DMMJOZD
DEKP5HX	DN	ANW-32821
DEKP5HX	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DEKP5HX	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DE2XQGW	EI	DE2XQGW
DE2XQGW	EN	Lauric acid omega-hydroxylase (CYP4A11)
DE2XQGW	DI	DM5T6US
DE2XQGW	DN	Estrone
DE2XQGW	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DE2XQGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DE2XQGW	EI	DE2XQGW
DE2XQGW	EN	Lauric acid omega-hydroxylase (CYP4A11)
DE2XQGW	DI	DMPC1J7
DE2XQGW	DN	Clofibrate
DE2XQGW	RN	Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41.
DE2XQGW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056802

DEXZA9U	EI	DEXZA9U
DEXZA9U	EN	Cytochrome P450 2A13 (CYP2A13)
DEXZA9U	DI	DMRQAM0
DEXZA9U	DN	Phenacetin
DEXZA9U	RN	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
DEXZA9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178771

DEXZA9U	EI	DEXZA9U
DEXZA9U	EN	Cytochrome P450 2A13 (CYP2A13)
DEXZA9U	DI	DMWX5CO
DEXZA9U	DN	Nicotine
DEXZA9U	RN	Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther. 2006 Jan;316(1):295-303.
DEXZA9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16188955

DEXZA9U	EI	DEXZA9U
DEXZA9U	EN	Cytochrome P450 2A13 (CYP2A13)
DEXZA9U	DI	DMC1TEV
DEXZA9U	DN	Testosterone cypionate
DEXZA9U	RN	Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 2005 Mar;26(3):621-9.
DEXZA9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15579482

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMXBLMP
DERSX5P	DN	Riociguat
DERSX5P	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMHO0AR
DERSX5P	DN	Ergocalciferol
DERSX5P	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMJPGUA
DERSX5P	DN	CV-4093
DERSX5P	RN	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30965050

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DM58XJN
DERSX5P	DN	Desmethylastemizole
DERSX5P	RN	Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos. 2002 Nov;30(11):1240-5.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12386130

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMQMBZ1
DERSX5P	DN	Rivaroxaban
DERSX5P	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMUVMWZ
DERSX5P	DN	LAS-X-113
DERSX5P	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DM1SMAI
DERSX5P	DN	DW-1030
DERSX5P	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMA16BR
DERSX5P	DN	Vorapaxar sulfate
DERSX5P	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DM2HN6Q
DERSX5P	DN	Astemizole
DERSX5P	RN	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22328583

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMIFCY2
DERSX5P	DN	H3B-6545
DERSX5P	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DM1237M
DERSX5P	DN	Alfacalcidol
DERSX5P	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMQRX24
DERSX5P	DN	Ebastine
DERSX5P	RN	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22328583

DERSX5P	EI	DERSX5P
DERSX5P	EN	Cytochrome P450 2J2 (CYP2J2)
DERSX5P	DI	DMWQUC9
DERSX5P	DN	Vitamin D
DERSX5P	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DERSX5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DEZT8FM	EI	DEZT8FM
DEZT8FM	EN	Retinoic acid 4-hydroxylase 26B1 (CYP26B1)
DEZT8FM	DI	DM2CZFA
DEZT8FM	DN	Etretinate
DEZT8FM	RN	Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1029-36.
DEZT8FM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17185629

DE6NMGO	EI	DE6NMGO
DE6NMGO	EN	Cytochrome P450 2S1 (CYP2S1)
DE6NMGO	DI	DMJ2AH4
DE6NMGO	DN	NSC-122758
DE6NMGO	RN	The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochim Biophys Acta. 2009 Mar;1791(3):220-8.
DE6NMGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19171200

DEFCMPI	EI	DEFCMPI
DEFCMPI	EN	Leukotriene B4 omega-hydroxylase (CYP4F3)
DEFCMPI	DI	DME26RS
DEFCMPI	DN	BML1-E04
DEFCMPI	RN	Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys. 2001 Jan 15;385(2):231-41.
DEFCMPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368003

DE6TYUK	EI	DE6TYUK
DE6TYUK	EN	Aldosterone synthase (CYP11B2)
DE6TYUK	DI	DMW6YLS
DE6TYUK	DN	Desoxycortone
DE6TYUK	RN	Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry. 2002 Feb 19;41(7):2311-21.
DE6TYUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11841224

DE6TYUK	EI	DE6TYUK
DE6TYUK	EN	Aldosterone synthase (CYP11B2)
DE6TYUK	DI	DM9S2JW
DE6TYUK	DN	BRN-3224996
DE6TYUK	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005 Oct 20;48(21):6632-42.
DE6TYUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16220979

DE6TYUK	EI	DE6TYUK
DE6TYUK	EN	Aldosterone synthase (CYP11B2)
DE6TYUK	DI	DMGEMB7
DE6TYUK	DN	Hydrocortisone
DE6TYUK	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DE6TYUK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DE0JMZ5	EI	DE0JMZ5
DE0JMZ5	EN	Steroid 21-hydroxylase (CYP21A2)
DE0JMZ5	DI	DMIKQH5
DE0JMZ5	DN	Hydroxyprogesterone caproate
DE0JMZ5	RN	Functional characterization of two novel point mutations in the CYP21 gene causing simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2005 Jan;90(1):445-54.
DE0JMZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483094

DE0JMZ5	EI	DE0JMZ5
DE0JMZ5	EN	Steroid 21-hydroxylase (CYP21A2)
DE0JMZ5	DI	DMUY35B
DE0JMZ5	DN	Progesterone
DE0JMZ5	RN	Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme progesterone substrate complex and rate-limiting C-H bond cleavage. J Biol Chem. 2015 May 22;290(21):13128-43.
DE0JMZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25855791

DEFI12S	EI	DEFI12S
DEFI12S	EN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DEFI12S	DI	DMN4CV5
DEFI12S	DN	Calcifediol
DEFI12S	RN	Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60.
DEFI12S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16600026

DEFI12S	EI	DEFI12S
DEFI12S	EN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DEFI12S	DI	DM8ZVJ7
DEFI12S	DN	Calcitriol
DEFI12S	RN	The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57.
DEFI12S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24705652

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DMJV2EK
DEP76YL	DN	Dasatinib
DEP76YL	RN	Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
DEP76YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18556438

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DM8K3EI
DEP76YL	DN	Ethionamide
DEP76YL	RN	Physiologically based pharmacokinetic modeling approach to predict drug-drug interactions with ethionamide involving impact of genetic polymorphism on FMO3. J Clin Pharmacol. 2019 Jun;59(6):880-889.
DEP76YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30690726

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DMFG5ST
DEP76YL	DN	Almotriptan malate
DEP76YL	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DEP76YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DML2DCR
DEP76YL	DN	Fedratinib hydrochloride
DEP76YL	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DEP76YL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DM7MLTR
DEP76YL	DN	Itopride
DEP76YL	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DEP76YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DEP76YL	EI	DEP76YL
DEP76YL	EN	Dimethylaniline oxidase 3 (FMO3)
DEP76YL	DI	DMAVIPZ
DEP76YL	DN	HSR-803
DEP76YL	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DEP76YL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM28UJG
DEB3CV1	DN	Dapagliflozin
DEB3CV1	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM4KI7O
DEB3CV1	DN	Zidovudine
DEB3CV1	RN	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18573701

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMJX6ZG
DEB3CV1	DN	Codeine
DEB3CV1	RN	Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010622

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMPQAGE
DEB3CV1	DN	Mycophenolate mofetil
DEB3CV1	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMHP21E
DEB3CV1	DN	Hydromorphone
DEB3CV1	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DML2D8Q
DEB3CV1	DN	MPC-4326
DEB3CV1	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DEB3CV1	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMZOLBI
DEB3CV1	DN	Carbamazepine
DEB3CV1	RN	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23252947

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMD8Q3J
DEB3CV1	DN	Gemfibrozil
DEB3CV1	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMRF9YK
DEB3CV1	DN	Empagliflozin
DEB3CV1	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMJ3HQY
DEB3CV1	DN	GTPL-1666
DEB3CV1	RN	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19462483

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM9OZWQ
DEB3CV1	DN	Lovastatin
DEB3CV1	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM3VFPD
DEB3CV1	DN	Troglitazone
DEB3CV1	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMFYBD0
DEB3CV1	DN	Dexibuprofen
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMLB0EZ
DEB3CV1	DN	Tamoxifen citrate
DEB3CV1	RN	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24328412

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMBY31K
DEB3CV1	DN	CS-011
DEB3CV1	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMSEVBH
DEB3CV1	DN	UK-453,061
DEB3CV1	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMK7CYX
DEB3CV1	DN	ASA-404
DEB3CV1	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMXNZM4
DEB3CV1	DN	Oxazepam
DEB3CV1	RN	Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12386133

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM7A8TW
DEB3CV1	DN	Ezetimibe
DEB3CV1	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMGN4BY
DEB3CV1	DN	Flurbiprofen sodium
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMMN36E
DEB3CV1	DN	Abacavir
DEB3CV1	RN	Product characteristics of Triumeq.
DEB3CV1	RU	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMK8U72
DEB3CV1	DN	Labetalol
DEB3CV1	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMPDW6T
DEB3CV1	DN	Epirubicin
DEB3CV1	RN	Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16985101

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMI4EL5
DEB3CV1	DN	Ketorolac
DEB3CV1	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM72JXH
DEB3CV1	DN	Losartan potassium
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMZ5RGV
DEB3CV1	DN	Naproxen
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM84ZXF
DEB3CV1	DN	Lorazepam
DEB3CV1	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMWMPD4
DEB3CV1	DN	Vorinostat
DEB3CV1	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMFLJHQ
DEB3CV1	DN	LCQ908-NXA
DEB3CV1	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM1UJO0
DEB3CV1	DN	Pitavastatin calcium
DEB3CV1	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM30SGU
DEB3CV1	DN	Simvastatin
DEB3CV1	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM9S2JW
DEB3CV1	DN	BRN-3224996
DEB3CV1	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMHMP05
DEB3CV1	DN	Carprofen
DEB3CV1	RN	Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. Chirality. 2015 Mar;27(3):189-93.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502512

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMXLSH3
DEB3CV1	DN	Tapentadol
DEB3CV1	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMRDZ4X
DEB3CV1	DN	Dabigatran etexilate
DEB3CV1	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM6WJO9
DEB3CV1	DN	Etodolac
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMBXVMZ
DEB3CV1	DN	Artenimol
DEB3CV1	RN	Eurartesim - European Medicines Agency
DEB3CV1	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM79VXT
DEB3CV1	DN	Ertugliflozin
DEB3CV1	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM8VCBE
DEB3CV1	DN	Ibuprofen
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMSC4A7
DEB3CV1	DN	Indomethacin
DEB3CV1	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMB0FWL
DEB3CV1	DN	Dihydrocodeine
DEB3CV1	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMPIHLS
DEB3CV1	DN	Diclofenac sodium
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMJSBT6
DEB3CV1	DN	Silodosin
DEB3CV1	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMKB79O
DEB3CV1	DN	Bromfenac
DEB3CV1	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMNP60F
DEB3CV1	DN	Anastrozole
DEB3CV1	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMHTEAO
DEB3CV1	DN	Carvedilol
DEB3CV1	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMRMS0L
DEB3CV1	DN	Morphine
DEB3CV1	RN	Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071451

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMD1QXW
DEB3CV1	DN	Ambrisentan
DEB3CV1	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMCFE9I
DEB3CV1	DN	Valproic acid
DEB3CV1	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DML6CN4
DEB3CV1	DN	Acemetacin
DEB3CV1	RN	Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
DEB3CV1	RU	https://link.springer.com/content/pdf/bfm%3A978-94-011-3804-8%2F1.pdf

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM8KLU9
DEB3CV1	DN	Cenobamate
DEB3CV1	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DEB3CV1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM1PV4Y
DEB3CV1	DN	CS-600G
DEB3CV1	RN	Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30072626

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DMRBMAU
DEB3CV1	DN	Mycophenolic acid
DEB3CV1	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM9RJH7
DEB3CV1	DN	Zaltoprofen
DEB3CV1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM2QKOU
DEB3CV1	DN	Tetrahydroaldosterone
DEB3CV1	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DEB3CV1	EI	DEB3CV1
DEB3CV1	EN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DEB3CV1	DI	DM6ZTOW
DEB3CV1	DN	Alpha-dihydroaldosterone
DEB3CV1	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DEB3CV1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMTP1DC
DEF2WXN	DN	Irbesartan
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM92AH3
DEF2WXN	DN	Cyproheptadine
DEF2WXN	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMF28YC
DEF2WXN	DN	Atorvastatin calcium
DEF2WXN	RN	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23580084

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM8SXYG
DEF2WXN	DN	Lamotrigine
DEF2WXN	RN	Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19387891

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMXCM7H
DEF2WXN	DN	Cerivastatin sodium
DEF2WXN	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMHP21E
DEF2WXN	DN	Hydromorphone
DEF2WXN	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DML2D8Q
DEF2WXN	DN	MPC-4326
DEF2WXN	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DEF2WXN	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMD8Q3J
DEF2WXN	DN	Gemfibrozil
DEF2WXN	RN	Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28940478

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMRF9YK
DEF2WXN	DN	Empagliflozin
DEF2WXN	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM9OZWQ
DEF2WXN	DN	Lovastatin
DEF2WXN	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM3VFPD
DEF2WXN	DN	Troglitazone
DEF2WXN	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMFYBD0
DEF2WXN	DN	Dexibuprofen
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMBY31K
DEF2WXN	DN	CS-011
DEF2WXN	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM7A8TW
DEF2WXN	DN	Ezetimibe
DEF2WXN	RN	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21368751

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMGN4BY
DEF2WXN	DN	Flurbiprofen sodium
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMICDLV
DEF2WXN	DN	Lorlatinib
DEF2WXN	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DEF2WXN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMRK8OT
DEF2WXN	DN	Candesartan cilexetil
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM72JXH
DEF2WXN	DN	Losartan potassium
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMZ5RGV
DEF2WXN	DN	Naproxen
DEF2WXN	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMV7YFT
DEF2WXN	DN	Darolutamide
DEF2WXN	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMWMPD4
DEF2WXN	DN	Vorinostat
DEF2WXN	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMFLJHQ
DEF2WXN	DN	LCQ908-NXA
DEF2WXN	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM1UJO0
DEF2WXN	DN	Pitavastatin calcium
DEF2WXN	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM30SGU
DEF2WXN	DN	Simvastatin
DEF2WXN	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMG3NFZ
DEF2WXN	DN	BMS-298585
DEF2WXN	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM7HLFD
DEF2WXN	DN	ML-3000
DEF2WXN	RN	In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab Dispos. 2008 May;36(5):894-903.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18268076

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM6WJO9
DEF2WXN	DN	Etodolac
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMS3GX2
DEF2WXN	DN	Telmisartan
DEF2WXN	RN	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22275465

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM1UV7F
DEF2WXN	DN	Baloxavir marboxil
DEF2WXN	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DEF2WXN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM8IL1U
DEF2WXN	DN	GV-150526
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMP8HEL
DEF2WXN	DN	Glinsuna
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM8VCBE
DEF2WXN	DN	Ibuprofen
DEF2WXN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMPIHLS
DEF2WXN	DN	Diclofenac sodium
DEF2WXN	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMIM5AP
DEF2WXN	DN	TAK-875
DEF2WXN	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMNP60F
DEF2WXN	DN	Anastrozole
DEF2WXN	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMRMS0L
DEF2WXN	DN	Morphine
DEF2WXN	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMD1QXW
DEF2WXN	DN	Ambrisentan
DEF2WXN	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMGNYIH
DEF2WXN	DN	Retigabine
DEF2WXN	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DMCFE9I
DEF2WXN	DN	Valproic acid
DEF2WXN	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DEF2WXN	EI	DEF2WXN
DEF2WXN	EN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DEF2WXN	DI	DM6ETS0
DEF2WXN	DN	Deferasirox
DEF2WXN	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DEF2WXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM28UJG
DE85D2P	DN	Dapagliflozin
DE85D2P	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM7V2LG
DE85D2P	DN	Chrysin
DE85D2P	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMM3L6Z
DE85D2P	DN	Ketobemidone
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMPQAGE
DE85D2P	DN	Mycophenolate mofetil
DE85D2P	RN	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142265

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMPNTDL
DE85D2P	DN	ABT-001
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM1S4AG
DE85D2P	DN	Lumiracoxib
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMD8Q3J
DE85D2P	DN	Gemfibrozil
DE85D2P	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMRF9YK
DE85D2P	DN	Empagliflozin
DE85D2P	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMLK2QH
DE85D2P	DN	Nateglinide
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM3VFPD
DE85D2P	DN	Troglitazone
DE85D2P	RN	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12582161

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMFYBD0
DE85D2P	DN	Dexibuprofen
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMQPH29
DE85D2P	DN	Curcumin
DE85D2P	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMFKXDY
DE85D2P	DN	Fenofibrate
DE85D2P	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMFRM1I
DE85D2P	DN	Canagliflozin
DE85D2P	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMT8J0I
DE85D2P	DN	GSK-1265744
DE85D2P	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMK7CYX
DE85D2P	DN	ASA-404
DE85D2P	RN	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487149

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMHSY1I
DE85D2P	DN	Regorafenib
DE85D2P	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DE85D2P	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM4GXW3
DE85D2P	DN	PTC-124
DE85D2P	RN	Ataluren pharmacokinetics in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev. 2019 Feb;8(2):172-178.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30629861

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMVRIC2
DE85D2P	DN	Zileuton
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMGN4BY
DE85D2P	DN	Flurbiprofen sodium
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMB4OLE
DE85D2P	DN	Propofol
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMK8U72
DE85D2P	DN	Labetalol
DE85D2P	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMW50NF
DE85D2P	DN	SN-38
DE85D2P	RN	Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett. 2012 Mar;3(3):694-698.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22740978

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM96SE0
DE85D2P	DN	Haloperidol decanoate
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMZ5RGV
DE85D2P	DN	Naproxen
DE85D2P	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMV7YFT
DE85D2P	DN	Darolutamide
DE85D2P	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMWMPD4
DE85D2P	DN	Vorinostat
DE85D2P	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMYA50U
DE85D2P	DN	Phloretin
DE85D2P	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMLBVKQ
DE85D2P	DN	Entacapone
DE85D2P	RN	Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15802387

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMXLSH3
DE85D2P	DN	Tapentadol
DE85D2P	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMRDZ4X
DE85D2P	DN	Dabigatran etexilate
DE85D2P	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMAY7H4
DE85D2P	DN	Valdecoxib
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMG3NFZ
DE85D2P	DN	BMS-298585
DE85D2P	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM6WJO9
DE85D2P	DN	Etodolac
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMBXVMZ
DE85D2P	DN	Artenimol
DE85D2P	RN	Eurartesim - European Medicines Agency
DE85D2P	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM7US1H
DE85D2P	DN	Eugenol
DE85D2P	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM8IL1U
DE85D2P	DN	GV-150526
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM79VXT
DE85D2P	DN	Ertugliflozin
DE85D2P	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM8VCBE
DE85D2P	DN	Ibuprofen
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMSC4A7
DE85D2P	DN	Indomethacin
DE85D2P	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMB08GE
DE85D2P	DN	Sulfamethoxazole
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMSB068
DE85D2P	DN	Glasdegib
DE85D2P	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMPIHLS
DE85D2P	DN	Diclofenac sodium
DE85D2P	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMUIE76
DE85D2P	DN	Acetaminophen
DE85D2P	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMS8IFC
DE85D2P	DN	Sorafenib
DE85D2P	RN	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20706860

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMA04DE
DE85D2P	DN	FYX-051
DE85D2P	RN	Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug Metab Dispos. 2007 Dec;35(12):2143-8.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17761779

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMD1QXW
DE85D2P	DN	Ambrisentan
DE85D2P	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMGNYIH
DE85D2P	DN	Retigabine
DE85D2P	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMCFE9I
DE85D2P	DN	Valproic acid
DE85D2P	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMW3QGJ
DE85D2P	DN	LM-94
DE85D2P	RN	The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18362158

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMRBMAU
DE85D2P	DN	Mycophenolic acid
DE85D2P	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DM2BO9W
DE85D2P	DN	BCP-13498
DE85D2P	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DE85D2P	EI	DE85D2P
DE85D2P	EN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DE85D2P	DI	DMN1YFU
DE85D2P	DN	Anthraflavic acid
DE85D2P	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DE85D2P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DEV3T4A	EI	DEV3T4A
DEV3T4A	EN	Catechol O-methyltransferase (COMT)
DEV3T4A	DI	DM3KJBC
DEV3T4A	DN	Epinephrine hydrochloride
DEV3T4A	RN	Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther. 1994 Mar;268(3):1242-51.
DEV3T4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8138937

DEV3T4A	EI	DEV3T4A
DEV3T4A	EN	Catechol O-methyltransferase (COMT)
DEV3T4A	DI	DMYVU47
DEV3T4A	DN	CCRIS-9277
DEV3T4A	RN	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
DEV3T4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228154

DEV3T4A	EI	DEV3T4A
DEV3T4A	EN	Catechol O-methyltransferase (COMT)
DEV3T4A	DI	DMD1B8Z
DEV3T4A	DN	Dobutamine hydrochloride
DEV3T4A	RN	Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52.
DEV3T4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2868577

DEV3T4A	EI	DEV3T4A
DEV3T4A	EN	Catechol O-methyltransferase (COMT)
DEV3T4A	DI	DMPGUCF
DEV3T4A	DN	Dopamine hydrochloride
DEV3T4A	RN	Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
DEV3T4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21656904

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DM3KJBC
DERE4TU	DN	Epinephrine hydrochloride
DERE4TU	RN	Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31556016

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DMOFCRY
DERE4TU	DN	Serotonin
DERE4TU	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DM1IB4Q
DERE4TU	DN	Zolmitriptan
DERE4TU	RN	Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/12075043

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DMX0G4F
DERE4TU	DN	Phenylethylamine
DERE4TU	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DMO50U2
DERE4TU	DN	Naratriptan
DERE4TU	RN	Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11249525

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DM0J2ZT
DERE4TU	DN	Safinamide mesylate
DERE4TU	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17824599

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DMFG5ST
DERE4TU	DN	Almotriptan malate
DERE4TU	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DERE4TU	EI	DERE4TU
DERE4TU	EN	Monoamine oxidase type A (MAO-A)
DERE4TU	DI	DMRM6ES
DERE4TU	DN	Benzylamine
DERE4TU	RN	Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
DERE4TU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401534

DET2NXO	EI	DET2NXO
DET2NXO	EN	Monoamine oxidase type B (MAO-B)
DET2NXO	DI	DMPGUCF
DET2NXO	DN	Dopamine hydrochloride
DET2NXO	RN	Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
DET2NXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20869994

DE3FYEM	EI	DE3FYEM
DE3FYEM	EN	Calcidiol 1-monooxygenase (CYP27B1)
DE3FYEM	DI	DMN4CV5
DE3FYEM	DN	Calcifediol
DE3FYEM	RN	Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
DE3FYEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20619365

DENUPDX	EI	DENUPDX
DENUPDX	EN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DENUPDX	DI	DMJX6ZG
DENUPDX	DN	Codeine
DENUPDX	RN	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
DENUPDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22092298

DENUPDX	EI	DENUPDX
DENUPDX	EN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DENUPDX	DI	DMFRM1I
DENUPDX	DN	Canagliflozin
DENUPDX	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DENUPDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DENUPDX	EI	DENUPDX
DENUPDX	EN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DENUPDX	DI	DMK8U72
DENUPDX	DN	Labetalol
DENUPDX	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DENUPDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DENUPDX	EI	DENUPDX
DENUPDX	EN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DENUPDX	DI	DMB0FWL
DENUPDX	DN	Dihydrocodeine
DENUPDX	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DENUPDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DM8SXYG
DELOY3P	DN	Lamotrigine
DELOY3P	RN	Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35.
DELOY3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19845433

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DML2D8Q
DELOY3P	DN	MPC-4326
DELOY3P	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DELOY3P	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DMICDLV
DELOY3P	DN	Lorlatinib
DELOY3P	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DELOY3P	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DMW16X2
DELOY3P	DN	UDP-glucuronate
DELOY3P	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DELOY3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DM8ZVJ7
DELOY3P	DN	Calcitriol
DELOY3P	RN	Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50.
DELOY3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18177842

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DMJ0QOW
DELOY3P	DN	Rilpivirine hydrochloride
DELOY3P	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DELOY3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DELOY3P	EI	DELOY3P
DELOY3P	EN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DELOY3P	DI	DMW3QGJ
DELOY3P	DN	LM-94
DELOY3P	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DELOY3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DM7A8TW
DENZ6B1	DN	Ezetimibe
DENZ6B1	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DM84ZXF
DENZ6B1	DN	Lorazepam
DENZ6B1	RN	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15961980

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DMUIE76
DENZ6B1	DN	Acetaminophen
DENZ6B1	RN	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21245288

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DMFSKYE
DENZ6B1	DN	Hydroxybenzo[a]pyrene
DENZ6B1	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DM9H5EN
DENZ6B1	DN	Hydroxybenzo(a)pyrene
DENZ6B1	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DENZ6B1	EI	DENZ6B1
DENZ6B1	EN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DENZ6B1	DI	DMOTU4P
DENZ6B1	DN	BRN-1980310
DENZ6B1	RN	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
DENZ6B1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16510539

DE7OAB3	EI	DE7OAB3
DE7OAB3	EN	N-acetyltransferase 1 (NAT1)
DE7OAB3	DI	DMK08L3
DE7OAB3	DN	Amifampridine
DE7OAB3	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DE7OAB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DE7OAB3	EI	DE7OAB3
DE7OAB3	EN	N-acetyltransferase 1 (NAT1)
DE7OAB3	DI	DMU8JGH
DE7OAB3	DN	Hydralazine hydrochloride
DE7OAB3	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DE7OAB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DE7OAB3	EI	DE7OAB3
DE7OAB3	EN	N-acetyltransferase 1 (NAT1)
DE7OAB3	DI	DMNMXR8
DE7OAB3	DN	Procainamide hydrochloride
DE7OAB3	RN	Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613-20.
DE7OAB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937477

DE7OAB3	EI	DE7OAB3
DE7OAB3	EN	N-acetyltransferase 1 (NAT1)
DE7OAB3	DI	DM3WVPJ
DE7OAB3	DN	Asacolitin
DE7OAB3	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DE7OAB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DMENSL5
DER7TA0	DN	Aminosalicylic acid
DER7TA0	RN	Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27416043

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DM672AH
DER7TA0	DN	Aspirin
DER7TA0	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DMK08L3
DER7TA0	DN	Amifampridine
DER7TA0	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DMU8JGH
DER7TA0	DN	Hydralazine hydrochloride
DER7TA0	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DMNMXR8
DER7TA0	DN	Procainamide hydrochloride
DER7TA0	RN	Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10692486

DER7TA0	EI	DER7TA0
DER7TA0	EN	N-acetyltransferase 2 (NAT2)
DER7TA0	DI	DM3WVPJ
DER7TA0	DN	Asacolitin
DER7TA0	RN	Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
DER7TA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11344150

DEAWHS8	EI	DEAWHS8
DEAWHS8	EN	Aldehyde oxidase (AOX1)
DEAWHS8	DI	DMML7BE
DEAWHS8	DN	XL-147
DEAWHS8	RN	Characterization of aldehyde oxidase